



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 193507**

**TO: Ralph J Gitomer**  
**Location: 3d65 / 3c18**  
**Art Unit: 1655**  
**Thursday, July 06, 2006**

**Case Serial Number: 09/607602**

**From: Noble Jarrell**  
**Location: Biotech-Chem Library**  
**Rem 1B71**  
**Phone: 272-2556**

**Noble.jarrell@uspto.gov**

### **Search Notes**

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:57:17 ON 06 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jul 2006 VOL 145 ISS 2  
FILE LAST UPDATED: 5 Jul 2006 (20060705/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l33 tot

L33 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:433672 HCAPLUS

DN 140:412026

ED Entered STN: 28 May 2004

TI Chewable solid unit dosage forms and methods for delivery of active agents such as fluoride into occlusal surfaces of teeth

IN Scott, Douglas Craig; Eversole, Sandra Lynn; Burgess, Steven Carl; Best, John Michael; Faller, Robert Vincent

PA USA

SO U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K-0007/16

INCL 424049000

CC 62-7 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2004101493	A1	20040527	2003US-0706103	20031112
	CA---2504488	AA	20040610	2003CA-2504488	20031125
	CA---2504489	AA	20040610	2003CA-2504489	20031125
	WO2004047784	A1	20040610	2003WO-US37879	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO2004047785	A1	20040610	2003WO-US37880	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,				

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU2003293110 A1 20040618 2003AU-0293110 20031125  
 AU2003298723 A1 20040618 2003AU-0298723 20031125  
 EP---1565154 A1 20050824 2003EP-0790102 20031125  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 EP---1575543 A1 20050921 2003EP-0796480 20031125  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN---1713884 A 20051228 CN 2003-80103898 20031125  
 CN---1713886 A 20051228 CN 2003-80103910 20031125  
 JP2006509767 T2 20060323 2004JP-0555782 20031125  
 JP2006509768 T2 20060323 2004JP-0555783 20031125  
 PRAI 2002US-429234P P 20021126  
 2003WO-US37879 W 20031125  
 2003WO-US37880 W 20031125

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004101493	ICM	A61K-0007/16
	INCL	424049000
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]
	NCL	424/049.000
	ECLA	A61K009/00M18B
CA---2504488	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
CA---2504489	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
WO2004047784	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
WO2004047785	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
AU2003293110	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
AU2003298723	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
EP---1565154	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
EP---1575543	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
	ECLA	A61K009/00M18B
CN---1713884	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
CN---1713886	IPCI	A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
JP2006509767	IPCI	A61K0008-00 [I,A]; A61Q0011-00 [I,A]; A61K0008-21 [I,A]; A61K0008-19 [I,C*]
	FTERM	4C083/AB172; 4C083/AB222; 4C083/AB281; 4C083/AB282; 4C083/AB292; 4C083/AB312; 4C083/AB322; 4C083/AB332; 4C083/AB442; 4C083/AB471; 4C083/AB472; 4C083/AC132; 4C083/AC242; 4C083/AC442; 4C083/AC541; 4C083/AC712; 4C083/AC742; 4C083/AC782; 4C083/AC812; 4C083/AC852; 4C083/AC862; 4C083/AD041; 4C083/AD042; 4C083/AD071; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD111; 4C083/AD112; 4C083/AD131; 4C083/AD211; 4C083/AD212; 4C083/AD222; 4C083/AD241; 4C083/AD242; 4C083/AD262; 4C083/AD271; 4C083/AD272; 4C083/AD281; 4C083/AD282;

4C083/AD301; 4C083/AD302; 4C083/AD351; 4C083/AD352;  
 4C083/AD412; 4C083/AD611; 4C083/BB21; 4C083/BB41;  
 4C083/BB48; 4C083/CC41; 4C083/DD21; 4C083/EE32;  
 4C083/EE35; 4C083/EE36; 4C083/EE37  
 JP2006509768 IPCI A61K0008-00 [I,A]; A61Q0011-00 [I,A]; A61K0009-20 [I,A]  
 FTERM 4C076/AA37; 4C076/BB22; 4C076/CC04; 4C076/CC31;  
 4C076/CC50; 4C076/DD25; 4C076/DD26; 4C076/DD27;  
 4C076/DD28; 4C076/DD29; 4C076/DD50; 4C076/DD51;  
 4C076/EE03; 4C076/FF06; 4C076/FF70; 4C083/AB03;  
 4C083/AB21; 4C083/AB24; 4C083/AB28; 4C083/AB31;  
 4C083/AB32; 4C083/AB33; 4C083/AB38; 4C083/AB43;  
 4C083/AB44; 4C083/AB47; 4C083/AC54; 4C083/AC58;  
 4C083/AD02; 4C083/AD61; 4C083/BB55; 4C083/CC41;  
 4C083/DD21; 4C083/EE31  
 AB The present invention relates to methods and an oral care composition for  
 topical, oral administration in a human or other animal comprising (a)  
 from about 1% to about 40%, by weight of the composition, of a retentive agent  
 selected from the group consisting of water soluble hydrophilic gums, water  
 soluble hydrophilic polymers, and mixts. thereof, the retentive agent having  
 the property of hydrating upon exposure to water or saliva resulting in  
 the composition forming an intact hydrated mass to provide a Retention Index of  
 about 1 to about 4; and (b) a safe and effective amount of a topical, oral  
 care carrier; wherein the composition is a non-cariogenic, chewable solid unit  
 dosage form; and the composition comprises less than about 65% by weight of water  
 insol. particulates. The present invention further relates to an oral  
 care dentifrice composition comprising: (a) from about 30% to about 65%, by weight  
 of the composition, of a water insol., particulate retentive agent having a  
 water solubility of less than about 1 g/30 g at 25°; (b) a safe and  
 effective amount of an oral care active; (c) a safe and effective amount of a  
 surfactant; and (d) a safe and effective amount of a buffer; wherein the  
 composition is a chewable dentifrice solid unit dosage form, is  
 non-effervescent, non-cariogenic; and wherein the composition has a Retention  
 Index of from about 1 to about 4. For example, chewable compressed  
 tablets containing stannous fluoride were made by conventional processing  
 techniques.  
 ST chewable tablet dentifrice active agent delivery tooth  
 IT **Antihistamines**  
 (H2; chewable solid composition for delivery of active agents into  
 occlusal surfaces of teeth)  
 IT **Dentifrices**  
 (anticalculus; chewable solid composition for delivery of active  
 agents into occlusal surfaces of teeth)  
 IT **Anesthetics**  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Buffers  
**Dentifrices**  
 Fungicides  
 Gums and Mucilages  
 Surfactants  
 Whitening agents  
 (chewable solid composition for delivery of active agents into occlusal  
 surfaces of teeth)  
 IT **Kaolin, biological studies**  
 Mica-group minerals, biological studies  
 Mineral elements, biological studies  
 Polymers, biological studies  
 Vitamins  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (chewable solid composition for delivery of active agents into occlusal  
 surfaces of teeth)  
 IT **Tooth mineralization**  
 (remineralization, agents for; chewable solid composition for delivery of  
 active agents into occlusal surfaces of teeth)  
 IT **Drug delivery systems**

(tablets, chewable; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Mica-group minerals, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (titanium; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT 123-03-5, Cetylpyridinium chloride 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1314-13-2, Zinc oxide, biological studies 1327-43-1, Magnesium aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 3380-34-5, Triclosan 7447-39-4, Copper chloride, biological studies 7646-85-7, Zinc chloride, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-93-9, Dicalcium phosphate 7758-29-4, Sodium tripolyphosphate 7783-47-3, Stannous fluoride 7787-59-9, Bismuth oxychloride 7790-76-3, Calcium pyrophosphate 10163-15-2, Sodium monofluorophosphate 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 16984-48-8, Fluoride, biological studies 18472-51-0, Chlorhexidine gluconate  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT 9002-88-4, Polyethylene 9003-53-6, Polystyrene  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (powder; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

L33 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:100955 HCAPLUS

DN 140:157441

ED Entered STN: 08 Feb 2004

TI Cyclooxygenase- 2 selective inhibitors, compositions and methods of use

IN Garvey, David S.; Khanapure, Subhash P.; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.

PA Nitromed, Inc., USA

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-7 (Pharmacology)

Section cross-reference(s): 7

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2004010945	A2	20040205	2003WO-US23605	20030729
WO2004010945	A3	20040422		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2493156	AA	20040205	2003CA-2493156	20030729
AU2003261281	A1	20040216	2003AU-0261281	20030729
US2004072883	A1	20040415	2003US-0628375	20030729
EP---1542972	A2	20050622	2003EP-0772004	20030729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

JP2005538110	T2	20051215	2004JP-0524981	20030729
PRAI 2002US-398829P	P	20020729		
2003WO-US23605	W	20030729		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004010945	ICM	A61K
	IPCI	A61K [ICM,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
CA---2493156	IPCI	C07D0401-04 [ICM,7]; C07D0401-00 [ICM,7,C*]; A61P0029-00 [ICS,7]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0207-325 [ICS,7]; C07D0207-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
AU2003261281	IPCI	C07D0207-325 [ICM,7]; C07D0207-00 [ICM,7,C*]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0403-04 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0413-04 [ICS,7]; C07D0413-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]; A61P0029-00 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
US2004072883	IPCI	A61K0031-427 [ICM,7]; A61K0031-422 [ICS,7]; A61K0031-4015 [ICS,7]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]; C07D0413-02 [ICS,7]; C07D0413-00 [ICS,7,C*]
	IPCR	A61K0031-4015 [I,A]; A61K0031-4015 [I,C*]; A61K0031-422 [I,A]; A61K0031-427 [I,C*]; C07D0413-00 [I,C*]; C07D0413-02 [I,A]; C07D0417-00 [I,C*]; C07D0417-02 [I,A]
	NCL	514/365.000
	ECLA	C07D213/50; C07D213/55; C07D231/12B5; C07D231/14
EP---1542972	IPCI	C07D0207-325 [ICM,7]; C07D0207-00 [ICM,7,C*]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0403-04 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0413-04 [ICS,7]; C07D0413-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]; A61P0029-00 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
JP2005538110	IPCI	C07D0213-38 [ICM,7]; A61K0031-167 [ICS,7]; A61K0031-192 [ICS,7]; A61K0031-196 [ICS,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-223 [ICS,7]; A61K0031-21 [ICS,7,C*]; A61K0031-405 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-415 [ICS,7]; A61K0031-4402 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-616 [ICS,7]; A61K0031-60 [ICS,7,C*]; A61K0045-00 [ICS,7]; A61P0001-00 [ICS,7]; A61P0001-04 [ICS,7]; A61P0003-00 [ICS,7]; A61P0007-02 [ICS,7]; A61P0007-00 [ICS,7,C*]; A61P0009-00 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00 [ICS,7]; A61P0011-02 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-02 [ICS,7]; A61P0013-12 [ICS,7]; A61P0013-00 [ICS,7,C*]; A61P0015-00 [ICS,7]; A61P0017-00 [ICS,7];

A61P0019-02 [ICS,7]; A61P0019-00 [ICS,7,C\*];  
 A61P0025-04 [ICS,7]; A61P0025-28 [ICS,7]; A61P0025-00  
 [ICS,7,C\*]; A61P0027-02 [ICS,7]; A61P0027-00  
 [ICS,7,C\*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];  
 A61P0031-00 [ICS,7,C\*]; A61P0035-00 [ICS,7];  
 A61P0035-02 [ICS,7]; A61P0037-08 [ICS,7]; A61P0037-00  
 [ICS,7,C\*]; A61P0043-00 [ICS,7]; C07D0213-50 [ICS,7];  
 C07D0213-00 [ICS,7,C\*]; C07D0231-12 [ICS,7];  
 C07D0231-14 [ICS,7]; C07D0231-00 [ICS,7,C\*]  
 FTERM 4C055/AA01; 4C055/BA02; 4C055/BA06; 4C055/BA08;  
 4C055/BA18; 4C055/CA03; 4C055/CA06; 4C055/CA08;  
 4C055/CA21; 4C055/CB15; 4C055/DA01; 4C055/EA01;  
 4C084/AA19; 4C084/MA02; 4C084/NA14; 4C084/ZA02;  
 4C084/ZA07; 4C084/ZA08; 4C084/ZA16; 4C084/ZA33;  
 4C084/ZA39; 4C084/ZA45; 4C084/ZA54; 4C084/ZA59;  
 4C084/ZA66; 4C084/ZA68; 4C084/ZA81; 4C084/ZA89;  
 4C084/ZA96; 4C084/ZB11; 4C084/ZB13; 4C084/ZB26;  
 4C084/ZB27; 4C084/ZB35; 4C084/ZC20; 4C084/ZC21;  
 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC14;  
 4C086/BC17; 4C086/BC36; 4C086/DA17; 4C086/MA01;  
 4C086/MA02; 4C086/MA05; 4C086/MA09; 4C086/MA10;  
 4C086/NA14; 4C086/ZA02; 4C086/ZA07; 4C086/ZA08;  
 4C086/ZA16; 4C086/ZA33; 4C086/ZA39; 4C086/ZA45;  
 4C086/ZA54; 4C086/ZA59; 4C086/ZA66; 4C086/ZA68;  
 4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB11;  
 4C086/ZB13; 4C086/ZB26; 4C086/ZB27; 4C086/ZB35;  
 4C086/ZC20; 4C086/ZC21; 4C206/AA01; 4C206/AA02;  
 4C206/AA03; 4C206/DA22; 4C206/DA24; 4C206/DA25;  
 4C206/FA31; 4C206/FA44; 4C206/GA02; 4C206/GA31;  
 4C206/JA76; 4C206/MA01; 4C206/MA02; 4C206/MA04;  
 4C206/MA12; 4C206/NA14; 4C206/ZA02; 4C206/ZA07;  
 4C206/ZA08; 4C206/ZA16; 4C206/ZA33; 4C206/ZA39;  
 4C206/ZA45; 4C206/ZA54; 4C206/ZA59; 4C206/ZA66;  
 4C206/ZA68; 4C206/ZA81; 4C206/ZA89; 4C206/ZA96;  
 4C206/ZB11; 4C206/ZB13; 4C206/ZB26; 4C206/ZB27;  
 4C206/ZB35; 4C206/ZC20; 4C206/ZC21

OS MARPAT 140:157441

AB The invention describes novel cyclooxygenase 2 (COX-2) selective  
 inhibitors and novel compns. comprising at least one cyclooxygenase 2  
 (COX-2) selective inhibitor, and, optionally, at least one compound that  
 donates, transfers or releases nitric oxide, stimulates endogenous  
 synthesis of nitric oxide, elevates endogenous levels of  
 endothelium-derived relaxing factor or is a substrate for nitric oxide  
 synthase, and/or at least one therapeutic agent. The invention also  
 provides novel kits comprising at least one COX-2 selective inhibitor,  
 optionally nitrosated and/or nitrosylated, and, optionally, at least one  
 nitric oxide donor, and/or, optionally, at least one therapeutic agent.  
 The novel cyclooxygenase 2 selective inhibitors of the invention can be  
 optionally nitrosated and/or nitrosylated. The invention also provides  
 methods for treating inflammation, pain and fever; for treating and/or  
 improving the gastrointestinal properties of COX-2 selective inhibitors;  
 for facilitating wound healing; for treating and/or preventing renal  
 and/or respiratory toxicity; for treating and/or preventing other  
 disorders resulting from elevated levels of cyclooxygenase-2; and for  
 improving the cardiovascular profile of COX-2 selective inhibitors.

ST antiinflammatory analgesic antiplatelet COX2 inhibitor cancer therapy

IT Inflammation  
 (Crohn's disease; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Intestine, disease  
 (Crohn's; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Antihistamines  
 (H2; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Thiols, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(S-nitroso; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Pancreas, neoplasm  
 (Zollinger-Ellison syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Neutrophil  
 (activation; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Carcinoma  
 (adenocarcinoma; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Neutrophil  
 (adhesion; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Allergy  
 Inflammation  
 Nose, disease  
 (allergic rhinitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine  
 (anastomosis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Thromboxanes  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antagonists; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 5-HT agonists  
 Alzheimer's disease  
 Analgesics  
 Angiogenesis  
 Anti-inflammatory agents  
 Antipyretics  
 Antitumor agents  
 Arthritis  
 Asthma  
 Atherosclerosis  
 Bladder, neoplasm  
 Bone, neoplasm  
 Brain, neoplasm  
 Carcinoma  
 Cardiovascular system, disease  
 Central nervous system, disease  
 Decongestants  
 Digestive tract, disease  
 Digestive tract, neoplasm  
 Diuretics  
 Drug delivery systems  
 Dyspepsia  
 Esophagus, neoplasm  
 Eye, disease  
 Fever and Hyperthermia  
 Human  
 Inflammation  
 Kidney  
 Liver, neoplasm  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Mouth, neoplasm  
 Nephrotoxicity  
 Ovary, neoplasm  
 Pain  
 Pancreas, neoplasm  
 Platelet aggregation inhibitors  
 Prostate gland, neoplasm  
 Respiratory distress syndrome  
 Skin, neoplasm  
 Stomach, neoplasm  
 Ulcer  
 Urogenital system, disease  
 Wound healing  
 (antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Opioids  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Infection  
 (bacterial; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Skin, neoplasm  
 (basal cell carcinoma; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Carcinoma  
 Skin  
 (basal cell; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Acute myeloid leukemia  
 (basophilic leukemia; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Bronchi, disease  
 Inflammation  
 (bronchitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Disease, animal  
 (bursitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Injury  
 (central nervous system; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Ischemia  
 (cerebral; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Uterus, neoplasm  
 (cervix; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, neoplasm  
 (colon; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Mental and behavioral disorders  
 (dementia, cortical, alc.; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Mental and behavioral disorders  
 (dementia, multi-infarct; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Mental and behavioral disorders  
 (dementia, vascular; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Animal tissue  
 Organ, animal  
 (deterioration; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Tendon  
 (disease, tendinitis; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Blood vessel, disease  
 (endothelium; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, neoplasm  
 (familial polyposis; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Ulcer  
 (gastric, stress, bleeding; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Inflammation  
 Stomach, disease  
 (gastritis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Digestive tract, disease  
 (gastroesophageal reflux; antiinflammatory cyclooxygenase-2 selective  
 inhibitors)

IT Stomach, disease  
 (gastroparesis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Neutrophil  
 (infiltration; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, disease  
 (inflammatory; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Helicobacter pylori  
 (inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Central nervous system, disease  
(injury; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, disease  
(irritable bowel syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Brain, disease  
(ischemia; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Prostanoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(isoprostane, inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Leukotriene receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(leukotriene B4, antagonists; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Neoplasm  
(lips; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Infection  
(microbial; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Cell migration  
(neutrophil infiltration; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Adhesion, biological  
Cell activation  
(neutrophil; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Anti-inflammatory agents  
(nonsteroidal; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Ulcer  
(peptic; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Medical goods  
(pharmaceutical kits; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Inflammation  
Lung, disease  
(pneumonitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, neoplasm  
(polyp; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Parturition  
(premature; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Transport proteins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(proton pump, inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Kidney, neoplasm  
(renal cell carcinoma; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Carcinoma  
(renal cell; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Fibrosis  
(resulting from radiation therapy; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Antihistamines  
(sedating or nonsedating; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Shock (circulatory collapse)  
(septic; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, disease  
(short bowel syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, neoplasm  
(small; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Muscle, disease  
(spasm, menstrual; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Carcinoma

(squamous cell; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Brain, disease  
(stroke; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Mastocytoma  
(systemic mastocytosis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Inflammation  
(tendinitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Respiratory system, disease  
(toxicity; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Brain, disease  
(trauma; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Digestive tract, disease  
(ulcer, peptic; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Stomach, disease  
(ulcer, stress, bleeding; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Inflammation  
Intestine, disease  
(ulcerative colitis; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Endothelium  
(vascular, disease; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 363-24-6, PGE-2 10102-43-9, Nitric oxide, biological studies  
90880-94-7, Endothelium derived relaxing factor 329900-75-6,  
Cyclooxygenase 2 329967-85-3, Cyclooxygenase-1  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 654058-48-7P 654058-50-1P 654058-51-2P 654058-52-3P 654058-53-4P  
654058-67-0P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 654058-54-5P 654058-56-7P 654058-58-9P 654058-60-3P 654058-62-5P  
654058-64-7P 654058-68-1P 654058-70-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological studies 70-26-8, L-Ornithine 74-79-3, L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated and/or nitrosylated derivs. 103-90-2, Acetaminophen 156-86-5, L-Homoarginine 156-86-5D, L-Homoarginine, nitrosated and/or nitrosylated derivs. 372-75-8, L-Citrulline 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 51209-75-7, S-Nitrosocysteine 53054-07-2 56577-02-7, S-Nitroso-N-acetylcysteine 57564-91-7, S-Nitrosoglutathione 79032-48-7, S-Nitroso-N-acetylpenicillamine 122130-63-6, S-Nitrosocaptopril 139427-42-2, S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine 273752-78-6D, nitrosated and/or nitrosylated derivs. 654058-66-9 654058-72-7 654058-74-9 654058-76-1  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 76-05-1, Trifluoroacetic acid, reactions 79-37-8, Oxalyl chloride 553-90-2, Dimethyl oxalate 622-08-2, 2-Benzyloxyethanol 870-46-2, tert-Butyl carbazate 1073-06-9, 1-Bromo-3-fluorobenzene 1073-62-7, Benzylhydrazine hydrochloride 1778-09-2, 4'-(Methylthio)acetophenone 2043-61-0, Cyclohexanecarboxaldehyde 10297-73-1 49609-84-9 98546-51-1, 4-(Methylthio)benzenboronic acid 191220-44-7 213994-27-5 654059-12-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 149267-56-1P 346684-15-9P, Methyl (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate 640727-90-8P, Methyl (2Z)-2-hydroxy-4-[4-(methylsulfonyl)phenyl]-4-oxobut-2-enoate 654058-77-2P 654058-80-7P  
 654058-81-8P 654058-83-0P 654058-86-3P 654058-88-5P 654058-90-9P  
 654058-92-1P 654058-94-3P 654058-95-4P 654058-96-5P 654058-98-7P  
 654058-99-8P 654059-02-6P 654059-05-9P 654059-07-1P 654059-10-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (antiinflammatory cyclooxygenase-2 selective inhibitors)  
 IT 51-45-6, Histamine, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (hyperhistaminemia; antiinflammatory cyclooxygenase-2 selective inhibitors)  
 IT 1553-55-5, 3-Hydroxy-3-methylglutaryl coenzyme A 9000-96-8, Arginase  
 9002-04-4, Thrombin 80619-02-9, 5-Lipoxygenase 90119-07-6, Leukotriene A4 hydrolase 501433-35-8, Inducible nitric oxide synthase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

L33 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:511412 HCAPLUS  
 DN 139:84365  
 ED Entered STN: 04 Jul 2003  
 TI Cereal beta glucan compositions, methods of preparation and uses thereof  
 IN Redmond, Mark J.; Fielder, David A.  
 PA Ceapro Inc., Can.  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C08L-0005/00  
 ICS C08J-0005/18; C09D-0105/00; A61K-0009/70; A61K-0009/36  
 CC 17-6 (Food and Feed Chemistry)  
 Section cross-reference(s): 43, 44, 63

## FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2003054077	A1	20030703	2002WO-CA01896	20021211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2467378	AA	20030703	2002CA-2467378	20021211
AU2002347165	A1	20030709	2002AU-0347165	20021211
EP---1453909	A1	20040908	2002EP-0782583	20021211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP2005513140	T2	20050512	2003JP-0554788	20021211
US2005031674	A1	20050210	2004US-0498568	20040721
PRAI 2001US-338649P	P	20011211		
2002WO-CA01896	W	20021211		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003054077	ICM	C08L-0005/00
	ICS	C08J-0005/18; C09D-0105/00; A61K-0009/70; A61K-0009/36
	IPCI	C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00 [ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
	IPCR	A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05

[I,C\*]; A23L0001-054 [I,A]; A23L0001-10 [I,A];  
A23L0001-10 [I,C\*]; A23L0001-22 [I,A]; A23L0001-22  
[I,C\*]; A23L0001-236 [I,A]; A23L0001-236 [I,C\*];  
A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0009-28  
[I,A]; A61K0009-28 [I,C\*]; A61K0009-70 [I,A];  
A61K0009-70 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C\*];  
A61Q0019-00 [I,A]; A61Q0019-00 [I,C\*]; C08J0005-18  
[I,A]; C08J0005-18 [I,C\*]; C08L0005-00 [I,A];  
C08L0005-00 [I,C\*]; C09D0105-00 [I,A]; C09D0105-00  
[I,C\*]

ECLA A23L001/00P8B6; A23L001/054C; A23L001/10E;  
A23L001/22B10; A23L001/236; A61K008/73; A61K009/28H6F;  
A61K009/70B; A61Q011/00; A61Q013/00; A61Q019/00;  
C08J005/18+L5/00; C08L005/00; C09D105/00

CA---2467378 IPCI C08L0005-00 [ICM,7]; C09D0105-00 [ICS,7]; C08J0005-18  
[ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C\*];  
A61K0009-70 [ICS,7]

IPCR A23L0001-00 [I,A]; A23L0001-00 [I,C\*]; A23L0001-05  
[I,C\*]; A23L0001-054 [I,A]; A23L0001-10 [I,A];  
A23L0001-10 [I,C\*]; A23L0001-22 [I,A]; A23L0001-22  
[I,C\*]; A23L0001-236 [I,A]; A23L0001-236 [I,C\*];  
A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0009-28  
[I,A]; A61K0009-28 [I,C\*]; A61K0009-70 [I,A];  
A61K0009-70 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C\*];  
A61Q0019-00 [I,A]; A61Q0019-00 [I,C\*]; C08J0005-18  
[I,A]; C08J0005-18 [I,C\*]; C08L0005-00 [I,A];  
C08L0005-00 [I,C\*]; C09D0105-00 [I,A]; C09D0105-00  
[I,C\*]

AU2002347165 IPCI C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00  
[ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7];  
A61K0009-30 [ICS,7,C\*]

IPCR A23L0001-00 [I,A]; A23L0001-00 [I,C\*]; A23L0001-05  
[I,C\*]; A23L0001-054 [I,A]; A23L0001-10 [I,A];  
A23L0001-10 [I,C\*]; A23L0001-22 [I,A]; A23L0001-22  
[I,C\*]; A23L0001-236 [I,A]; A23L0001-236 [I,C\*];  
A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0009-28  
[I,A]; A61K0009-28 [I,C\*]; A61K0009-70 [I,A];  
A61K0009-70 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C\*];  
A61Q0019-00 [I,A]; A61Q0019-00 [I,C\*]; C08J0005-18  
[I,A]; C08J0005-18 [I,C\*]; C08L0005-00 [I,A];  
C08L0005-00 [I,C\*]; C09D0105-00 [I,A]; C09D0105-00  
[I,C\*]

EP---1453909 IPCI C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00  
[ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7];  
A61K0009-30 [ICS,7,C\*]

IPCR A23L0001-00 [I,A]; A23L0001-00 [I,C\*]; A23L0001-05  
[I,C\*]; A23L0001-054 [I,A]; A23L0001-10 [I,A];  
A23L0001-10 [I,C\*]; A23L0001-22 [I,A]; A23L0001-22  
[I,C\*]; A23L0001-236 [I,A]; A23L0001-236 [I,C\*];  
A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0009-28  
[I,A]; A61K0009-28 [I,C\*]; A61K0009-70 [I,A];  
A61K0009-70 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C\*];  
A61Q0019-00 [I,A]; A61Q0019-00 [I,C\*]; C08J0005-18  
[I,A]; C08J0005-18 [I,C\*]; C08L0005-00 [I,A];  
C08L0005-00 [I,C\*]; C09D0105-00 [I,A]; C09D0105-00  
[I,C\*]

JP2005513140 IPCI A61K0047-36 [ICM,7]; A23L0001-22 [ICS,7]; A61J0003-06  
[ICS,7]; A61J0003-07 [ICS,7]; A61K0009-08 [ICS,7];  
A61K0009-107 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30  
[ICS,7,C\*]; A61K0009-48 [ICS,7]; A61K0009-70 [ICS,7];  
A61K0047-46 [ICS,7]; A61M0029-02 [ICS,7]; A61P0001-12  
[ICS,7]; A61P0001-00 [ICS,7,C\*]; A61P0009-10 [ICS,7];

A61P0009-00 [ICS,7,C\*]; A61P0011-00 [ICS,7];  
 A61P0011-10 [ICS,7]; A61P0025-00 [ICS,7]; A61P0025-04  
 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-26 [ICS,7];  
 A61P0025-28 [ICS,7]; A61P0029-00 [ICS,7]; A61P0031-04  
 [ICS,7]; A61P0031-00 [ICS,7,C\*]; A61P0043-00 [ICS,7]  
 IPCR A23L0001-00 [I,A]; A23L0001-00 [I,C\*]; A23L0001-05  
 [I,C\*]; A23L0001-054 [I,A]; A23L0001-10 [I,A];  
 A23L0001-10 [I,C\*]; A23L0001-22 [I,A]; A23L0001-22  
 [I,C\*]; A23L0001-236 [I,A]; A23L0001-236 [I,C\*];  
 A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0009-28  
 [I,A]; A61K0009-28 [I,C\*]; A61K0009-70 [I,A];  
 A61K0009-70 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
 [I,C\*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C\*];  
 A61Q0019-00 [I,A]; A61Q0019-00 [I,C\*]; C08J0005-18  
 [I,A]; C08J0005-18 [I,C\*]; C08L0005-00 [I,A];  
 C08L0005-00 [I,C\*]; C09D0105-00 [I,A]; C09D0105-00  
 [I,C\*]  
 FTERM 4B047/LB02; 4B047/LE10; 4B047/LG05; 4B047/LP09;  
 4C076/AA12; 4C076/AA17; 4C076/AA44; 4C076/AA45;  
 4C076/AA60; 4C076/AA74; 4C076/AA94; 4C076/AA95;  
 4C076/BB01; 4C076/BB31; 4C076/CC01; 4C076/CC05;  
 4C076/CC11; 4C076/CC29; 4C076/CC32; 4C076/CC40;  
 4C076/DD01; 4C076/DD37; 4C076/DD43; 4C076/DD67;  
 4C076/EE30; 4C076/EE32; 4C076/EE53; 4C076/EE58;  
 4C076/FF25; 4C076/FF27; 4C076/FF31; 4C167/AA50;  
 4C167/BB06; 4C167/CC09; 4C167/DD01; 4C167/GG50  
 US2005031674 IPCI A61K0009-70 [ICM,7]; A61K0035-78 [ICS,7]  
 IPCR A61K0009-70 [I,A]; A61K0009-70 [I,C\*]  
 NCL 424/443.000  
 ECLA A23L001/00P8E; A23L001/10E; A23L001/22B10;  
 A23L001/236D; A23L001/30; A61K008/73; A61K009/28H6F;  
 A61L031/10+C08L5/00; A61Q011/00; A61Q013/00; A61Q019/00  
 AB Cereal  $\beta(1\rightarrow3)$   $\beta(1\rightarrow4)$  glucan is used as a film or  
 coating agent to produce clear, edible, biodegradable, delivery,  
 lubricating, and protecting agents. Cereal  $\beta(1\rightarrow3)$   $\beta$   
 $(1\rightarrow4)$  glucans are distinctive polymers of glucose differentiated  
 from other polymers by not only their source but also their physicochem.  
 properties. The  $\beta(1\rightarrow3)$   $\beta(1\rightarrow4)$  forms a matrix to  
 sequester other materials, such as pharmaceutical, medical and therapeutic  
 agents, flavors, fragrances. The technol. has applications to essential  
 oils and non-aqueous materials that are rendered deliverable by the  
 $\beta(1\rightarrow3)$   $\beta(1\rightarrow4)$  glucan. The  $\beta(1\rightarrow3)$   
 $\beta(1\rightarrow4)$  glucan films described may be consumed whereby they  
 dissolve in the mouth in a controlled manner and may be used for the  
 delivery of pharmaceutical, medical or confectionery products.  
 ST cereal beta glucan film pharmaceutical medical goods confectionery  
 IT Antihistamines  
 (H2; preparation and uses of cereal beta glucan compns. for  
 delivery of pharmaceutical, medical or confectionery products)  
 IT Quaternary ammonium compounds, biological studies  
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological  
 study); USES (Uses)  
 (antimicrobial; preparation and uses of cereal beta glucan compns. for  
 delivery of pharmaceutical, medical or confectionery products)  
 IT Drug delivery systems  
 (capsules; preparation and uses of cereal beta glucan compns. for delivery  
 of pharmaceutical, medical or confectionery products)  
 IT Dentifrices  
 (dental floss; preparation and uses of cereal beta  
 glucan compns. for delivery of pharmaceutical, medical or confectionery  
 products)  
 IT Food  
 (films; preparation and uses of cereal beta glucan compns. for delivery of  
 pharmaceutical, medical or confectionery products)  
 IT Anti-inflammatory agents  
 Antidiarrheals

Antihistamines  
 Antimicrobial agents  
 Antiparkinsonian agents  
 Antipyretics  
 Antitussives  
 Avena sativa  
 Cereal (grain)  
 Confectionery  
 Decongestants  
 Drugs  
 Expectorants  
 Flavor  
 Flavoring materials  
 Food emulsions  
 Hordeum vulgare  
 Narcotics  
 Nervous system agents  
 Nervous system depressants  
 Nervous system stimulants  
 Odor and Odorous substances  
 Panicum  
 Secale cereale  
 Sorghum bicolor  
 Sweetening agents  
 Triticum aestivum  
 Zea mays

- (preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT Essential oils
- RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT Medical goods
- (stents; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT Drug delivery systems
- (tablets; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT Paper
- (tissue; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT 60-00-4, EDTA, biological studies 89-78-1, Menthol 89-83-8, Thymol 119-36-8, Methyl salicylate 123-03-5, Cetyl pyridinium chloride 470-82-6, Eucalyptol 538-71-6, Domiphen bromide 2447-54-3, Sanguinarine 3380-34-5, Triclosan 7440-66-6D, Zinc, compds. 7761-88-8, Silver nitrate, biological studies 16984-48-8, Fluoride, biological studies 22573-93-9, Alexidine 71251-02-0, Octenidine
- RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (antimicrobial; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT 9041-22-9P,  $\beta$  Glucan
- RL: FFD (Food or feed use); IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
- (preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)
- IT 55589-62-3, Acesulfame potassium
- RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; PATENT ABSTRACTS OF JAPAN 1996, V1996(11)
- (2) Brennen Medical Inc; WO--02076358 A 2002
- (3) Fuji Capsule Kk; JP--08169817 A 1996 HCAPLUS
- (4) Fuji Capsule Kk; JP--08169817 A 1996 HCAPLUS
- (5) Granate Seed Limited; WO---0157092 A 2001 HCAPLUS
- (6) Industrial Research Limited; WO---9813056 A 1998
- (7) Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo; FR---2537496 A 1984 HCAPLUS
- (8) Marine Bioproducts International; WO--02072687 A 2002
- (9) New Zealand Institute For Crop And Food Research Limited; WO---0056268 A 2000 HCAPLUS
- (10) Potter; US---6323338 B1 2001 HCAPLUS
- (11) Provonchee; US---4774093 A 1998 HCAPLUS
- (12) Takeda Chemical Industries Ltd; EP--0328317 A 1989 HCAPLUS
- (13) Warner-Lambert Company; WO---0018365 A 2000 HCAPLUS
- (14) Williams; US---5676967 A 1997 HCAPLUS

L33 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:397376 HCAPLUS

DN 127:23599

ED Entered STN: 27 Jun 1997

TI Enhanced anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils

IN Pan, Pauline; Sturdivant, Linda D.; Rubin, Michael

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0007/16

ICS A61K-0007/26; A61K-0035/78

CC 62-7 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9716159	A1	19970509	1996WO-US16948	19961023 <--
	W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU---9674680	A1	19970522	1996AU-0074680	19961023 <--
PRAI	1995US-0550045	A	19951030	<--	
	1996WO-US16948	W	19961023	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9716159	ICM	A61K-0007/16
	ICS	A61K-0007/26; A61K-0035/78
	IPCI	A61K0007-16 [ICM,6]; A61K0007-26 [ICS,6]; A61K0035-78 [ICS,6]
	IPCR	A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K008/49H; A61K008/92C; A61K035/78+M; A61Q011/00
AU---9674680	IPCI	A61K0007-16 [ICM,6]; A61K0007-26 [ICS,6]; A61K0035-78 [ICS,6]
	IPCR	A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

AB An anti-inflammatory oral composition that is effective in preventing and treating gingivitis and periodontitis contains an H2 receptor antagonist and antimicrobial oils. A method of preventing or treating inflammations in the oral cavity by applying an effective amount of the anti-inflammatory oral composition to the oral cavity is also provided. The H2 receptor antagonists include ranitidine, cimetidine, nizatidine, and famotidine and

the antimicrobial oils are selected from the group consisting of thymol, Me salicylate, menthol, eucalyptol, spearmint oil, cinnamon oil, clove oil, rosemary oil, and peppermint oil. The oral compns. are preferably in the forms of toothpastes, mouthwashes, and the like.

- ST dentifrice antiinflammatory H2 receptor antagonist bactericide
- IT Antihistamines  
(H2; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Anti-inflammatory agents  
Antimicrobial agents  
Dentifrices  
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Alkali metal fluorides  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Essential oils  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cinnamon; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Essential oils  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(clove; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Gingiva  
(gingivitis; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Drug delivery systems  
(oral; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Essential oils  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peppermint; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Periodontium  
(periodontitis; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Essential oils  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(rosemary; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT Essential oils  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(spearmint; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)
- IT 89-78-1, Menthol 89-83-8, Thymol 119-36-8, Methyl salicylate 470-82-6, Eucalyptol 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid 51481-61-9, Cimetidine 59481-66-2, 66357-35-5, Ranitidine 74847-31-7 76824-35-6, Famotidine 76963-41-2, Nizatidine  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

=> d all,134 tot

L34 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

noble jarrell 06/07/2006

AN 2004:162193 HCAPLUS  
 DN 140:204860  
 ED Entered STN: 29 Feb 2004  
 TI Method of applying oral composition  
 IN Moneuze, Gaelle; Strand, Ross; White, Christopher David; Williams, Michael Kevin  
 PA The Procter & Gamble Company, USA  
 SO U.S. Pat. Appl. Publ., 9 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16  
 ICS A61K-0007/18  
 INCL 424049000; X42-4 5.2  
 CC 62-7 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 63

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2004037789	A1	20040226	2003US-0641430	20030815
	EP---1393710	A1	20040303	2002EP-0255842	20020821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA---2492790	AA	20040304	2003CA-2492790	20030820
	WO2004017933	A1	20040304	2003WO-US26269	20030820
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2003262777	A1	20040311	2003AU-0262777	20030820
	EP---1542651	A1	20050622	2003EP-0793258	20030820
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1674860	A	20050928	2003CN-0818903	20030820
	JP2005537310	T2	20051208	2004JP-0529819	20030820
PRAI	2002EP-0255842	A	20020821		
	2003WO-US26269	W	20030820		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004037789	ICM	A61K-0007/16
	ICS	A61K-0007/18
	INCL	424049000; X42-4 5.2
	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
	ECLA	A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M; A61Q011/00
EP---1393710	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M; A61Q011/00
CA---2492790	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49

[I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A];  
A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
WO2004017933 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-34 [I,A]; A61K0008-49  
[I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A];  
A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
ECLA A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M;  
A61Q011/00  
AU2003262777 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-34 [I,A]; A61K0008-49  
[I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A];  
A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
EP---1542651 IPCI A61K0007-16 [ICM,7]  
CN---1674860 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-34 [I,A]; A61K0008-49  
[I,A]; A61K0008-72 [I,C\*]; A61K0008-73 [I,A];  
A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
JP2005537310 IPCI A61K0007-16 [ICM,7]  
FTERM 4C083/AC121; 4C083/AC122; 4C083/AC131; 4C083/AC132;  
4C083/AC691; 4C083/AC692; 4C083/AC811; 4C083/AC812;  
4C083/AC862; 4C083/AD111; 4C083/AD112; 4C083/AD281;  
4C083/AD282; 4C083/BB55; 4C083/CC41; 4C083/DD41;  
4C083/EE32; 4C083/EE33; 4C083/EE34; 4C083/EE36  
AB The present invention relates to a method of applying oral care benefit  
agent to the oral tissues. More specifically, a method for treating an  
oral cavity is provided comprising the application of an aqueous composition  
comprising oral care benefit agents to a large proportion of the oral  
cavity, application occurring as part of the daily oral care routine  
shortly before retiring, and the composition remaining in contact with the oral  
tissues while sleeping. The method and aqueous compns. of the invention  
provide overnight application and delivery of oral care benefit agents  
with improved ease of use and consumer aesthetics. Thus, a formulation  
contained water 66.90, HPMC 3.30, sodium saccharin 0.20, cetylpyridinium  
chloride 1.00, propylene glycol 22.00, xylitol 6.00, and flavor 0.80%.  
ST oral thickener alc polymer  
IT Alcohols, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(C1-6; method of applying oral composition)  
IT Antihistamines  
(H2; method of applying oral composition)  
IT Tooth, disease  
(calculus; method of applying oral composition)  
IT Calculi  
(dental; method of applying oral composition)  
IT Dentifrices  
(gels; method of applying oral composition)  
IT Abrasives  
Antimicrobial agents  
Antioxidants  
Humectants  
Nutrients  
Shear  
Thickening agents  
Viscosity  
(method of applying oral composition)  
IT Alditols  
Clays, biological studies  
Glycols, biological studies  
Polyoxyalkylenes, biological studies  
Polysaccharides, biological studies  
Polysiloxanes, biological studies  
Proteins

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(method of applying oral composition)

IT Tooth, disease  
(plaque; method of applying oral composition)

IT Alcohols, biological studies  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(polyhydric; method of applying oral composition)

IT 9011-16-9, Gantrez AN 69  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(Gantrez AN 69; method of applying oral composition)

IT 79-10-7D, Acrylic acid, esters, polymers  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(crosslinked; method of applying oral composition)

IT 87-99-0, Xylitol 123-03-5, Cetylpyridinium chloride 3380-34-5,  
Triclosan 9004-62-0, Natrosol 250 9004-65-3, Hydroxypropyl methyl  
cellulose 16984-48-8, Fluoride, biological studies 25322-68-3,  
Polyethylene glycol  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(method of applying oral composition)

L34 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:892231 HCAPLUS  
DN 139:369392  
ED Entered STN: 14 Nov 2003  
TI Compositions comprising anionic functionalized polyorganosiloxanes for  
hydrophobically modifying surfaces and enhancing delivery of active agents  
to surfaces treated therewith  
IN Majeti, Satyanarayana; Reno, Elizabeth Ann Brown; Kovacs, Stephen Andras  
PA The Procter & Gamble Company, USA  
SO U.S. Pat. Appl. Publ., 17 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
IC ICM A61K-0007/16  
ICS A61K-0007/20  
INCL 424049000; 424053000  
CC 62-7 (Essential Oils and Cosmetics)  
Section cross-reference(s): 46, 63  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US2003211050	A1	20031113	2003US-0430520	20030506
AU2003233532	A1	20031111	2003AU-0233532	20030509
CA---2483928	AA	20031120	2003CA-2483928	20030509
WO2003095559	A1	20031120	2003WO-US14696	20030509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP---1501895	A1	20050202	2003EP-0728810	20030509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN---1653136	A	20050810	2003CN-0810360	20030509
JP2005524750	T2	20050818	2004JP-0503560	20030509
RU---2271376	C2	20060310	2004RU-0135919	20030509
ZA2004008527	A	20050622	2004ZA-0008527	20041021
PRAI 2002US-378997P	P	20020509		
2003WO-US14696	W	20030509		

CLASS  
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

```

-----
US 2003211050  ICM  A61K-0007/16
                ICS  A61K-0007/20
                INCL  424049000; 424053000
                IPCI  A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
                NCL  424/049.000
AU2003233532  IPCI  C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00
                [ICS,7,C*]; A61K0007-16 [ICS,7]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
CA---2483928  IPCI  C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00
                [ICS,7,C*]; A61K0007-16 [ICS,7]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
WO2003095559  IPCI  C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00
                [ICS,7,C*]; A61K0007-16 [ICS,7]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
EP---1501895  IPCI  C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00
                [ICS,7,C*]; A61K0007-16 [ICS,7]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
CN---1653136  IPCI  C08L0083-04 [ICM,7]; A61K0007-16 [ICS,7]; C08L0083-10
                [ICS,7]; C08L0083-00 [ICS,7,C*]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
JP2005524750  IPCI  C08L0083-04 [ICM,7]; C08L0083-00 [ICM,7,C*];
                A61K0007-00 [ICS,7]; A61K0007-16 [ICS,7]; A61K0007-24
                [ICS,7]; C08G0077-04 [ICS,7]; C08G0077-00 [ICS,7,C*];
                C08K0003-00 [ICS,7]
                IPCR  A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A];
                C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S];
                C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10
                [I,A]
                FTERM  4C083/AB172; 4C083/AB212; 4C083/AB282; 4C083/AB412;
                4C083/AB472; 4C083/AC032; 4C083/AC072; 4C083/AC122;
                4C083/AC132; 4C083/AC392; 4C083/AC482; 4C083/AC532;
                4C083/AC562; 4C083/AC782; 4C083/AC852; 4C083/AC862;
                4C083/AD022; 4C083/AD042; 4C083/AD092; 4C083/AD161;
                4C083/AD162; 4C083/AD242; 4C083/AD352; 4C083/AD662;
                4C083/CC41; 4C083/EE31; 4C083/EE35; 4J002/CP051;
                4J002/DE046; 4J002/DE196; 4J002/DE206; 4J002/DE226;
                4J002/DG056; 4J002/DK006; 4J002/FD206; 4J002/GB01;
                4J246/AA03; 4J246/AB01; 4J246/BA02X; 4J246/BA020;
                4J246/BB02X; 4J246/BB020; 4J246/BB022; 4J246/CA01U;
                4J246/CA010; 4J246/CA26M; 4J246/CA260; 4J246/CA27M;
                4J246/CA27X; 4J246/CA270; 4J246/CA52M; 4J246/CA520;
                4J246/CA53M; 4J246/CA53X; 4J246/CA530; 4J246/CA58M;
                4J246/CA58U; 4J246/CA580; 4J246/CA63M; 4J246/CA630;
                4J246/CA64M; 4J246/CA640; 4J246/CA76M; 4J246/CA760;
                4J246/CB03; 4J246/FA222; 4J246/FC162; 4J246/GC30;
                4J246/GC49; 4J246/HA36; 4J246/HA52; 4J246/HA53
RU---2271376  IPCI  C08L0083-04 [I,A]; C08L0083-10 [I,A]; C08L0083-00
                [I,C*]; A61K0006-093 [I,A]; A61K0006-02 [I,C*]
ZA2004008527  IPCI  A61K [ICM,7]; C08L [ICS,7]
AB Disclosed are compns. and methods for treating and modifying surfaces and

```

for enhancing delivery of active agents to surfaces treated therewith, wherein the compns. comprise siloxane polymers functionalized with pendant moieties comprising two or more anionic groups, at least one anionic group being a carboxy group. When applied to a suitable surface, the present composition forms a substantially hydrophobic coating of the anionic functionalized siloxane polymer on the treated surface. These polymers effectively deposit on surfaces that have cationic sites, which are capable of forming bonds or linkages with the anionic groups of the polymer. The treated surface becomes hydrophobic due to the deposition of the anionic functionalized siloxane polymer, which then imparts a variety of end use benefits to that surface such as ease of cleaning, soil release, stain removal and prevention, conditioning, etc. The anionic functionalized siloxane polymer further acts as a carrier to deposit active agents onto the surface and to improve retention and efficacy of the active agents on the treated surface. The present compns. are useful in a variety of applications including oral care, hair and skin care, personal care, cosmetics, and fabric and hard surface cleaning and conditioning. For example, a denture adhesive cream can be made by blending together white mineral oil 23.93, white petrolatum 21.77, CM-cellulose sodium 20.00, colloidal silica 1.14, colorant 0.06, functionalized siloxane polymer (polysiloxane functionalized with malic acid or phthalic anhydride) 0.10, and alkyl vinyl ether-maleic acid (AVE/MA) copolymer salt 33.00 parts.

ST anionic functionalized polysiloxane hydrophobic coating surface treatment; cosmetic dentifrice anionic functionalized polysiloxane

IT Antihistamines

(H2; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Polysiloxanes, biological studies

RL: COS (Cosmetic use); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)

(anionic group-containing; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Dentifrices

(chewing gums; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Textiles

(cleaning and conditioning; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Cosmetics

Wipes

(cleansing; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Analgesics

Anti-inflammatory agents

Antimicrobial agents

Antiviral agents

Bleaching agents

Cosmetics

Dentifrices

Hair preparations

Mouthwashes

Shampoos

Softening agents

Whitening agents

(compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Chlorites

Peroxides, biological studies

Peroxy acids

## Peroxysulfates

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (compsn. comprising anionic functionalized polysiloxanes for  
 hydrophobically modifying surfaces and enhancing delivery of active  
 agents)

- IT Chewing gum  
 (dentifrices; compns. comprising anionic functionalized polysiloxanes  
 for hydrophobically modifying surfaces and enhancing delivery of active  
 agents)
- IT Dental materials and appliances  
 (denture adhesives; compns. comprising anionic functionalized  
 polysiloxanes for hydrophobically modifying surfaces and enhancing  
 delivery of active agents)
- IT Drug delivery systems  
 (gels, topical; compns. comprising anionic functionalized polysiloxanes  
 for hydrophobically modifying surfaces and enhancing delivery of active  
 agents)
- IT Detergents  
 (liquid; compns. comprising anionic functionalized polysiloxanes for  
 hydrophobically modifying surfaces and enhancing delivery of active  
 agents)
- IT Cosmetics  
 (lotions; compns. comprising anionic functionalized polysiloxanes for  
 hydrophobically modifying surfaces and enhancing delivery of active  
 agents)
- IT 88-99-3D, Phthalic acid, reaction products with polysiloxanes 123-03-5,  
 Cetylpyridinium chloride 124-43-6 563-69-9D, Carbonoperoxoic acid,  
 salts 1305-79-9, Calcium peroxide 3380-34-5, Triclosan 6915-15-7D,  
 Malic acid, reaction products with polysiloxanes 7722-84-1, Hydrogen  
 peroxide, biological studies 7758-19-2, Sodium chlorite 12674-33-8D,  
 Perboric acid, salts 14314-27-3, Potassium chlorite 15630-89-4, Sodium  
 percarbonate  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (compsn. comprising anionic functionalized polysiloxanes for  
 hydrophobically modifying surfaces and enhancing delivery of active  
 agents)

L34 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:874766 HCAPLUS

DN 139:354473

ED Entered STN: 07 Nov 2003

TI Promoting whole body health with topical oral compositions containing  
 antimicrobials

IN Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph  
 ; Glandorf, William Michael; White, Donald James

PA The Procter & Gamble Company, USA

SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 39,620.  
 CODEN: USXXCO

DT Patent

LA English

IC ICM A61K-0007/16

ICS A61K-0007/28

INCL 424049000; 424050000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 62

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US2003206874	A1	20031106	2003US-0454843	20030605
	US---5939052	A	19990817	1996US-0754577	19961121
	US---6350436	B1	20020226	1999US-0451420	19991130
	US---6555094	B1	20030429	2000US-0710440	20001110
	US2002106336	A1	20020808	2001US-0039620	20011024
	US---6667027	B2	20031223		
	US2003152527	A1	20030814	2003US-0351205	20030124
	US---6821507	B2	20041123		

US2005112070	A1	20050526	2004US-0975963	20041028
PRAI 1996US-0754577	A2	19961121		
1998US-0203216	B2	19981130		
1999US-0451420	A3	19991130		
2000US-0607240	A2	20000630		
2000US-0710440	A2	20001110		
2001US-0039620	A2	20011024		
1999US-165350P	P	19991112		
2003US-0351205	A3	20030124		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003206874	ICM	A61K-0007/16
	ICS	A61K-0007/28
	INCL	424049000; 424050000
	IPCI	A61K0007-16 [ICM,7]; A61K0007-28 [ICS,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
	ECLA	A61Q011/00; A61K008/19; A61K008/21; A61K008/24; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06
US---5939052	IPCI	A61K0007-16 [ICM,6]; A61K0007-18 [ICS,6]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-72 [I,C*]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/057.000
	ECLA	A61Q011/00; A61K008/19; A61K008/21; A61K008/24; A61K008/90
US---6350436	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/059.000
	ECLA	A61K007/16B; A61K007/16D8; A61K007/16P; A61K008/21; A61K008/24; A61Q011/00
US---6555094	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/057.000
	ECLA	A61K008/19; A61K008/21; A61K008/24; A61Q011/00
US2002106336	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/057.000
	ECLA	A61K007/16B; A61K008/24; A61Q011/00; A61K007/16D8; A61K007/16P; A61K008/21
US2003152527	IPCI	A61K0007-18 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000

US2005112070 ECLA A61K008/19; A61K008/21; A61K008/24; A61K008/365;  
A61K008/73; A61K008/73C; A61K008/81; A61K008/81K2;  
A61K008/90; A61Q011/00  
IPCI A61K0007-18 [ICM,7]  
IPCR A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-21  
[I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C\*];  
A61K0008-365 [I,A]; A61K0008-72 [I,C\*]; A61K0008-73  
[I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A];  
A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
NCL 424/052.000  
ECLA A61K008/19; A61K008/21; A61K008/24; A61K008/365;  
A61K008/73; A61K008/73C; A61K008/81; A61K008/81K2;  
A61K008/90; A61Q011/00

AB The present invention relates to promoting whole body health by using  
topical oral compns. comprising an antimicrobial agent, in particular  
stannous salts, such as stannous fluoride and stannous chloride in  
combination with a polymeric mineral surface active agent such as  
condensed polyphosphates or polyphosphonates. In addition to providing a  
spectrum of intraoral benefits, topical administration of the present  
compns. to the oral cavity surprisingly provides benefits to systemic  
health. In particular, the present invention relates to methods of using  
the present topical oral compns. to reduce the risk in development of  
cardiovascular disease, stroke, atherosclerosis, diabetes, severe  
respiratory infections, premature births and low birth weight, post-partum  
dysfunction in neurol. and developmental functions, and associated increased  
risk of mortality. For example, a mouthwash composition contained flavor 0.05,  
FD&C Blue number 1 0.02, Na saccharin 0.06, glycerin 7.5, stannous chloride  
0.2, cetylpyridinium chloride 0.045, polyphosphonate 0.5, Na gluconate,  
ethanol 14.46, and water balance to 100 %.

ST dentifrice stannous compd polyphosphate systemic therapeutic effect

IT Antihistamines  
(H2; topical compns. for oral cavity containing stannous compds.  
and polyphosphates and addnl. drugs for promoting whole body health)

IT Quaternary ammonium compounds, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkylbenzyltrimethyl, chlorides; topical compns. for oral cavity containing  
stannous compds. and polyphosphates and addnl. drugs for promoting  
whole body health)

IT Cytokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; topical compns. for oral cavity containing stannous compds.  
and polyphosphates and addnl. drugs for promoting whole body health)

IT Redox reaction  
(biochem., modifiers; topical compns. for oral cavity containing stannous  
compds. and polyphosphates and addnl. drugs for promoting whole body  
health)

IT Drug delivery systems  
(buccal, sprays; topical compns. for oral cavity containing stannous  
compds. and polyphosphates and addnl. drugs for promoting whole body  
health)

IT Lipopolysaccharides  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(complexing agents; topical compns. for oral cavity containing stannous  
compds. and polyphosphates and addnl. drugs for promoting whole body  
health)

IT Drug delivery systems  
(lozenges; topical compns. for oral cavity containing stannous compds. and  
polyphosphates and addnl. drugs for promoting whole body health)

IT Analgesics  
Anti-inflammatory agents  
Antimicrobial agents  
Chewing gum  
Dentifrices  
Human  
Immunostimulants  
Mouthwashes

(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Bacteriocins  
Essential oils  
Growth factors, animal  
Hormones, animal, biological studies  
Minerals, biological studies  
Polyphosphates  
Polyphosphoric acids  
Vitamins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT 55-56-1, Chlorhexidine 87-17-2, Salicylanilide 123-03-5, Cetylpyridinium chloride 141-94-6, Hexetidine 538-71-6, Domiphen bromide 638-39-1, Stannous acetate 814-94-8, Stannous oxalate 815-85-0, Stannous tartrate 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 7440-50-8D, Copper, compds. 7440-66-6D, Zinc, compds. 7488-55-3, Stannous sulfate 7772-99-8, Stannous chloride, biological studies 7783-47-3, Stannous fluoride 22573-93-9, Alexidine 34509-48-3, Stannous lactate 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 35984-19-1, Stannous gluconate 67651-57-4, Triclosan monophosphate 71138-71-1, Octapinol 71251-02-0, Octenidine 79874-76-3, Delmopinol 145266-99-5, Metalloproteinase inhibitor  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

L34 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:888450 HCAPLUS  
DN 137:369112  
ED Entered STN: 22 Nov 2002  
TI Crunchy and non-cariogenic confectionery compositions for oral care  
IN Day, Trevor Neil; Greenwood, Mark; Strand, Ross  
PA The Procter & Gamble Company, USA  
SO PCT Int. Appl., 35 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
IC ICM A23G-0003/00  
ICS A61K-0007/16  
CC 17-6 (Food and Feed Chemistry)  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002091847	A1	20021121	2002WO-US15264	20020514
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2442771	AA	20021121	2002CA-2442771	20020514
EP---1392125	A1	20040303	2002EP-0769738	20020514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US2003008062	A1	20030109	2002US-0146698	20020515
US---6719962	B2	20040413		
PRAI 2001US-291167P	P	20010515		
2002WO-US15264	W	20020514		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002091847	ICM	A23G-0003/00
	ICS	A61K-0007/16
	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A23G003/00+D; A23G003/00+D4; A23G003/00+F; A23G003/00+H; A23G003/00+H6; A23G003/30+D; A23G003/30+D4; A23G003/30+F; A23G003/30+H6; A61K008/02; A61K008/19; A61K008/24; A61K008/27; A61K008/365; A61Q011/00
CA---2442771	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
EP---1392125	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
US2003008062	IPCI	A23G0003-00 [ICM,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	426/660.000
	ECLA	A23G003/00+D; A23G003/00+F; A23G003/00+H; A23G003/30+D; A23G003/30+F; A23G003/30+H; A61K008/02; A61K008/19; A61K008/24; A61K008/27; A61K008/365; A61Q011/00
AB		A crunchy, non-cariogenic oral care confectionery composition comprises: (i) from about 0.1 % to about 50 %, by weight of the composition, of an oral care active selected from the group consisting of anti-calculus agents; anti-plaque agents; desensitizing agents; oral malodor control agents; H2 antagonists; and mixts. thereof; (ii) from about 0.1 % to about 50 %, by weight of the composition, of a solid particulate wherein the solid particulate has a particle size such that passes through a 2000µm mesh and is retained by a 100µm mesh and has an aqueous solubility of at least 1 g per 100mL at 25°; (iii) greater than about 10 %, by weight of the composition, of a confectionery carrier material; and wherein compns. comprising polyphosphate with an average anion chain length of greater than or equal to 4 and having the solid particulate properties of (ii) are excluded. The present invention relates to stable, portable, oral care confectionery wherein the confectionery composition has a crunchy texture which acts to reinforce for the consumer the oral care benefit of the product. Thus, an chewing gum comprises gumbase 32.0, sorbitol 58.0, glycerin 5.0, water 1.0, zinc acetate 0.45, sodium tripolyphosphate 1.0, flavor 2.5, acesulfam K 0.05%.
ST		anticariogenic confectionery oral care odor texture
IT		<b>Antihistamines</b> (H2; crunchy and non-cariogenic confectionery compns. for oral care)
IT		<b>Polyphosphoric acids</b> RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses) (alkali metal salts; crunchy and non-cariogenic confectionery compns. for oral care)
IT		<b>Chewing gum</b> (anticariogenic dentifrices; crunchy and non-cariogenic confectionery compns. for oral care)
IT		<b>Tooth, disease</b> (calculus, anti-; crunchy and non-cariogenic confectionery compns. for

oral care)

IT Candy  
Chewing gum  
(carrier; crunchy and non-cariogenic confectionery compns. for oral care)

IT Carbohydrates, biological studies  
Gelatins, biological studies  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(carrier; crunchy and non-cariogenic confectionery compns. for oral care)

IT Dentifrices  
(chewing gums, anticariogenic; crunchy and non-cariogenic confectionery compns. for oral care)

IT Confectionery  
Flavoring materials  
Food solubility  
Food texture  
Particle size  
(crunchy and non-cariogenic confectionery compns. for oral care)

IT Diphosphates  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(crunchy and non-cariogenic confectionery compns. for oral care)

IT Calculi  
(dental, anti-; crunchy and non-cariogenic confectionery compns. for oral care)

IT Sweetening agents  
(noncariogenic; crunchy and non-cariogenic confectionery compns. for oral care)

IT Odor and Odorous substances  
(off-odor; crunchy and non-cariogenic confectionery compns. for oral care)

IT Tooth, disease  
(plaque, anti-; crunchy and non-cariogenic confectionery compns. for oral care)

IT Polyphosphoric acids  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(potassium salts; crunchy and non-cariogenic confectionery compns. for oral care)

IT Polyphosphoric acids  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(sodium salts; crunchy and non-cariogenic confectionery compns. for oral care)

IT 50-70-4, Sorbitol, biological studies 56-81-5, Glycerin, biological studies 557-34-6, Zinc acetate 7440-31-5D, Tin, salts 7440-66-6D, Zinc, salts 7440-70-2D, Calcium, salts 7732-18-5, Water, biological studies 7758-29-4, Sodium tripolyphosphate 15477-76-6, Phosphonate 55589-62-3  
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
(crunchy and non-cariogenic confectionery compns. for oral care)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Chow, L; US---5833954 A 1998 HCAPLUS
- (2) Gen Foods Corp; GB---1372932 A 1974 HCAPLUS
- (3) Reed, M; US---4792453 A 1988 HCAPLUS
- (4) Warner Lambert Pharmaceutical; GB---1102024 A 1968
- (5) Winston, A; US---5958380 A 1999 HCAPLUS

L34 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:736084 HCAPLUS

DN 137:268220

ED Entered STN: 27 Sep 2002

TI Denture care compositions and kits containing polybutene

IN Rajalah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/30  
 CC 62-7 (Essential Oils and Cosmetics)  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074276	A2	20020926	2002WO-US08137	20020315
	WO2002074276	A3	20030912		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6500406	B1	20021231	2002US-0085383	20020228
	US2003082113	A1	20030501	2002US-0242012	20020912
	US---6905673	B2	20050614		
	US2003086878	A1	20030508	2002US-0241961	20020912
	US2003099603	A1	20030529	2002US-0242645	20020912
PRAI	2001US-276976P	P	20010319		
	2001US-276978P	P	20010319		
	2001US-276979P	P	20010319		
	2002US-0084870	A1	20020228		
	2002US-0084898	A1	20020228		
	2002US-0085383	A1	20020228		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074276	ICM	A61K-0007/30
	IPCI	A61K0007-30 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US---6500406	IPCI	C11D0001-02 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000; 134/002.000; 134/042.000; 510/117.000;

523/120.000

US2003082113 ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6;  
A23G003/30P; A23G004/08; A61K008/02; A61K008/04F;  
A61K008/19; A61K008/22; A61K008/23; A61K008/25;  
A61K008/365; A61K008/37; A61K008/38; A61K008/41;  
A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C;  
A61Q011/00; A61Q011/02

US2003082113 IPCI A61K0007-16 [ICM,7]

US2003082113 IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C\*]; A23G0004-02  
[I,A]; A23G0004-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*];  
A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
[I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02  
[I,C\*]

US2003086878 NCL 424/049.000

US2003086878 ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6;  
A23G003/30P; A61K008/19; A61K008/22; A61K008/37;  
A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00;  
A61Q011/02

US2003086878 IPCI A61K0007-16 [ICM,7]

US2003086878 IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C\*]; A23G0004-02  
[I,A]; A23G0004-02 [I,C\*]; A61K0008-02 [I,A];  
A61K0008-02 [I,C\*]; A61K0008-04 [I,A]; A61K0008-04  
[I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*];  
A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];  
A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41  
[I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*];  
A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
[I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02  
[I,C\*]

US2003086878 NCL 424/049.000

US2003086878 ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6;  
A23G003/30P; A23G004/08; A61K008/02; A61K008/04F;  
A61K008/19; A61K008/22; A61K008/23; A61K008/25;  
A61K008/365; A61K008/37; A61K008/38; A61K008/41;  
A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C;  
A61Q011/00; A61Q011/02

US2003099603 IPCI A61K0007-20 [ICM,7]

US2003099603 IPCR A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-04  
[I,A]; A61K0008-04 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-23  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];  
A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41  
[I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*];  
A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
[I,A]; A61K0008-92 [I,C\*]; A61Q0011-02 [I,A];  
A61Q0011-02 [I,C\*]

US2003099603 NCL 424/053.000

US2003099603 ECLA A61K008/02; A61K008/04F; A61K008/19; A61K008/22;  
A61K008/23; A61K008/365; A61K008/37; A61K008/38;  
A61K008/41; A61K008/42; A61K008/81C2; A61K008/898;  
A61K008/92C; A61Q011/02

AB A non-self-supporting denture care composition comprises polybutene with a mol.  
weight of about 300 to about 3000 and a denture care active. The denture  
care composition may further comprise a denture care carrier. Kits comprising  
polybutene, a container and instructions for use or an applicator for  
applying the composition directly to the denture surface are also disclosed.  
The polybutene composition of the kits can further comprise a denture care  
active such as triclosan.

ST denture care compn polybutene

IT Antihistamines  
(H2; denture care compns. and kits containing polybutene)

IT Analgesics  
 Anesthetics  
 Anti-inflammatory agents  
 Antioxidants  
 Antiviral agents  
   Dentifrices  
   Fungicides  
     (denture care compns. and kits containing polybutene)

IT Fats and Glyceridic oils, biological studies  
 Paraffin oils  
 Petrolatum  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
   (denture care compns. and kits containing polybutene)

IT Dental materials and appliances  
   (dentures; denture care compns. and kits containing polybutene)

IT Citrus paradisi  
   (seed extract; denture care compns. and kits containing polybutene)

IT Polyphosphoric acids  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (sodium salts; denture care compns. and kits containing polybutene)

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
   (vegetable; denture care compns. and kits containing polybutene)

IT 13473-26-2  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (Opatint D&C Red 27; denture care compns. and kits containing polybutene)

IT 123-03-5, Cetylpyridinium chloride 144-55-8, Sodium bicarbonate, biological studies 1400-61-9, Nystatin 3380-34-5, Triclosan 7631-99-4, Sodium nitrate, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-79-1, Potassium nitrate, biological studies 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid 16984-48-8, Fluoride, biological studies  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (denture care compns. and kits containing polybutene)

IT 9003-29-6, Polybutene 9044-17-1, Indopol H 300  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
   (denture care compns. and kits containing polybutene)

L34 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:736083 HCAPLUS  
 DN 137:268219  
 ED Entered STN: 27 Sep 2002  
 TI Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier  
 IN Rajalah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16  
 ICS A61C-0019/00  
 CC 62-7 (Essential Oils and Cosmetics)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074275	A2	20020926	2002WO-US08139	20020315
	WO2002074275	A3	20030605		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

US2002176827 A1 20021128 2002US-0084896 20020228  
 US---6514484 B2 20030204  
 CA---2441860 AA 20020926 2002CA-2441860 20020315  
 EP---1370228 A2 20031217 2002EP-0715139 20020315  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN---1503658 A 20040609 2002CN-0806529 20020315  
 JP2004535372 T2 20041125 2002JP-0572983 20020315  
 RU---2257888 C2 20050810 2003RU-0130734 20020315  
 US2003113276 A1 20030619 2002US-0241990 20021218  
 US---6719995 B2 20040413  
 PRAI 2001US-276977P P 20010319  
 2002US-0084896 A1 20020228  
 2002WO-US08139 W 20020315

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074275	ICM	A61K-0007/16
	ICS	A61C-0019/00
	IPCI	A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
US2002176827	ECLA	A61C019/06B; A61K008/81C2; A61Q011/00
	IPCI	A61K0007-16 [ICM,7]; A61C0015-00 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
CA---2441860	ECLA	A61C019/06B; A61K008/81C2; A61Q011/00
	IPCI	A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
EP---1370228	IPCI	A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
CN---1503658	IPCI	A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2004535372	ECLA	A61C019/06B; A61K008/81C2; A61Q011/00
	IPCI	A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61K0031-085 [ICS,7]; A61K0031-075 [ICS,7,C*]; A61K0031-17 [ICS,7]; A61K0033-40 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	FTERM	4C076/AA74; 4C076/BB22; 4C076/CC03; 4C076/CC16; 4C076/DD45; 4C076/DD60; 4C076/EE03; 4C076/FF70; 4C083/AA111; 4C083/AB081; 4C083/AB172; 4C083/AB272; 4C083/AB281; 4C083/AB311; 4C083/AB372; 4C083/AB411; 4C083/AB471; 4C083/AB472; 4C083/AC012; 4C083/AC312; 4C083/AC342; 4C083/AC442; 4C083/AC681; 4C083/AC812;

4C083/AC852; 4C083/AD021; 4C083/AD022; 4C083/AD072;  
 4C083/AD412; 4C083/AD532; 4C083/BB47; 4C083/BB48;  
 4C083/BB55; 4C083/CC41; 4C083/CC42; 4C083/DD12;  
 4C083/EE03; 4C083/EE05; 4C083/EE32; 4C083/EE35;  
 4C083/EE36; 4C086/AA10; 4C086/HA22; 4C086/MA03;  
 4C086/MA05; 4C086/MA32; 4C086/MA57; 4C086/NA10;  
 4C086/ZA67; 4C206/AA10; 4C206/HA27; 4C206/MA03;  
 4C206/MA05; 4C206/MA52; 4C206/MA77; 4C206/NA20;  
 4C206/ZA67  
 RU---2257888 IPCI A61K0007-16 [ICM,7]  
 ECLA A61C019/06B; A61K008/81C2; A61Q011/00  
 US2003113276 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20  
 [ICS,7]  
 IPCR A61C0019-00 [I,C\*]; A61C0019-06 [I,A]; A61K0008-72  
 [I,C\*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];  
 A61Q0011-00 [I,C\*]  
 NCL 424/049.000  
 ECLA A61C019/06B; A61K008/81C2; A61Q011/00  
 AB Systems for delivering cosmetic and therapeutic actives to the oral cavity  
 employ a strip comprising a first layer of material, a second layer  
 comprising polybutene with a mol. weight of about 300 to about 3000, and a  
 cosmetic or therapeutic active included within the second layer.  
 Therapeutic and cosmetic actives in compns. comprising polybutene inhibit  
 or prevent gingivitis, caries, staining, fungi, bacteria and plaque  
 build-up in the oral cavity by means of the delivery system. A composition  
 contains Indopol H-300, Glass H, and triclosan.  
 ST polybutene cosmetic drug delivery oral  
 IT Antihistamines  
 (H2; systems for delivering a cosmetic and/or therapeutic  
 active to oral surfaces using an integral carrier)  
 IT Drug delivery systems  
 (oral; systems for delivering a cosmetic and/or therapeutic active to  
 oral surfaces using an integral carrier)  
 IT Tooth, disease  
 (plaque; systems for delivering a cosmetic and/or therapeutic active to  
 oral surfaces using an integral carrier)  
 IT Analgesics  
 Anesthetics  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Antioxidants  
 Antiviral agents  
 Dentifrices  
 Fungicides  
 Nutrients  
 Pigments, nonbiological  
 (systems for delivering a cosmetic and/or therapeutic active to oral  
 surfaces using an integral carrier)  
 IT 13473-26-2  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (Opatint D&C Red 27; systems for delivering a cosmetic and/or  
 therapeutic active to oral surfaces using an integral carrier)  
 IT 123-03-5, Cetylpyridinium chloride 124-43-6, Carbamide peroxide  
 144-55-8, Sodium bicarbonate, biological studies 1400-61-9, Nystatin  
 3380-34-5, Triclosan 7631-99-4, Sodium nitrate, biological studies  
 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium  
 pyrophosphate 7757-79-1, Potassium nitrate, biological studies  
 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid  
 16984-48-8, Fluoride, biological studies  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (systems for delivering a cosmetic and/or therapeutic active to oral  
 surfaces using an integral carrier)  
 IT 9003-29-6, Polybutene 9044-17-1, Indopol H 300  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);

## USES (Uses)

(systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

L34 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:736082 HCAPLUS  
 DN 137:268218  
 ED Entered STN: 27 Sep 2002  
 TI Dentifrice compositions containing polybutene  
 IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16  
 CC 62-7 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 63

## FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074274	A2	20020926	2002WO-US08136	20020315
	WO2002074274	A3	20030925		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US2002187108	A1	20021212	2002US-0084898	20020228
	US---6509007	B2	20030121		
	CA---2441865	AA	20020926	2002CA-2441865	20020315
	EP---1370227	A2	20031217	2002EP-0707983	20020315
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004524334	T2	20040812	2002JP-0572982	20020315
	CN---1635866	A	20050706	2002CN-0806545	20020315
	US2003082113	A1	20030501	2002US-0242012	20020912
	US---6905673	B2	20050614		
	US2003086878	A1	20030508	2002US-0241961	20020912
PRAI	2001US-276978P	P	20010319		
	2001US-276979P	P	20010319		
	2001US-276976P	P	20010319		
	2002US-0084898	A1	20020228		
	2002US-0085383	A1	20020228		
	2002WO-US08136	W	20020315		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074274	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A61K008/19; A61K008/22; A61K008/37; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2002187108	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02

[I,A]; A23G0004-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*];  
A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
[I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02  
[I,C\*]

NCL 424/049.000  
ECLA A61K008/19; A61K008/22; A61K008/37; A61K008/81C2;  
A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02

CA---2441865 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-22  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-37 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-898  
[I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C\*];  
A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]; A61Q0011-02  
[I,A]; A61Q0011-02 [I,C\*]

EP---1370227 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-22  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-37 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-898  
[I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C\*];  
A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]; A61Q0011-02  
[I,A]; A61Q0011-02 [I,C\*]

JP2004524334 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]  
IPCR A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-22  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-37 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-898  
[I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C\*];  
A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]; A61Q0011-02  
[I,A]; A61Q0011-02 [I,C\*]

FTERM 4C083/AA112; 4C083/AB102; 4C083/AB172; 4C083/AB242;  
4C083/AB282; 4C083/AB312; 4C083/AB412; 4C083/AB472;  
4C083/AB502; 4C083/AC122; 4C083/AC132; 4C083/AC472;  
4C083/AC682; 4C083/AC782; 4C083/AC812; 4C083/AC852;  
4C083/AC862; 4C083/AD021; 4C083/AD022; 4C083/AD042;  
4C083/AD072; 4C083/AD272; 4C083/AD352; 4C083/AD532;  
4C083/BB41; 4C083/CC41; 4C083/DD06; 4C083/EE37

CN---1635866 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-22  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-37 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-898  
[I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C\*];  
A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]; A61Q0011-02  
[I,A]; A61Q0011-02 [I,C\*]

US2003082113 IPCI A61K0007-16 [ICM,7]  
IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C\*]; A23G0004-02  
[I,A]; A23G0004-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-37 [I,A]; A61K0008-72 [I,C\*];  
A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
[I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02  
[I,C\*]

NCL 424/049.000  
ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6;  
A23G003/30P; A61K008/19; A61K008/22; A61K008/37;  
A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00;  
A61Q011/02

US2003086878 IPCI A61K0007-16 [ICM,7]  
IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C\*]; A23G0004-02  
[I,A]; A23G0004-02 [I,C\*]; A61K0008-02 [I,A];  
A61K0008-02 [I,C\*]; A61K0008-04 [I,A]; A61K0008-04  
[I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*];  
A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25  
[I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];

A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C\*]  
 NCL 424/049.000  
 ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A23G004/08; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/25; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02  
 AB An oral care composition (a dentifrice) comprises polybutene with a mol. weight of about 300 to about 3000 and an oral care active. The oral care composition may further comprise an oral care carrier. Kits comprising polybutene, a container and instructions for use or an applicator for applying the composition directly to the tooth surfaces are also disclosed. The polybutene component of the kits can further comprise an oral care active or an oral care carrier. Thus, a formulation contained polybutene 99.757, and NaF 0.243%.  
 ST dentifrice polybutene fluoride  
 IT Antihistamines  
 (H2; dentifrice compns. containing polybutene)  
 IT Tooth, disease  
 (calculus; dentifrice compns. containing polybutene)  
 IT Calculi  
 (dental; dentifrice compns. containing polybutene)  
 IT Abrasives  
 Analgesics  
 Anesthetics  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Antioxidants  
 Antiviral agents  
 Buffers  
 Dentifrices  
 Flavoring materials  
 Fungicides  
 Humectants  
 Mouthwashes  
 Nutrients  
 Opacifiers  
 Surfactants  
 Sweetening agents  
 Thickening agents  
 Whitening agents  
 (dentifrice compns. containing polybutene)  
 IT Dentifrices  
 (gels; dentifrice compns. containing polybutene)  
 IT Viscosity  
 (modifiers; dentifrice compns. containing polybutene)  
 IT Tooth, disease  
 (plaque; dentifrice compns. containing polybutene)  
 IT Vitis vinifera  
 (seed exts.; dentifrice compns. containing polybutene)  
 IT Polyphosphoric acids  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sodium salts; dentifrice compns. containing polybutene)  
 IT 13473-26-2  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Opatint D&C Red 27; dentifrice compns. containing polybutene)  
 IT 87-99-0, Xylitol 123-03-5, Cetylpyridinium chloride 144-55-8, Baking soda, biological studies 1400-61-9, Nystatin 3380-34-5, Triclosan

7440-31-5, Tin, biological studies 7631-99-4, Nitric acid sodium salt, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-79-1, Nitric acid potassium salt, biological studies 7783-47-3, Tin fluoride (SnF<sub>2</sub>) 9003-27-4, Indopol H 1900 9003-28-5, Polybutene 9044-17-1, Indopol H 300 13537-32-1, Phosphorofluoridic acid 16984-48-8, Fluoride, biological studies

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dentifrice compns. containing polybutene)

L34 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:736071 HCAPLUS

DN 137:252754

ED Entered STN: 27 Sep 2002

TI Polybutene-containing denture cleanser compositions

IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0007/00

CC 62-7 (Essential Oils and Cosmetics)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074263	A2	20020926	2002WO-US08140	20020315
	WO2002074263	A3	20030904		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6491896	B1	20021210	2002US-0084870	20020228
	US2003086878	A1	20030508	2002US-0241961	20020912
	US2003099603	A1	20030529	2002US-0242645	20020912
PRAI	2001US-276976P	P	20010319		
	2001US-276978P	P	20010319		
	2002US-0084870	A1	20020228		
	2002US-0085383	A1	20020228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074263	ICM	A61K-0007/00
	IPCI	A61K0007-00 [ICM,7]
	IPCR	A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02
US---6491896	IPCI	A61K0009-46 [ICM,7]; C11D0007-18 [ICS,7]; C11D0007-02

[ICS,7,C\*]; C11D0007-54 [ICS,7]; C11Q0017-00 [ICS,7]  
 IPCR A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-04  
 [I,A]; A61K0008-04 [I,C\*]; A61K0008-19 [I,A];  
 A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-23  
 [I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];  
 A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41  
 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*];  
 A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
 [I,A]; A61K0008-92 [I,C\*]; A61Q0011-02 [I,A];  
 A61Q0011-02 [I,C\*]  
 NCL 424/044.000; 510/117.000  
 ECLA A61K008/02; A61K008/19; A61K008/22; A61K008/23;  
 A61K008/365; A61K008/37; A61K008/38; A61K008/42;  
 A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02  
 US2003086878 IPCI A61K0007-16 [ICM,7]  
 IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C\*]; A23G0004-02  
 [I,A]; A23G0004-02 [I,C\*]; A61K0008-02 [I,A];  
 A61K0008-02 [I,C\*]; A61K0008-04 [I,A]; A61K0008-04  
 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*];  
 A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25  
 [I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];  
 A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41  
 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*];  
 A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
 [I,A]; A61K0008-92 [I,C\*]; A61Q0011-00 [I,A];  
 A61Q0011-00 [I,C\*]; A61Q0011-02 [I,A]; A61Q0011-02  
 [I,C\*]  
 NCL 424/049.000  
 ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6;  
 A23G003/30P; A23G004/08; A61K008/02; A61K008/04F;  
 A61K008/19; A61K008/22; A61K008/23; A61K008/25;  
 A61K008/365; A61K008/37; A61K008/38; A61K008/41;  
 A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C;  
 A61Q011/00; A61Q011/02  
 US2003099603 IPCI A61K0007-20 [ICM,7]  
 IPCR A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-04  
 [I,A]; A61K0008-04 [I,C\*]; A61K0008-19 [I,A];  
 A61K0008-19 [I,C\*]; A61K0008-22 [I,A]; A61K0008-23  
 [I,A]; A61K0008-30 [I,C\*]; A61K0008-365 [I,A];  
 A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41  
 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C\*];  
 A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92  
 [I,A]; A61K0008-92 [I,C\*]; A61Q0011-02 [I,A];  
 A61Q0011-02 [I,C\*]  
 NCL 424/053.000  
 ECLA A61K008/02; A61K008/04F; A61K008/19; A61K008/22;  
 A61K008/23; A61K008/365; A61K008/37; A61K008/38;  
 A61K008/41; A61K008/42; A61K008/81C2; A61K008/898;  
 A61K008/92C; A61Q011/02  
 AB A denture cleanser composition comprises polybutene, with a mol. weight of about  
 300 to about 3000, an effervescence generator and a bleaching agent.  
 Optionally, denture cleanser compns. may further comprise tablet binders,  
 organic peroxyacid bleach precursors, surfactants including a dimethicone  
 copolyol, lipophilic compds. such as flavorants and coolants, chelating  
 agents, and other therapeutic and cosmetic active agents.  
 ST denture cleanser polybutene  
 IT Antihistamines  
 (H2; polybutene-containing denture cleanser compns.)  
 IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (anise; polybutene-containing denture cleanser compns.)  
 IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (bay; polybutene-containing denture cleanser compns.)  
 IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

- (bitter almond; polybutene-containing denture cleanser compns.)
- IT Polyphosphoric acids
  - RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
  - (calcium salts; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (cedar leaf; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (cinnamon; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (citronella; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (clove; polybutene-containing denture cleanser compns.)
- IT Dentifrices
  - (denture cleansers; polybutene-containing denture cleanser compns.)
- IT Polysiloxanes, biological studies
  - RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
  - (di-Me, 3-hydroxypropyl Me, ethoxylated propoxylated; polybutene-containing denture cleanser compns.)
- IT Polyoxyalkylenes, biological studies
  - Polyoxyalkylenes, biological studies
  - RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
  - (di-Me, Me hydrogen polysiloxane-; polybutene-containing denture cleanser compns.)
- IT Polysiloxanes, biological studies
  - Polysiloxanes, biological studies
  - RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
  - (di-Me, Me hydrogen, polyoxyalkylene-; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (lavender; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (lemon; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (margoram; polybutene-containing denture cleanser compns.)
- IT Fats and Glyceridic oils, biological studies
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (mustard; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (orange, sweet; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (oregano; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (peppermint; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (pine leaf; polybutene-containing denture cleanser compns.)
- IT Essential oils
  - RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
  - (pine; polybutene-containing denture cleanser compns.)
- IT Tooth, disease
  - (plaque; polybutene-containing denture cleanser compns.)

IT Analgesics  
 Anesthetics  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Antioxidants  
 Antiviral agents  
 Bleaching agents  
 Flavoring materials  
 Fungicides  
 Nutrients  
 (polybutene-containing denture cleanser compns.)

IT Aluminosilicates, biological studies  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (rosemary; polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sage, *Salvia officinalis*; polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (sassafras; polybutene-containing denture cleanser compns.)

IT Polyphosphoric acids  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
 (sodium salts; polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (spearmint; polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (thyme, *Thymus vulgaris*; polybutene-containing denture cleanser compns.)

IT Essential oils  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (wintergreen; polybutene-containing denture cleanser compns.)

IT 9003-29-6, Polybutene 9044-17-1, Indopol H-300  
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
 (polybutene-containing denture cleanser compns.)

IT 65-85-0, Benzoic acid, biological studies 76-22-2, Camphor 89-78-1, Menthol 89-83-8, Thymol 94-13-3, Propylparaben 94-26-8, Butylparaben 94-36-0, Benzoyl peroxide, biological studies 99-76-3, Methylparaben 100-52-7, Benzaldehyde, biological studies 108-95-2, Phenol, biological studies 136-77-6, 4-Hexylresorcinol 470-82-6, Eucalyptol 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1343-88-0, Magnesium silicate 1344-28-1, Alumina, biological studies 3380-34-5, Triclosan 5329-14-6, Sulfamic acid 7631-86-9, Silica, biological studies 7758-87-4, Calcium orthophosphate 10086-45-0, Calcium pyrophosphate 10101-52-7, Zirconium silicate 13477-39-9, Calcium metaphosphate 16984-48-8, Fluoride, biological studies  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)  
 (polybutene-containing denture cleanser compns.)

L34 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:331997 HCAPLUS  
 DN 136:345525  
 ED Entered STN: 03 May 2002  
 TI Dental care compositions containing polysiloxanes  
 IN Lawlor, Thomas Mark  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16

ICS A61K-0007/48; C08L-0083/04  
 CC 62-7 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002034221	A1	20020502	2000WO-US29384	20001025
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA---2424566	AA	20020502	2000CA-2424566	20001025
AU2001016543	A5	20020506	2001AU-0016543	20001025
EP---1328245	A1	20030723	2000EP-0979130	20001025
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
BR2000017362	A	20031028	2000BR-0017362	20001025
JP2004517820	T2	20040617	2002JP-0537275	20001025
RU---2248787	C2	20050327	2003RU-0115439	20001025
US2003198604	A1	20031023	2003US-0424640	20030425
US---6685921	B2	20040203		
PRAI 2000WO-US29384	W	20001025		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002034221	ICM	A61K-0007/16
	ICS	A61K-0007/48; C08L-0083/04
	IPCI	A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04 [ICS,7]; C08L0083-00 [ICS,7,C*]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
CA---2424566	ECLA	A61K006/02; A61K006/093; A61K007/16D14; A61K007/48N16
	IPCI	A61K0007-16 [ICM,7]; C08L0083-04 [ICS,7]; C08L0083-00 [ICS,7,C*]; A61K0007-48 [ICS,7]
AU2001016543	IPCI	A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04 [ICS,7]; C08L0083-00 [ICS,7,C*]
EP---1328245	IPCI	A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04 [ICS,7]; C08L0083-00 [ICS,7,C*]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR2000017362	IPCI	A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04 [ICS,7]; C08L0083-00 [ICS,7,C*]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2004517820	IPCI	A61K0006-00 [ICM,7]; A61K0006-093 [ICS,7]; A61K0006-02 [ICS,7,C*]; A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-34 [ICS,7]; A61K0047-36 [ICS,7]; A61K0047-38 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];

A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C\*];  
 A61P0043-00 [ICS,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0006-093  
 [I,A]; A61K0008-30 [I,C\*]; A61K0008-34 [I,A];  
 A61K0008-72 [I,C\*]; A61K0008-73 [I,A]; A61K0008-81  
 [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
 A61Q0011-00 [I,C\*]  
 FTERM 4C076/AA09; 4C076/BB22; 4C076/BB23; 4C076/CC01;  
 4C076/CC07; 4C076/CC09; 4C076/CC21; 4C076/CC31;  
 4C076/CC35; 4C076/DD22; 4C076/DD23; 4C076/DD26;  
 4C076/DD28F; 4C076/DD29; 4C076/DD37; 4C076/DD38;  
 4C076/EE08F; 4C076/EE23F; 4C076/EE27F; 4C076/EE30F;  
 4C076/EE31F; 4C076/FF21; 4C076/FF22; 4C076/FF51;  
 4C076/FF53; 4C089/AA20; 4C089/BA07; 4C089/BA09;  
 4C089/BA11; 4C089/BA13; 4C089/BA16; 4C089/BA20;  
 4C089/BC03; 4C089/BC06; 4C089/BE01; 4C089/BE11;  
 4C089/BE15; 4C089/CA03  
 RU--2248787 IPCI A61K0007-16 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00  
 [ICS,7,C\*]  
 US2003198604 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-06  
 [ICS,7]; A61K0007-11 [ICS,7]  
 IPCR A61K0006-02 [I,C\*]; A61K0006-093 [I,A]; A61K0008-30  
 [I,C\*]; A61K0008-34 [I,A]; A61K0008-72 [I,C\*];  
 A61K0008-891 [I,A]; A61K0008-892 [I,A]; A61K0008-893  
 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 NCL 424/049.000  
 ECLA A61K006/093; A61K008/34D; A61K008/891; A61K008/892;  
 A61K008/893; A61Q011/00  
 AB The present invention relates to non volatile compns. that comprises: i)  
 from about 0.5 % to about 60 % by weight, of a silicone resin; ii) from about  
 0.1 % to about 30 %, by weight, of a silicon gum; iii) from about 0.1 % to  
 about 95 %, by weight, of a non volatile polysiloxane fluid which has a  
 viscosity from about 1cStk to about 1000cStk; and from about 0.01 % to  
 about 50 %, by weight, of an oral care active selected from teeth color  
 modifying substances, antitartar agents, antiplaque agents, fluoride ion  
 sources, antimicrobial agents, nutrients, antioxidants, H-2 antagonists,  
 analgesics, antiviral agents, mucosally absorbed pharmacol. agents and  
 mixts. thereof. A second aspect of the present invention relates to the  
 user of non volatile oral care silicone compns. in the oral cavity to  
 treat the hard and soft tissue surfaces wherein the composition comprises: (i)  
 from about 0.5 % to about 60 %, by weight, of a silicone resin; (ii) from  
 about 0.1 % to about 30 %, by weight of a silicone gum; (iii) from about  
 1cStk to about 1000cStk. Compns. of the present invention are useful for  
 providing a substantive composition on the surfaces of the oral cavity which  
 can provide prophylactic, therapeutic or cosmetic benefits. A composition  
 contained silicone reson (SR1000) 30.00, silicone gum (SE30) 10.00,  
 silicone fluid (SC200) 60.00 % weight/weight  
 ST oral dental compn silicone; polysiloxane dental compn  
 IT Antihistamines  
 (H2; dental care compns. containing polysiloxanes)  
 IT Analgesics  
 Antimicrobial agents  
 Antioxidants  
 Antiviral agents  
 Dentifrices  
 Nutrients  
 (dental care compns. containing polysiloxanes)  
 IT Clays, biological studies  
 Polyphosphates  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (dental care compns. containing polysiloxanes)  
 IT Polysiloxanes, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (dental care compns. containing polysiloxanes)

IT Silicone rubber, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (di-Me, SE 30; dental care compns. containing polysiloxanes)

IT Drug delivery systems  
 (oral; dental care compns. containing polysiloxanes)

IT 87-99-0, Xylitol 3380-34-5, Triclosan 7440-66-6D, Zinc, salts  
 7631-86-9, Silica, biological studies 7732-18-5, Water, biological  
 studies 7757-79-1, Potassium nitrate, biological studies 7783-47-3,  
 Stannous fluoride 9004-34-6D, Cellulose, polymers 11138-66-2, Xanthan  
 gum 14915-07-2, Peroxide 16984-48-8, Fluoride, biological studies  
 106392-12-5, Oxirane, polymer with methyloxirane, block  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (dental care compns. containing polysiloxanes)

IT 9016-00-6, Polydimethylsiloxane 31900-57-9, Polydimethylsiloxane  
 56275-01-5, SR 1000  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (dental care compns. containing polysiloxanes)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Dow Corning France; WO---0122923 A 2001 HCAPLUS
- (2) Kanebo; JP--11222420 A CAPLUS 1999:518667 1999 HCAPLUS
- (3) Procter & Gamble; WO---9210161 A 1992 HCAPLUS
- (4) Procter & Gamble; WO---9717059 A 1997 HCAPLUS
- (5) Procter & Gamble; WO---0101942 A 2001 HCAPLUS

L34 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:151471 HCAPLUS

DN 136:189127

ED Entered STN: 27 Feb 2002

TI Oral care compositions comprising chlorite

IN Witt, Jonathan James; Wimalasena, Rohan Lalith; Wong, Andrew Lee;  
 Goulbourne, Eric Altman, Jr.; Doyle, Matthew Joseph

PA The Procter & Gamble Company, USA

SO U.S., 15 pp., Cont.-in-part of U.S. 6,251,372.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K-0007/16

ICS A61K-0007/20

INCL 424053000

CC 62-7 (Essential Oils and Cosmetics)

Section cross-reference(s): 1, 63

FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US---6350438	B1	20020226	2000US-0607242	20000630
US---6077502	A	20000620	1998US-0032238	19980227
US---6132702	A	20001017	1998US-0032234	19980227
US---6251372	B1	20010626	1998US-0032237	19980227
CA---2414573	AA	20020110	2001CA-2414573	20010628
WO2002002061	A2	20020110	2001WO-US20614	20010628
WO2002002061	A3	20020627		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP---1294347	A2	20030326	2001EP-0946731	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP2004501942	T2	20040122 2002JP-0506684 20010628
PRAI 1998US-0032234	A2	19980227
1998US-0032237	A2	19980227
1998US-0032238	A2	19980227
2000US-0607242	A	20000630
2001WO-US20614	W	20010628

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6350438	ICM	A61K-0007/16
	ICS	A61K-0007/20
	INCL	424053000
	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/053.000; 424/049.000
	ECLA	A61K033/20; A23K001/18N; A61K008/20; A61Q011/00
US---6077502	IPCI	A61K0007-20 [ICM,7]; A61K0033-20 [ICS,7]; A61K0009-20 [ICS,7]
	IPCR	A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/053.000; 424/049.000; 424/464.000; 424/613.000; 424/661.000
	ECLA	A61K033/20; A61K008/20; A61Q011/00
US---6132702	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0033-20 [ICS,7]
	IPCR	A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/053.000; 424/661.000
	ECLA	A61K008/20; A61Q011/00
US---6251372	IPCI	A61K0007-20 [ICM,7]
	NCL	424/053.000
	ECLA	A61Q011/00; A61K008/20
CA---2414573	IPCI	A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2002002061	IPCI	A61K0007-00 [ICM,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A23K001/18N; A61K008/20; A61Q011/00
EP---1294347	IPCI	A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2004501942	IPCI	A61K0007-20 [ICM,7]; A61C0017-00 [ICS,7]; A61K0007-22 [ICS,7]; A61K0007-24 [ICS,7]; A61L0002-18 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	FTERM	4C058/AA13; 4C058/AA28; 4C058/BB07; 4C058/JJ07; 4C083/AB032; 4C083/AB101; 4C083/AB102; 4C083/AB172; 4C083/AB211; 4C083/AB242; 4C083/AB312; 4C083/AB331; 4C083/AB332; 4C083/AB472; 4C083/AC102; 4C083/AC122; 4C083/AC132; 4C083/AC242; 4C083/AC442; 4C083/AC471; 4C083/AC482; 4C083/AC641; 4C083/AC691; 4C083/AC741; 4C083/AC782; 4C083/AC791; 4C083/AC811; 4C083/AC842; 4C083/AC851; 4C083/AC862; 4C083/AD092; 4C083/AD211; 4C083/AD272; 4C083/AD352; 4C083/AD412; 4C083/AD591; 4C083/AD611; 4C083/BB41; 4C083/BB43; 4C083/BB48; 4C083/BB55; 4C083/CC41; 4C083/DD05; 4C083/DD08; 4C083/DD15; 4C083/DD22; 4C083/DD23; 4C083/DD27; 4C083/DD41; 4C083/EE03; 4C083/EE31; 4C083/EE33; 4C083/EE36; 4C083/FF05

AB The present invention relates to topical oral compns., including

therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, lozenges (including breath mints), dental implements (such as dental floss and tape), and pet care products comprising at least a minimally effective amount of chlorite ion, wherein the pH of the final composition is > 7 and the composition is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing diseases and conditions of the oral cavity such as gingivitis, plaque, periodontal disease, herpetic lesions, and infections that may develop following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, and scaling and root planing, in humans and other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity. For example, an oral spray contained sodium chlorite (80%) 1.25%, sodium bicarbonate 0.192%, sodium carbonate 0.289%, and water up to 100%. Chlorite-containing pet rawhide chips and toy ropes were prepared by spraying with the oral spray (10-20 mL per item). The impregnated items are given to dogs immediately or stored in sealed plastic bags to remain moist.

- ST chlorite dentifrice topical oral care
- IT **Antihistamines**  
(H2; chlorite-containing oral care compns.)
- IT Bone resorption  
(alveolar, prevention of; chlorite-containing oral care compns.)
- IT Cytokine receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists; chlorite-containing oral care compns.)
- IT **Dentifrices**  
(antiplaque; chlorite-containing oral care compns.)
- IT Deodorants (personal)  
(breath fresheners; chlorite-containing oral care compns.)
- IT **Dentifrices**  
(chewing gums; chlorite-containing oral care compns.)
- IT Syringes  
(chlorite delivery to periodontal pockets with; chlorite-containing oral care compns.)
- IT Gingiva  
Tongue  
(chlorite delivery to; chlorite-containing oral care compns.)
- IT Analgesics  
Anti-inflammatory agents  
Antimicrobial agents  
Human  
Immunostimulants  
**Mouthwashes**  
Periodontium, disease  
Redox agents  
(chlorite-containing oral care compns.)
- IT Chlorites  
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chlorite-containing oral care compns.)
- IT Growth factors, animal  
Hormones, animal, biological studies  
Mineral elements, biological studies  
Vitamins  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chlorite-containing oral care compns.)
- IT Lipopolysaccharides  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(complexing agents; chlorite-containing oral care compns.)
- IT **Dentifrices**  
(dental floss, and tapes; chlorite-containing oral care compns.)
- IT Chewing gum  
(dentifrices; chlorite-containing oral care compns.)

IT Dentifrices  
(gels; chlorite-containing oral care compns.)

IT Gingiva, disease  
Inflammation  
(gingivitis; chlorite-containing oral care compns.)

IT Mouth, disease  
(lesions, herpetic; chlorite-containing oral care compns.)

IT Herpesviridae  
Human herpesvirus  
(lesions; chlorite-containing oral care compns.)

IT Tooth  
(loose; chlorite-containing oral care compns.)

IT Drug delivery systems  
(lozenges; chlorite-containing oral care compns.)

IT Mouth  
(mucosa, chlorite delivery to; chlorite-containing oral care compns. for)

IT Pet animal  
(oral care products; chlorite-containing oral care compns.)

IT Periodontium  
(pockets; chlorite-containing oral care compns.)

IT Dentifrices  
(powders; chlorite-containing oral care compns.)

IT Mouth, disease  
(prevention and treatment of; chlorite-containing oral care compns.)

IT Drug delivery systems  
(sprays, oral; chlorite-containing oral care compns.)

IT Drug delivery systems  
(topical, oral; chlorite-containing oral care compns.)

IT 123-03-5, Cetylpyridinium chloride 7758-19-2, Sodium Chlorite  
14998-27-7, Chlorite  
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chlorite-containing oral care compns.)

IT 10049-04-4, Chlorine dioxide  
RL: MSC (Miscellaneous)  
(chlorite-containing oral care compns. free of chlorine dioxide)

IT 13898-47-0, Chlorous acid  
RL: MSC (Miscellaneous)  
(chlorite-containing oral care compns. free of chlorous acid)

IT 14380-61-1, Hypochlorite  
RL: MSC (Miscellaneous)  
(chlorite-containing oral care compns. free of hypochlorite)

IT 7790-92-3D, Hypochlorous acid, salts  
RL: MSC (Miscellaneous)  
(chlorite-containing oral care compns. free of hypochlorous acid)

IT 81669-70-7, Metalloproteinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; chlorite-containing oral care compns.)

RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agricola; US---4902498 A 1990 HCAPLUS
- (2) Alliger; US---4084747 A 1978 HCAPLUS
- (3) Alliger; US---4330531 A 1982 HCAPLUS
- (4) Alliger; US---6039934 A 2000 HCAPLUS
- (5) Anon; DE---2329753 1973 HCAPLUS
- (6) Anon; JP--60054311 1985
- (7) Anon; JP--60105610 1985 HCAPLUS
- (8) Anon; EP---0287074 1988 HCAPLUS
- (9) Anon; WO---8903179 1989 HCAPLUS
- (10) Anon; JP--2104509 A 1990
- (11) Anon; EP---0565134 A1 1993 HCAPLUS
- (12) Anon; WO---9318781 1993 HCAPLUS
- (13) Anon; GB---2289841 A 1995 HCAPLUS
- (14) Anon; GB---2290233 A 1995 HCAPLUS
- (15) Anon; WO---9527472 1995 HCAPLUS
- (16) Anon; WO---9625916 1996 HCAPLUS

(17) Anon; JP--09183706 1997  
(18) Anon; WO---9804235 1998 HCAPLUS  
(19) Berger; US---4574084 A 1986 HCAPLUS  
(20) Davidson; US---4986990 A 1991 HCAPLUS  
(21) Davidson; US---5185161 A 1993 HCAPLUS  
(22) Davidson; US---RE36064 E 1999  
(23) Gaffar; US---4273759 A 1981 HCAPLUS  
(24) Gordon; US---4880638 A 1989 HCAPLUS  
(25) Haefele; US---3954002 A 1976 HCAPLUS  
(26) Hutchings; US---4861514 A 1989 HCAPLUS  
(27) Hutchings; US---5091107 A 1992 HCAPLUS  
(28) Kelley; US---4829912 A 1989  
(29) Kross; US---4891216 A 1990 HCAPLUS  
(30) Kross; US---5019402 A 1991 HCAPLUS  
(31) Kross; US---5100652 A 1992 HCAPLUS  
(32) Kross; US---5772986 A 1998 HCAPLUS  
(33) Kross; US---5820822 A 1998 HCAPLUS  
(34) Lukacovic; US---5281412 A 1994 HCAPLUS  
(35) Lynch; Free Rad Res 1996, V26, P209  
(36) McNicholas; US---3271242 A 1966 HCAPLUS  
(37) McNicholas; US---3278447 A 1966 HCAPLUS  
(38) Montgomery; US---5944528 A 1999 HCAPLUS  
(39) Ratcliff; US---4689215 A 1987 HCAPLUS  
(40) Ratcliff; US---4696811 A 1987 HCAPLUS  
(41) Ratcliff; US---4786492 A 1988 HCAPLUS  
(42) Ratcliff; US---4788053 A 1988 HCAPLUS  
(43) Ratcliff; US---4792442 A 1988 HCAPLUS  
(44) Ratcliff; US---4793989 A 1988 HCAPLUS  
(45) Ratcliff; US---4808389 A 1989 HCAPLUS  
(46) Ratcliff; US---4818519 A 1989 HCAPLUS  
(47) Ratcliff; US---4837009 A 1989 HCAPLUS  
(48) Ratcliff; US---4851213 A 1989 HCAPLUS  
(49) Ratcliff; US---4855135 A 1989 HCAPLUS  
(50) Ratcliff; US---4886657 A 1989 HCAPLUS  
(51) Ratcliff; US---4889714 A 1989 HCAPLUS  
(52) Ratcliff; US---4925656 A 1990 HCAPLUS  
(53) Ratcliff; US---4975285 A 1990 HCAPLUS  
(54) Ratcliff; US---4978535 A 1990 HCAPLUS  
(55) Ratcliff; US---5052590 A 1991  
(56) Ratcliff; US---5200171 A 1993 HCAPLUS  
(57) Ratcliff; US---5348734 A 1994 HCAPLUS  
(58) Ratcliff; US---5489435 A 1996 HCAPLUS  
(59) Ratcliff; US---5618550 A 1997 HCAPLUS  
(60) Richter; US---5738840 A 1998 HCAPLUS  
(61) Richter; Compendium 1996, V17(4), P370 MEDLINE  
(62) Sagel; US---5891453 A 1999 HCAPLUS  
(63) Sagel; US---6096328 A 2000 HCAPLUS  
(64) Sagel; US---6136297 A 2000 HCAPLUS  
(65) Sasson; US---6280775 B1 2001 HCAPLUS  
(66) Simon; US---4592487 A 1986 HCAPLUS  
(67) Tell; US---4690772 A 1987 HCAPLUS  
(68) Tice; US---4585482 A 1986 HCAPLUS  
(69) Vit; US---4060600 A 1977  
(70) Wellingshoff; US---5631300 A 1997 HCAPLUS  
(71) Wellingshoff; US---5650446 A 1997 HCAPLUS  
(72) White; Industrial and Engineering Chemistry 1942, V34(7), P782  
(73) Witt; US--09032234 1998  
(74) Witt; US--09032237 1998  
(75) Witt; US--09032238 1998  
(76) Witt; US--09481624 2000  
(77) Witt; US--09487692 2000  
(78) Witt; US---6077502 A 2000 HCAPLUS  
(79) Witt; US---6132702 A 2000 HCAPLUS  
(80) Witt; US---6235269 B1 2001 HCAPLUS  
(81) Witt; US---6251372 B1 2001 HCAPLUS  
(82) Witt; US---6264924 B1 2001 HCAPLUS

(83) Yates; J Clin Periodontol 1997, V24, P603 HCAPLUS

L34 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:31268 HCAPLUS  
 DN 136:90976  
 ED Entered STN: 11 Jan 2002  
 TI Topical oral compositions containing antimicrobial agents for promoting whole body health  
 IN Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph  
 ; Singer, Robert Ernest, Jr.  
 PA Procter & Gamble Company, USA  
 SO PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0033/00  
 ICS A61K-0031/05; A61K-0031/155; A61K-0031/14; A61K-0033/30;  
 A61K-0033/34; A61K-0045/06; A61P-0001/02; A61K-0007/16; A61K-0007/22  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 62  
 FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002002128	A2	20020110	2001WO-US20516	20010628
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA---2415068	AA	20020110	2001CA-2415068	20010628
EP---1294383	A2	20030326	2001EP-0950570	20010628
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP2004517038	T2	20040610	2002JP-0506749	20010628
CN---1522149	A	20040818	2001CN-0812035	20010628
US2005163727	A1	20050728	2004US-0854065	20040525
PRAI 2000US-0607240	A	20000630		
2001WO-US20516	W	20010628		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002128	ICM	A61K-0033/00
	ICS	A61K-0031/05; A61K-0031/155; A61K-0031/14; A61K-0033/30; A61K-0033/34; A61K-0045/06; A61P-0001/02; A61K-0007/16; A61K-0007/22
	IPCI	A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045 [ICS,7,C*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]; A61K0007-22 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34;

CA---2415068 IPCI A61K045/06  
A61K0033-00 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61K0031-05 [ICS,7]; A61K0031-045  
[ICS,7,C\*]; A61K0045-06 [ICS,7]; A61K0045-00  
[ICS,7,C\*]; A61K0031-14 [ICS,7]; A61K0031-155 [ICS,7];  
A61K0007-16 [ICS,7]; A61K0007-22 [ICS,7]; A61K0033-30  
[ICS,7]; A61K0033-34 [ICS,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-41 [I,A]; A61K0008-43  
[I,A]; A61K0031-045 [I,C\*]; A61K0031-05 [I,A];  
A61K0031-14 [I,A]; A61K0031-14 [I,C\*]; A61K0031-155  
[I,A]; A61K0031-155 [I,C\*]; A61K0033-24 [I,A];  
A61K0033-24 [I,C\*]; A61K0033-30 [I,A]; A61K0033-30  
[I,C\*]; A61K0033-34 [I,A]; A61K0033-34 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61Q0011-00  
[I,A]; A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43;  
A61K008/49; A61K008/49C4; A61K031/05; A61K031/14;  
A61K031/155; A61K033/24; A61K033/30; A61K033/34;  
A61K045/06

EP---1294383 IPCI A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045  
[ICS,7,C\*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7];  
A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06  
[ICS,7]; A61K0045-00 [ICS,7,C\*]; A61P0001-02 [ICS,7];  
A61P0001-00 [ICS,7,C\*]; A61K0007-16 [ICS,7];  
A61K0007-22 [ICS,7]  
IPCR A61K0008-30 [I,C\*]; A61K0008-41 [I,A]; A61K0008-43  
[I,A]; A61K0031-045 [I,C\*]; A61K0031-05 [I,A];  
A61K0031-14 [I,A]; A61K0031-14 [I,C\*]; A61K0031-155  
[I,A]; A61K0031-155 [I,C\*]; A61K0033-24 [I,A];  
A61K0033-24 [I,C\*]; A61K0033-30 [I,A]; A61K0033-30  
[I,C\*]; A61K0033-34 [I,A]; A61K0033-34 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61Q0011-00  
[I,A]; A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43;  
A61K008/49; A61K008/49C4; A61K031/05; A61K031/14;  
A61K031/155; A61K033/24; A61K033/30; A61K033/34;  
A61K045/06

JP2004517038 IPCI A61K0031-14 [ICM,7]; A61K0007-16 [ICS,7]; A61K0031-085  
[ICS,7]; A61K0031-075 [ICS,7,C\*]; A61K0031-155 [ICS,7];  
A61K0031-4425 [ICS,7]; A61K0033-24 [ICS,7]; A61K0045-00  
[ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C\*];  
A61P0003-10 [ICS,7]; A61P0003-00 [ICS,7,C\*];  
A61P0009-00 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00  
[ICS,7]; A61P0015-00 [ICS,7]; A61P0031-02 [ICS,7];  
A61P0031-00 [ICS,7,C\*]  
IPCR A61K0008-30 [I,C\*]; A61K0008-41 [I,A]; A61K0008-43  
[I,A]; A61K0031-045 [I,C\*]; A61K0031-05 [I,A];  
A61K0031-14 [I,A]; A61K0031-14 [I,C\*]; A61K0031-155  
[I,A]; A61K0031-155 [I,C\*]; A61K0033-24 [I,A];  
A61K0033-24 [I,C\*]; A61K0033-30 [I,A]; A61K0033-30  
[I,C\*]; A61K0033-34 [I,A]; A61K0033-34 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61Q0011-00  
[I,A]; A61Q0011-00 [I,C\*]  
FTERM 4C083/AB032; 4C083/AB172; 4C083/AB242; 4C083/AB271;  
4C083/AB272; 4C083/AB282; 4C083/AB312; 4C083/AB331;  
4C083/AB472; 4C083/AC102; 4C083/AC122; 4C083/AC132;  
4C083/AC302; 4C083/AC312; 4C083/AC442; 4C083/AC471;  
4C083/AC482; 4C083/AC691; 4C083/AC692; 4C083/AC782;  
4C083/AC841; 4C083/AC851; 4C083/AC852; 4C083/AD042;  
4C083/AD092; 4C083/AD272; 4C083/AD352; 4C083/AD411;  
4C083/CC41; 4C083/DD08; 4C083/DD22; 4C083/DD27;  
4C083/EE32; 4C083/EE33; 4C084/AA19; 4C084/MA13;  
4C084/MA17; 4C084/MA28; 4C084/MA35; 4C084/MA52;  
4C084/MA57; 4C084/NA14; 4C084/ZA082; 4C084/ZA361;  
4C084/ZA451; 4C084/ZA671; 4C084/ZB022; 4C084/ZB092;  
4C084/ZB112; 4C084/ZB352; 4C084/ZC032; 4C084/ZC202;

4C084/ZC212; 4C084/ZC222; 4C084/ZC351; 4C084/ZC372;  
 4C084/ZC442; 4C086/AA01; 4C086/AA02; 4C086/BC17;  
 4C086/MA02; 4C086/MA04; 4C086/MA10; 4C086/MA13;  
 4C086/MA17; 4C086/MA28; 4C086/MA35; 4C086/MA52;  
 4C086/MA57; 4C086/NA14; 4C086/ZA36; 4C086/ZA45;  
 4C086/ZA59; 4C086/ZA67; 4C086/ZA81; 4C086/ZC35;  
 4C206/AA01; 4C206/AA02; 4C206/CA28; 4C206/HA31;  
 4C206/MA02; 4C206/MA04; 4C206/MA14; 4C206/MA33;  
 4C206/MA37; 4C206/MA48; 4C206/MA72; 4C206/MA77;  
 4C206/NA14; 4C206/ZA36; 4C206/ZA45; 4C206/ZA59;  
 4C206/ZA67; 4C206/ZA81; 4C206/ZC35

CN---1522149 IPCI A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045  
 [ICS,7,C\*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7];  
 A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06  
 [ICS,7]; A61K0045-00 [ICS,7,C\*]; A61P0001-02 [ICS,7];  
 A61P0001-00 [ICS,7,C\*]; A61K0007-16 [ICS,7]

IPCR A61K0008-30 [I,C\*]; A61K0008-41 [I,A]; A61K0008-43  
 [I,A]; A61K0031-045 [I,C\*]; A61K0031-05 [I,A];  
 A61K0031-14 [I,A]; A61K0031-14 [I,C\*]; A61K0031-155  
 [I,A]; A61K0031-155 [I,C\*]; A61K0033-24 [I,A];  
 A61K0033-24 [I,C\*]; A61K0033-30 [I,A]; A61K0033-30  
 [I,C\*]; A61K0033-34 [I,A]; A61K0033-34 [I,C\*];  
 A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61Q0011-00  
 [I,A]; A61Q0011-00 [I,C\*]

ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43;  
 A61K008/49; A61K008/49C4; A61K031/05; A61K031/14;  
 A61K031/155; A61K033/24; A61K033/30; A61K033/34;  
 A61K045/06

US2005163727 IPCI A61K0009-68 [ICM,7]; A61K0007-16 [ICS,7]; A61K0007-20  
 [ICS,7]; A61K0031-44 [ICS,7]; A01N0033-12 [ICS,7];  
 A01N0033-00 [ICS,7,C\*]

IPCR A61K0008-30 [I,C\*]; A61K0008-41 [I,A]; A61K0008-43  
 [I,A]; A61K0031-045 [I,C\*]; A61K0031-05 [I,A];  
 A61K0031-14 [I,A]; A61K0031-14 [I,C\*]; A61K0031-155  
 [I,A]; A61K0031-155 [I,C\*]; A61K0033-24 [I,A];  
 A61K0033-24 [I,C\*]; A61K0033-30 [I,A]; A61K0033-30  
 [I,C\*]; A61K0033-34 [I,A]; A61K0033-34 [I,C\*];  
 A61K0045-00 [I,C\*]; A61K0045-06 [I,A]; A61Q0011-00  
 [I,A]; A61Q0011-00 [I,C\*]

NCL 424/048.000

ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43;  
 A61K008/49; A61K008/49C4; A61K031/05; A61K031/14;  
 A61K031/155; A61K033/24; A61K033/30; A61K033/34;  
 A61K045/06

AB The present invention relates to promoting whole body health in humans and  
 animals by using topical oral compns. comprising a safe and effective amount  
 of an antimicrobial agent in admixt. with a pharmaceutically acceptable  
 carrier, said compns. being effective in controlling bacterial-mediated  
 diseases and conditions present in the oral cavity and in inhibiting the  
 spread into the bloodstream of pathogenic oral bacteria, associated bacterial  
 toxins and endotoxins, and resultant inflammatory cytokines and mediators.  
 The present invention also encompasses methods of use of these compns. by  
 topically applying to the oral cavity, a safe and effective amount of an  
 antimicrobial agent to promote and/or enhance whole body health in humans  
 and other animals. A dual phase stannous fluoride dentifrice was prepared

ST antimicrobial oral compn; dentifrice compn

IT Antihistamines  
 (H2; topical oral compns. containing antimicrobial agents for  
 promoting whole body health)

IT Quaternary ammonium compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkylbenzyltrimethyl, chlorides; topical oral compns. containing  
 antimicrobial agents for promoting whole body health)

IT Cytokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antagonists; topical oral compns. containing antimicrobial agents for

promoting whole body health)

IT Lipopolysaccharides  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (complexing agents; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Anti-inflammatory agents  
 (nonsteroidal; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Drug delivery systems  
 (oral; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Essential oils  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (peppermint; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Analgesics  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Dentifrices  
 Immunostimulants  
 (topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Amino acids, biological studies  
 Antibodies and Immunoglobulins  
 Antigens  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Bacteriocins  
 Chlorophylls, biological studies  
 Essential oils  
 Fats and Glyceridic oils, biological studies  
 Hormones, animal, biological studies  
 Minerals, biological studies  
 Vitamins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Drug delivery systems  
 (topical; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT 81669-70-7, Metalloproteinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin c, biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine 56-95-1, Chlorhexidine diacetate 59-02-9,  $\alpha$ -Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 60-54-8, Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0, Eugenol 108-95-2D, Phenol, derivs. 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0, Bht, biological studies 137-58-6, Lidocaine 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies 303-98-0, Coenzyme q10 443-48-1, Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2, Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 7439-97-6D, Mercury, derivs. 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7757-79-1, Potassium nitrate, biological studies 8063-07-8, Kanamycin 10118-90-8, Minocycline 10476-85-4, Strontium chloride 11103-57-4, Vitamin a 14769-73-4, Levamisole 15158-11-9D, derivs., biological studies 15687-27-1, Ibuprofen 18323-44-9, Clindamycin 22071-15-4,

Ketoprofen 22204-53-1, Naproxen 22573-93-9, Alexidine 23713-49-7D,  
 Zinc ion, derivs., biological studies 26787-78-0, Amoxicillin  
 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4,  
 Piroxicam 51481-61-9, Cimetidine 66357-35-5, Ranitidine 67651-57-4,  
 Triclosan monophosphate 71138-71-1, Octapinol 71251-02-0, Octenidine  
 72909-34-3, Pqq 74103-06-3, Ketorolac 74469-00-4, Augmentin  
 76824-35-6, Famotidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine  
 79874-76-3, Delmopinol 83184-43-4, Mifentidine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (topical oral compns. containing antimicrobial agents for promoting whole  
 body health)

L34 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:31237 HCAPLUS  
 DN 136:107507  
 ED Entered STN: 11 Jan 2002  
 TI Topical oral compositions for periodontal disease and promoting whole body  
 health  
 IN Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph  
 ; Singer, Robert Ernest, Jr.  
 PA Procter & Gamble Company, USA  
 SO PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0031/00  
 ICS A61K-0031/4164; A61K-0031/426; A61K-0031/662; A61K-0031/407;  
 A61K-0045/06; A61P-0001/02; A61K-0007/16  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 62

## FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002002096	A2	20020110	2001WO-US20515	20010628 <--
WO2002002096	A3	20020912		
WO2002002096	C1	20031106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA---2415065	AA	20020110	2001CA-2415065	20010628 <--
EP---1294367	A2	20030326	2001EP-0950569	20010628 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP2004501966	T2	20040122	2002JP-0506718	20010628 <--
CN---1536989	A	20041013	2001CN-0811860	20010628 <--
PRAI 2000US-0607602	A	20000630	<--	
2001WO-US20515	W	20010628		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002096	ICM	A61K-0031/00
	ICS	A61K-0031/4164; A61K-0031/426; A61K-0031/662; A61K-0031/407; A61K-0045/06; A61P-0001/02; A61K-0007/16
	IPCI	A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407

[I,A]; A61K0031-407 [I,C\*]; A61K0031-4164 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-426 [I,A]; A61K0031-426  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-662 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

CA---2415065 ECLA A61K007/16; A61K007/22; A61K031/00; A61K031/407;  
A61K031/4164; A61K031/426; A61K031/662; A61K045/06  
IPCI A61K0031-00 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61K0045-06 [ICS,7]; A61K0045-00  
[ICS,7,C\*]; A61K0007-16 [ICS,7]; A61K0031-407 [ICS,7];  
A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7];  
A61K0031-662 [ICS,7]

IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C\*]; A61K0031-407  
[I,A]; A61K0031-407 [I,C\*]; A61K0031-4164 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-426 [I,A]; A61K0031-426  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-662 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

EP---1294367 ECLA A61K007/16; A61K007/22; A61K031/00; A61K031/407;  
A61K031/4164; A61K031/426; A61K031/662; A61K045/06  
IPCI A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7];  
A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7];  
A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00  
[ICS,7,C\*]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61K0007-16 [ICS,7]

IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C\*]; A61K0031-407  
[I,A]; A61K0031-407 [I,C\*]; A61K0031-4164 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-426 [I,A]; A61K0031-426  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-662 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

JP2004501966 IPCI A61K0045-00 [ICM,7]; A61K0009-06 [ICS,7]; A61K0009-08  
[ICS,7]; A61K0009-12 [ICS,7]; A61K0009-20 [ICS,7];  
A61K0009-68 [ICS,7]; A61K0031-341 [ICS,7]; A61K0031-407  
[ICS,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7];  
A61K0045-06 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61P0003-02 [ICS,7]; A61P0003-00  
[ICS,7,C\*]; A61P0029-00 [ICS,7]; A61P0043-00 [ICS,7]

IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C\*]; A61K0031-407  
[I,A]; A61K0031-407 [I,C\*]; A61K0031-4164 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-426 [I,A]; A61K0031-426  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-662 [I,C\*];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]

FTERM 4C076/AA09; 4C076/AA12; 4C076/AA24; 4C076/AA29;  
4C076/AA36; 4C076/AA69; 4C076/BB22; 4C076/BB23;  
4C076/CC01; 4C076/CC04; 4C076/CC09; 4C076/CC22;  
4C076/CC26; 4C076/CC29; 4C076/CC32; 4C076/CC34;  
4C076/FF01; 4C076/FF11; 4C076/FF52; 4C076/FF68;  
4C084/AA02; 4C084/AA03; 4C084/AA17; 4C084/BA44;  
4C084/CA59; 4C084/MA02; 4C084/MA17; 4C084/MA27;  
4C084/MA28; 4C084/MA35; 4C084/MA43; 4C084/MA47;  
4C084/MA57; 4C084/NA09; 4C084/NA10; 4C084/NA14;  
4C084/ZA022; 4C084/ZA082; 4C084/ZA672; 4C084/ZB112;  
4C084/ZB212; 4C084/ZB352; 4C086/AA01; 4C086/AA02;  
4C086/BC38; 4C086/BC82; 4C086/CB03; 4C086/MA01;  
4C086/MA02; 4C086/MA17; 4C086/MA27; 4C086/MA28;  
4C086/MA35; 4C086/MA43; 4C086/MA47; 4C086/MA57;  
4C086/NA09; 4C086/NA10; 4C086/NA14; 4C086/ZA02;  
4C086/ZA08; 4C086/ZA67; 4C086/ZB11; 4C086/ZB21;  
4C086/ZB35

CN---1536989 IPCI A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7];  
A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7];  
A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00  
[ICS,7,C\*]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61K0007-16 [ICS,7]

IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C\*]; A61K0031-407  
[I,A]; A61K0031-407 [I,C\*]; A61K0031-4164 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-426 [I,A]; A61K0031-426  
[I,C\*]; A61K0031-662 [I,A]; A61K0031-662 [I,C\*];

A61K0045-00 [I,C\*]; A61K0045-06 [I,A]  
 ECLA A61K007/16; A61K007/22; A61K031/00; A61K031/407;  
 A61K031/4164; A61K031/426; A61K031/662; A61K045/06

AB The present invention relates to promoting whole body health in humans and animals by using topical oral compns. comprising a safe and effective amount of a host-response modulating agent in admixt. with a pharmaceutically acceptable carrier, said compns. being effective in mediating host reaction to the presence of periodontal pathogens in the oral cavity as well as the toxins and endotoxins released by these pathogens and the inflammatory cytokines and mediators prompted by these oral pathogens. Dentifrices were prepared as well as an oral composition containing ketorolac tromethamine 0.10, ethanol 12.00, glycerin 10.00, disodium phosphate heptahydrate 0.07, saccharin sodium 0.08, monosodium phosphate monohydrate 2.03, Polysorbate 80 0.33, FD&C Blue (1% solution) 0.02, and flavor 0.15 and water q.s.

ST oral topical compn periodontal disease

IT **Antihistamines**  
 (H2; topical oral compns. for periodontal disease and promoting whole body health)

IT Transcription factors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (NF- $\kappa$ B (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells), activation of, inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT Biofilms (microbial)  
 (inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT Anesthetics  
 (local; topical oral compns. for periodontal disease and promoting whole body health)

IT Anti-inflammatory agents  
 (nonsteroidal; topical oral compns. for periodontal disease and promoting whole body health)

IT Drug delivery systems  
 (oral; topical oral compns. for periodontal disease and promoting whole body health)

IT **Tooth, disease**  
 (plaque, inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT Anti-inflammatory agents  
 Antimicrobial agents  
 Chewing gum  
 Dental materials and appliances  
 Dentifrices  
 Periodontium, disease  
 Pet animal  
 (topical oral compns. for periodontal disease and promoting whole body health)

IT 81669-70-7, Metalloproteinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT 50-78-2, Aspirin 50-81-7, Vitamin c, biological studies 53-86-1, Indomethacine 303-98-0, Coenzyme q10 500-38-9, Nordihydroguaiaretic acid 532-11-6, Anethole dithiolthione 644-62-2, Meclofenamic acid 989-51-5, Epigallocatechin gallate 1406-18-4, Vitamin e 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 11103-57-4, Vitamin a 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine 72909-34-3, PQQ 73278-54-3, Lamtidine 74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine 75438-42-5, ORF-17578 76824-35-6, Famotidine 76956-02-0, Loxitidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine 80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine 84071-15-8, Ramixotidine 84545-30-2, ICI-162846

85195-15-9, L-643728 85604-00-8, Zaltidine 86134-80-7, BMY-25368  
 87107-94-6, BL-6548 89077-71-4, BMY-25405 89250-13-5, DA-4634  
 90287-93-7, SR 58042 93064-63-2, D-16637 94662-53-0, Wy-45727  
 96153-56-9, Bisfentidine 99248-32-5, Donetidine 100981-43-9,  
 Ebrotidine 104428-51-5, HB-408 105805-28-5, HE-30256 108498-50-6,  
 FRG-8701 118288-08-7, FRG-8813  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (topical oral compns. for periodontal disease and promoting whole body  
 health)

L34 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:31206 HCAPLUS  
 DN 136:90959  
 ED Entered STN: 11 Jan 2002  
 TI Promoting whole body health using chlorite-containing compositions  
 IN Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph  
 ; Singer, Robert Ernest, Jr.; Wimalasena, Rohan Lalith  
 PA Procter & Gamble Company, USA  
 SO PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16  
 ICS A61K-0007/20  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1, 62  
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002002063	A2	20020110	2001WO-US20517	20010628
	WO2002002063	A3	20020725		
	WO2002002063	C1	20031106		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US---6846478	B1	20050125	2000US-0607729	20000630
	CA---2414576	AA	20020110	2001CA-2414576	20010628
	EP---1294345	A2	20030326	2001EP-0948785	20010628
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP2004501944	T2	20040122	2002JP-0506686	20010628
PRAI	2000US-0607729	A	20000630		
	1998US-0032234	A3	19980227		
	1998US-0032237	A3	19980227		
	1998US-0032238	A3	19980227		
	2000US-0481624	A2	20000112		
	2001WO-US20517	W	20010628		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002063	ICM	A61K-0007/16
	ICS	A61K-0007/20
	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
	ECLA	A61K007/16P; A61K007/20
US---6846478	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/049.000
	ECLA	A61K033/20; A61K008/20; A61Q011/00
CA---2414576	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]

EP---1294345 IPCI A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]  
 JP2004501944 IPCI A61K0007-16 [ICM,7]  
 FTERM 4C083/AB011; 4C083/AB012; 4C083/AB102; 4C083/AB172;  
 4C083/AB211; 4C083/AB242; 4C083/AB282; 4C083/AB312;  
 4C083/AC102; 4C083/AC112; 4C083/AC122; 4C083/AC132;  
 4C083/AC241; 4C083/AC482; 4C083/AC531; 4C083/AC581;  
 4C083/AC641; 4C083/AC691; 4C083/AC782; 4C083/AC811;  
 4C083/AC841; 4C083/AC851; 4C083/AC862; 4C083/AD042;  
 4C083/AD112; 4C083/AD272; 4C083/AD352; 4C083/AD411;  
 4C083/AD471; 4C083/AD531; 4C083/AD641; 4C083/AD661;  
 4C083/CC41; 4C083/DD08; 4C083/DD15; 4C083/DD17;  
 4C083/DD22; 4C083/DD23; 4C083/EE33

AB The present invention relates to promoting whole body health in humans and animals by using topical oral compns. comprising a safe and effective amount of chlorite ion in admixt. with a pharmaceutically acceptable carrier, said compns. being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and inhibiting the spread into the bloodstream of oral pathogenic bacteria and associated bacterial toxins and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compns. by topically applying to the oral cavity, a safe and effective amount of chlorite ion to promote and/or enhance whole body health in humans and other animals. For example, an oral spray was prepared containing sodium chlorite (80%) 1.25%, sodium bicarbonate 0.192%, sodium carbonate 0.289%, and water up to 100%. The formulation has a pH of approx. 10. In an animal clin. study conducted among Beagle dogs, 30 mL of the spray solution according was applied evenly throughout the dog's mouth twice daily (n = 10). After 9 mo, significant redns. in attachment loss were observed in the treated animals compared to those receiving placebo (n = 30), i.e., a spray solution containing the same ingredients but without sodium chlorite.

ST chlorite topical oral pharmaceutical dentifrice mouthrinse health;  
 antibacterial antiinflammatory chlorite topical oral

IT Antihistamines  
 (H2; chlorite-containing topical oral compns. for promoting whole body health)

IT Mouth  
 (administration to; chlorite-containing topical oral compns. for promoting whole body health)

IT Quaternary ammonium compounds, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (alkylbenzylidimethyl, chlorides; chlorite-containing topical oral compns. for promoting whole body health)

IT Cytokine receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antagonists; chlorite-containing topical oral compns. for promoting whole body health)

IT Redox reaction  
 (biochem., cellular, modifiers; chlorite-containing topical oral compns. for promoting whole body health)

IT Dentifrices  
 (chewing gums; chlorite-containing topical oral compns. for promoting whole body health)

IT Analgesics  
 Anti-inflammatory agents  
 Antibacterial agents  
 Antimicrobial agents  
 Dentifrices  
 Immunostimulants  
 Mouthwashes  
 (chlorite-containing topical oral compns. for promoting whole body health)

IT Chlorites  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chlorite-containing topical oral compns. for promoting whole body health)

IT Amino acids, biological studies

Antibodies and Immunoglobulins  
 Antigens  
 Bacteriocins  
 Chlorophylls, biological studies  
 Essential oils  
 Growth factors, animal  
 Hormones, animal, biological studies  
 Hydroxamic acids  
 Mineral elements, biological studies  
 Phenols, biological studies  
 Sulfonamides  
 Vitamins  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (chlorite-containing topical oral compns. for promoting whole body health)  
 IT Health  
 Human  
 Pet animal  
 (chlorite-containing topical oral compns. for promoting whole body health  
 in humans and pets)  
 IT Hypochlorites  
 RL: MSC (Miscellaneous)  
 (chlorite-containing topical oral compns. free of chlorine dioxide,  
 chlorous acid, and hypochlorite)  
 IT Lipopolysaccharides  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (complexing agents; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT Chewing gum  
 (dentifrices; chlorite-containing topical oral compns. for promoting whole  
 body health)  
 IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (essential; chlorite-containing topical oral compns. for promoting whole  
 body health)  
 IT Dentifrices  
 Drug delivery systems  
 (gels; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT Drug delivery systems  
 (lozenges; chlorite-containing topical oral compns. for promoting whole  
 body health)  
 IT Essential oils  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (peppermint; chlorite-containing topical oral compns. for promoting whole  
 body health)  
 IT Dentifrices  
 (powders; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT Drug delivery systems  
 (sprays, mouth; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT Drug delivery systems  
 (topical, oral; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT 56-03-1D, Biguanide, derivs.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (bisguanidines; chlorite-containing topical oral compns. for promoting  
 whole body health)  
 IT 7758-19-2, Sodium chlorite 14998-27-7, Chlorite  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (chlorite-containing topical oral compns. for promoting whole body health)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine 59-02-9,  $\alpha$ -Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 60-54-8, Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0, Eugenol 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0, Butylated hydroxytoluene, biological studies 137-58-6, Lidocaine 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies 303-98-0, Coenzyme Q10 443-48-1, Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2, Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 6303-21-5D, Phosphinic acid, amides 7440-31-5D, Tin, compds. 7440-66-6D, Zinc, compds. 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7757-79-1, Potassium nitrate, biological studies 8063-07-8, Kanamycin 9001-63-2, Lysozyme 9025-70-1, Dextranase 9075-84-7, Mutanase 10118-90-8, Minocycline 10476-85-4, Strontium chloride 11103-57-4, Vitamin A 14769-73-4, Levamisole 15687-27-1, Ibuprofen 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22573-93-9, Alexidine 26787-78-0, Amoxicillin 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4, Piroxicam 51481-61-9, Cimetidine 66357-35-5, Ranitidine 71138-71-1, Octapinol 71251-02-0, Octenidine 72909-34-3, Pyrroloquinoline quinone 74103-06-3, Ketorolac 74469-00-4, Augmentin antibiotic 76824-35-6, Famotidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 79874-76-3, Delmopinol 83184-43-4, Mifentidine 85554-61-6D, Furanone, derivs.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chlorite-containing topical oral compns. for promoting whole body health)

IT 10049-04-4, Chlorine dioxide 13898-47-0, Chlorous acid 14380-61-1, Hypochlorite  
 RL: MSC (Miscellaneous)  
 (chlorite-containing topical oral compns. free of chlorine dioxide, chlorous acid, and hypochlorite)

IT 81669-70-7, Metalloproteinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; chlorite-containing topical oral compns. for promoting whole body health)

IT 7439-97-6D, Mercury, compds.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mercurials; chlorite-containing topical oral compns. for promoting whole body health)

L34 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:31204 HCAPLUS

DN 136:90958

ED Entered STN: 11 Jan 2002

TI Oral care compositions comprising chlorite, and methods

IN Witt, Jonathan James; Wimalasena, Rohan Lalith; Wong, Andrew Lee; Goulbourne, Eric Altman, Jr.; Doyle, Matthew Joseph

PA Procter & Gamble Company, USA

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0007/00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 62

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002002061	A2	20020110	2001WO-US20614	20010628
	WO2002002061	A3	20020627		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,  
 YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US---6350438 B1 20020226 2000US-0607242 20000630  
 CA---2414573 AA 20020110 2001CA-2414573 20010628  
 EP---1294347 A2 20030326 2001EP-0946731 20010628  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP2004501942 T2 20040122 2002JP-0506684 20010628  
 PRAI 2000US-0607242 A 20000630  
 1998US-0032234 A2 19980227  
 1998US-0032237 A2 19980227  
 1998US-0032238 A2 19980227  
 2001WO-US20614 W 20010628

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002061	ICM	A61K-0007/00
	IPCI	A61K0007-00 [ICM,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
US---6350438	ECLA	A23K001/18N; A61K008/20; A61Q011/00
	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/053.000; 424/049.000
CA---2414573	ECLA	A61K033/20; A23K001/18N; A61K008/20; A61Q011/00
	IPCI	A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
EP---1294347	IPCI	A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2004501942	IPCI	A61K0007-20 [ICM,7]; A61C0017-00 [ICS,7]; A61K0007-22 [ICS,7]; A61K0007-24 [ICS,7]; A61L0002-18 [ICS,7]
	IPCR	A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	FTERM	4C058/AA13; 4C058/AA28; 4C058/BB07; 4C058/JJ07; 4C083/AB032; 4C083/AB101; 4C083/AB102; 4C083/AB172; 4C083/AB211; 4C083/AB242; 4C083/AB312; 4C083/AB331; 4C083/AB332; 4C083/AB472; 4C083/AC102; 4C083/AC122; 4C083/AC132; 4C083/AC242; 4C083/AC442; 4C083/AC471; 4C083/AC482; 4C083/AC641; 4C083/AC691; 4C083/AC741; 4C083/AC782; 4C083/AC791; 4C083/AC811; 4C083/AC842; 4C083/AC851; 4C083/AC862; 4C083/AD092; 4C083/AD211; 4C083/AD272; 4C083/AD352; 4C083/AD412; 4C083/AD591; 4C083/AD611; 4C083/BB41; 4C083/BB43; 4C083/BB48; 4C083/BB55; 4C083/CC41; 4C083/DD05; 4C083/DD08; 4C083/DD15; 4C083/DD22; 4C083/DD23; 4C083/DD27; 4C083/DD41; 4C083/EE03; 4C083/EE31; 4C083/EE33; 4C083/EE36; 4C083/FF05

AB The present invention relates to topical oral compns., including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, lozenges (including breath mints), dental implements (such as dental floss and tape), and pet care products comprising at least a minimally effective amount of chlorite ion

(0.02-6.0%), wherein the pH of the final composition is greater than 7 and the composition is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing diseases and conditions of the oral cavity such as gingivitis, plaque, periodontal disease, herpetic lesions, and infections that may develop following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, and scaling and root planing, in humans and other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity. For example, a sub-gingival gel was prepared containing sodium chlorite (80%) 2.0%, poly(lactide-co-glycolide) 30.0%, and propylene carbonate 68.0%. The resulting gel-like fluid can be inserted into or around the periodontal pocket or gingival region via syringe.

- ST chlorite topical oral pharmaceutical dentifrice mouthrinse; antibacterial antiinflammatory chlorite topical oral
- IT **Antihistamines**
  - (H2; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Quaternary ammonium compounds, biological studies
  - RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (alkylbenzylidimethyl, chlorides; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Bone resorption
  - (alveolar; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Cytokine receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (antagonists; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Syringes
  - (application by; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Redox reaction
  - (biochem., cellular, modifiers; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT **Dentifrices**
  - (chewing gums; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Hypochlorites
  - RL: MSC (Miscellaneous)
  - (chlorite-containing oral care compns. free of chlorine dioxide, chlorous acid, or hypochlorites)
- IT Lipopolysaccharides
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
  - (complexing agents; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT **Dentifrices**
  - (dental floss, and tapes; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Chewing gum
  - (dentifrices; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Fats and Glyceridic oils, biological studies
  - RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (essential; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT **Dentifrices**
  - Drug delivery systems
  - (gels; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Gingiva, disease
  - Inflammation
  - (gingivitis; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

- IT Mouth, disease  
(infection; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Herpesviridae  
(lesions from; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Tooth  
(loose; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Drug delivery systems  
(lozenges; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Mouth  
(mucosa; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Human herpesvirus  
(oral lesions; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Infection  
(oral; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Essential oils  
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peppermint; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Tooth, disease  
(plaque; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Dentifrices  
(powders; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Drug delivery systems  
(sprays, oral; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Dentifrices  
Mouthwashes  
(topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Analgesics  
Anti-inflammatory agents  
Antimicrobial agents  
Gingiva  
Immunostimulants  
Periodontium, disease  
Tongue  
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Chlorites  
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
- IT Amino acids, biological studies  
Antibodies and Immunoglobulins  
Antigens  
Bacteriocins  
Chlorophylls, biological studies  
Essential oils  
Growth factors, animal  
Hormones, animal, biological studies  
Hydroxamic acids  
Mineral elements, biological studies  
Phenols, biological studies  
Sulfonamides  
Vitamins

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (topical oral care compns. comprising chlorite for prevention or  
 treatment of oral cavity diseases)

IT Human  
 Pet animal  
 (topical oral care compns. comprising chlorite for prevention or  
 treatment of oral cavity diseases in humans and pets)

IT Drug delivery systems  
 (topical, oral; topical compns. comprising chlorite for prevention or  
 treatment of oral cavity diseases)

IT 56-03-1D, Biguanide, derivs.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (bisbiquanides; topical oral care compns. comprising chlorite for  
 prevention or treatment of oral cavity diseases)

IT 10049-04-4, Chlorine dioxide 13898-47-0, Chlorous acid 14380-61-1,  
 Hypochlorite  
 RL: MSC (Miscellaneous)  
 (chlorite-containing oral care compns. free of chlorine dioxide, chlorous  
 acid, or hypochlorites)

IT 81669-70-7, Metalloproteinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; topical oral care compns. comprising chlorite for  
 prevention or treatment of oral cavity diseases)

IT 7439-97-6D, Mercury, compds.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (mercurials; topical oral care compns. comprising chlorite for  
 prevention or treatment of oral cavity diseases)

IT 7758-19-2, Sodium chlorite 14998-27-7, Chlorite  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (topical compns. comprising chlorite for prevention or treatment of  
 oral cavity diseases)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin C,  
 biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine  
 59-02-9,  $\alpha$ -Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid,  
 biological studies 59-67-6, Niacin, biological studies 60-54-8,  
 Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0,  
 Eugenol 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0,  
 Butylated hydroxytoluene, biological studies 137-58-6, Lidocaine  
 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies  
 303-98-0, Coenzyme Q10 443-48-1, Metronidazole 538-71-6, Domiphen  
 bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2,  
 Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin  
 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride  
 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 6303-21-5D, Phosphinic  
 acid, amides 7440-31-5D, Tin, compds. 7440-66-6D, Zinc, compds.  
 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride,  
 biological studies 7757-79-1, Potassium nitrate, biological studies  
 8063-07-8, Kanamycin 9001-63-2, Lysozyme 9025-70-1, Dextranase  
 9075-84-7, Mutanase 10118-90-8, Minocycline 10476-85-4, Strontium  
 chloride 11103-57-4, Vitamin A 14769-73-4, Levamisole 15687-27-1,  
 Ibuprofen 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 22204-53-1,  
 Naproxen 22573-93-9, Alexidine 26787-78-0, Amoxicillin 35014-84-7,  
 N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4, Piroxicam  
 51481-61-9, Cimetidine 66357-35-5, Ranitidine 71138-71-1, Octapinol  
 71251-02-0, Octenidine 72909-34-3, PQQ 74103-06-3, Ketorolac  
 74469-00-4, Augmentin 76824-35-6, Famotidine 76963-41-2, Nizatidine  
 78273-80-0, Roxatidine 79874-76-3, Delmopinol 83184-43-4, Mifentidine  
 85554-61-6D, Furanone, derivs.  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (topical oral care compns. comprising chlorite for prevention or  
 treatment of oral cavity diseases)

L34 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:31304 HCAPLUS  
 DN 134:90937  
 ED Entered STN: 12 Jan 2001  
 TI Oral delivery system compositions comprising organosiloxanes using a  
 removable backing strip  
 IN Ye, Hai; Buckley, Christopher David; Yue, Jiang  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0009/00  
 ICS A61K-0007/16  
 CC 62-7 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 63  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001001958	A1	20010111	2000WO-US18188	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2373868	AA	20010111	2000CA-2373868	20000609
	WO2001001939	A1	20010111	2000WO-US15890	20000609
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO2001001940	A1	20010111	2000WO-US15891	20000609
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP---1196136	A1	20020417	2000EP-0941306	20000609
	EP---1196136	B1	20050413		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR2000012122	A	20020507	2000BR-0012122	20000609
	JP2003525210	T2	20030826	2001JP-0507436	20000609
	NZ---516272	A	20031128	2000NZ-0516272	20000609
	AU---769263	B2	20040122	2000AU-0056027	20000609
	RU---2222315	C2	20040127	2002RU-0102712	20000609
	AT---292953	E	20050415	2000AT-0941306	20000609
	ES---2240109	T3	20051016	2000ES-0941306	20000609
	CA---2375093	AA	20010111	2000CA-2375093	20000630
	AU2000059074	A5	20010122	2000AU-0059074	20000630
	AU---768471	B2	20031211		
	BR2000012145	A	20020430	2000BR-0012145	20000630
	EP---1200064	A1	20020502	2000EP-0945084	20000630
	EP---1200064	B1	20030502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL		
AT---238766	E	20030515	2000AT-0945084 20000630
JP2003531814	T2	20031028	2001JP-0507453 20000630
RU---2223746	C2	20040220	2002RU-0102710 20000630
ZA2001010448	A	20020724	2001ZA-0010448 20011220
US---6589512	B1	20030708	2001US-0019029 20011220
NO2002000004	A	20020228	2002NO-0000004 20020102
NO2002000005	A	20020228	2002NO-0000005 20020102
US---6649147	B1	20031118	2002US-0019032 20020320
HK---1046633	A1	20051202	2002HK-0107134 20020926
HK---1047035	A1	20040305	2002HK-0107161 20020927
PRAI 1999WO-US15130	A	19990702	
1999WO-US15131	A	19990702	
2000WO-US15890	A	20000609	
2000WO-US15891	A	20000609	
2000WO-US18188	W	20000630	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001958	ICM	A61K-0009/00
	ICS	A61K-0007/16
	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2001001939	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001940	IPCI	A61K0007-16 [ICM]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K007/16D14; A61Q011/00

EP---1196136	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR2000012122	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2003525210	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10 [ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NZ---516272	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K [I,S]
AU---769263	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
RU---2222315	IPCI	A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C*]; A61K0007-16 [ICS,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
AT---292953	IPCI	A61K0007-16 [ICM,7]
ES---2240109	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
CA---2375093	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];

		A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000059074	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
BR2000012145	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1200064	IPCI	A61K0009-00 [ICM,6]; A61K0007-16 [ICS,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AT----238766	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
JP2003531814	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0009-70

[ICS,7]; A61K0031-4164 [ICS,7]; A61K0033-40 [ICS,7];  
A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7]; A61K0047-06  
[ICS,7]; A61K0047-08 [ICS,7]; A61K0047-32 [ICS,7];  
A61K0047-34 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61P0025-04 [ICS,7]; A61P0025-00  
[ICS,7,C\*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];  
A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C\*];  
A61P0043-00 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
RU---2223746 IPCI A61K0007-16 [ICM,7]; A61K0009-20 [ICS,7]  
ECLA A61K006/02; A61K008/02; A61K008/19; A61K008/20;  
A61K008/22; A61K008/25; A61K008/26; A61K008/31;  
A61K008/35; A61K008/37; A61K008/70; A61K008/891;  
A61K009/00M18D; A61K009/00M20B; A61Q011/00  
ZA2001010448 IPCI A61K [ICM,7]  
US---6589512 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-19 [I,C\*]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
NCL 424/049.000; 424/052.000; 424/053.000; 424/054.000;  
424/058.000  
ECLA A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/41L; A61K008/891; A61Q011/00  
NO2002000004 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
NO2002000005 IPCI A61K [ICM,7]  
US---6649147 IPCI A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61C0013-23  
[ICS,7]; A61C0013-225 [ICS,7,C\*]  
IPCR A61C0019-00 [I,C\*]; A61C0019-06 [I,A]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,C\*];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A];  
A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
NCL 424/049.000; 424/401.000; 424/414.000; 424/443.000;  
424/447.000; 433/217.100; 433/228.100  
ECLA A61C019/06B; A61K008/02; A61K008/25; A61K008/26;  
A61K008/41L; A61K008/891; A61K009/00M18D; A61Q011/00  
HK---1046633 IPCI A61K [ICM,7]  
ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22;  
A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/70; A61K008/891; A61Q011/00  
HK---1047035 IPCI A61K [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;

A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
 A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
 A61K008/891; A61K009/00M18D

- AB A delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip having sufficient flexibility so as to be readily conformable to an oral surface when the delivery system is placed there against and an oral care composition applied to the strip of material such that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface. The oral care composition contains an organosiloxane resin, a rheol. modifier and at least 1 oral care substance wherein the oral care composition remains on the oral surface after the backing strip is removed. Further disclosed are such delivery systems in which the oral care composition further comprises fluid diorganopolysiloxane-based polymers; such compns. may further comprise carriers for solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymers. Thus, a composition contained MQ resin-1170-002 25, dimethicone gum 12.5, sodium percarbonate 17, oral care substance 44.5, and Bentone clay 1%.
- ST organosiloxane oral delivery backing strip; polysiloxane percarbonate oral delivery backing strip
- IT **Antihistamines**  
 (H2; oral delivery system comprising organosiloxane using removable backing strip)
- IT Silicone rubber, biological studies  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (di-Me, Me vinyl, SE 63; oral delivery system comprising organosiloxane using removable backing strip)
- IT Silicone rubber, biological studies  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (di-Me, SE 30; oral delivery system comprising organosiloxane using removable backing strip)
- IT Analgesics  
 Anti-inflammatory agents  
 Antimicrobial agents  
 Antioxidants  
 Antiviral agents  
 Dentifrices  
 Flavoring materials  
 Gums and Mucilages  
 Nutrients  
 Opacifiers  
 Paper  
 Pigments, nonbiological  
 Surfactants  
 Sweetening agents  
 Tooth  
 (oral delivery system comprising organosiloxane using removable backing strip)
- IT Chelates  
 Chlorites  
 Clays, biological studies  
 Hydrocarbon oils  
 Peroxides, biological studies  
 Peroxy acids  
 Peroxysulfates  
 Polysiloxanes, biological studies  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral delivery system comprising organosiloxane using removable backing strip)
- IT Drug delivery systems  
 (oral; oral delivery system comprising organosiloxane using removable backing strip)
- IT Group IIIA element compounds

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perborates; oral delivery system comprising organosiloxane using removable backing strip)

IT 1343-98-2D, Silicic acid, organosilylated

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MQ derivs.; oral delivery system comprising organosiloxane using removable backing strip)

IT 87-99-0, Xylitol 563-69-9D, Carbonoperoxoic acid, derivs. 3313-92-6, Sodium percarbonate 7631-86-9, Silica, biological studies 7681-49-4, Sodium Fluoride, biological studies 9002-88-4, Polyethylene 9006-65-9, Dimethicone 9016-00-6, Poly[oxy(dimethylsilylene)] 16984-48-8, Fluoride, biological studies 31900-57-9, Polydimethyl siloxane 42557-10-8, Dow Corning 200/350 318238-22-1, MQ 1170-002

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral delivery system comprising organosiloxane using removable backing strip)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Kedrowski, B; US---5866630 A 1999 HCAPLUS
- (2) Procter & Gamble; WO---9855079 A 1998 HCAPLUS
- (3) Sanvordeker, D; US---4900552 A 1990
- (4) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:31293 HCAPLUS

DN 134:90928

ED Entered STN: 12 Jan 2001

TI Systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery

IN Yue, Jiang; Mitra, Sekhar

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0007/16

CC 62-6 (Essential Oils and Cosmetics)

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2001001942	A1	20010111	2000WO-US18189	20000630
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA---2373868	AA	20010111	2000CA-2373868	20000609
WO2001001939	A1	20010111	2000WO-US15890	20000609
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
WO2001001940	A1	20010111	2000WO-US15891	20000609
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,	

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP---1196136 A1 20020417 2000EP-0941306 20000609  
 EP---1196136 B1 20050413

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

BR2000012122 A 20020507 2000BR-0012122 20000609  
 JP2003525210 T2 20030826 2001JP-0507436 20000609  
 NZ---516272 A 20031128 2000NZ-0516272 20000609  
 AU---769263 B2 20040122 2000AU-0056027 20000609  
 RU---2222315 C2 20040127 2002RU-0102712 20000609  
 AT---292953 E 20050415 2000AT-0941306 20000609  
 ES---2240109 T3 20051016 2000ES-0941306 20000609  
 CA---2373983 AA 20010111 2000CA-2373983 20000630  
 AU2000059075 A5 20010122 2000AU-0059075 20000630  
 EP---1196137 A1 20020417 2000EP-0945085 20000630  
 EP---1196137 B1 20041222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

AT---285220 E 20050115 2000AT-0945085 20000630  
 ZA2001010448 A 20020724 2001ZA-0010448 20011220  
 US---6589512 B1 20030708 2001US-0019029 20011220  
 NO2002000005 A 20020228 2002NO-0000005 20020102  
 US---6692727 B1 20040217 2002US-0019031 20020320  
 HK---1046633 A1 20051202 2002HK-0107134 20020926

PRAI 1999WO-US15130 A 19990702  
 1999WO-US15131 A 19990702  
 2000WO-US15890 A 20000609  
 2000WO-US15891 A 20000609  
 2000WO-US18189 W 20000630

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001942	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2001001939	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 WO2001001940 ECLA A61K0006/02; A61K0008/02; A61K0008/19; A61K0008/20; A61K0008/22; A61K0008/25; A61K0008/26; A61K0008/31; A61K0008/35; A61K0008/37; A61K0008/70; A61K0008/891; A61K0009/00M18D; A61K0009/00M20B; A61Q011/00  
 IPCI A61K0007-16 [ICM]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 EP---1196136 ECLA A61K0006/02; A61K0007/16D14; A61Q011/00  
 IPCI A61K0007-16 [ICM,6]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 BR2000012122 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 JP2003525210 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C\*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C\*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10 [ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C\*]; A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C\*]; A61P0043-00 [ICS,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 NZ----516272 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K [I,S]  
 AU----769263 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 RU---2222315 IPCI A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C\*]; A61K0007-16 [ICS,7]  
 ECLA A61K0006/02; A61K0008/19; A61K0008/20; A61K0008/22; A61K0008/26; A61K0008/31; A61K0008/35; A61K0008/37; A61K0008/70; A61K0008/891; A61Q011/00  
 AT----292953 IPCI A61K0007-16 [ICM,7]

ES---2240109 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00  
 CA---2373983 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D  
 AU2000059075 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D  
 EP---1196137 IPCI A61K0007-16 [ICM,6]  
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C\*]  
 AT---285220 IPCI A61K0007-16 [ICM,7]  
 ZA2001010448 IPCI A61K [ICM,7]  
 US---6589512 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0008-19 [I,C\*]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 NCL 424/049.000; 424/052.000; 424/053.000; 424/054.000; 424/058.000  
 ECLA A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/41L; A61K008/891; A61Q011/00  
 NO2002000005 IPCI A61K [ICM,7]  
 US---6692727 IPCI A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0006-08 [ICS,7]; A61K0006-02 [ICS,7,C\*]  
 IPCR A61K0006-02 [I,C\*]; A61K0006-093 [I,A]; A61K0008-19 [I,C\*]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 NCL 424/053.000; 424/049.000; 433/215.000; 433/216.000  
 ECLA A61K006/093; A61K008/26; A61K008/31; A61K008/34; A61K008/891; A61Q011/00  
 HK---1046633 IPCI A61K [ICM,7]  
 ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22;

A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/70; A61K008/891; A61Q011/00

- AB Disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a volatile carrier capable of solubilizing the organosiloxane resin; (iii) a rheol. modifier; and (iv) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin. Further disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a fluid diorganopolysiloxane-based polymer; (iii) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer; (iv) a rheol. modifier; and (v) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin. The protective composition may further comprise a fluid diorganopolysiloxane-based polymer and/or a rheol. modifier. Still further disclosed is a method of using these systems. A hydrophobic oral care composition contained organosiloxane resin (MQ resin) 25, silicone gum (dimethicone gum) 12.5, oral care substance (sodium percarbonate) 17, volatile carrier (isododecane) 44.5, and bentone clay (Bentone 27) 1%.
- ST siloxane resin delivery oral care dentifrice
- IT **Antihistamines**  
(H2; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Tooth  
(color; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Tooth  
(enamel; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Chlorites  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(metal salts; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Group IIIA element compounds  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(perborates; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Polyamide fibers, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(powders; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Analgesics  
Antimicrobial agents  
Antioxidants  
Antiviral agents  
Chelating agents  
Dentifrices  
Dyes  
Flavoring materials  
Opacifiers  
Pigments, nonbiological  
Surfactants  
Sweetening agents  
(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)
- IT Clays, biological studies  
Hydrocarbon oils  
Peroxides, biological studies  
Peroxy acids  
Peroxy sulfates

Polysiloxanes, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT 87-99-0, Xylitol 109-60-4, Propyl acetate 141-78-6, Ethyl acetate, biological studies 563-69-9, Carbonoperoxoic acid 7631-86-9, Silica, biological studies 9002-88-4, Polyethylene 9006-65-9, Dimethicone 9016-00-6, Dimethylpolysiloxane 9016-00-6D, Polydimethylsiloxane, polyalkylene oxide-modified 12691-60-0, (Bentone 27) 16984-48-8, Fluoride ion, biological studies 31807-55-3, (Isododecane) 31900-57-9, Polydimethylsiloxane 31900-57-9D, Polydimethylsiloxane, polyalkylene oxide-modified 56091-38-4, Bentone gel ipm 163702-07-6, Methyl nonafluorobutyl ether 163702-08-7 219484-64-7, Hfe 7100

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Hill, I; US---5651959 A 1997 HCAPLUS
- (2) Kedrowski, B; US---5866630 A 1999 HCAPLUS
- (3) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:31292 HCAPLUS

DN 134:90935

ED Entered STN: 12 Jan 2001

TI Compositions comprising organosiloxane resins for delivering xylitol to the oral cavity

IN Yue, Jiang; Mitra, Sekhar

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0007/16

CC 62-7 (Essential Oils and Cosmetics)

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2001001941	A1	20010111	2000WO-US18187	20000630
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA---2373868	AA	20010111	2000CA-2373868	20000609
WO2001001939	A1	20010111	2000WO-US15890	20000609
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
WO2001001940	A1	20010111	2000WO-US15891	20000609
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP---1196136 A1 20020417 2000EP-0941306 20000609  
 EP---1196136 B1 20050413  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

BR2000012122 A 20020507 2000BR-0012122 20000609  
 JP2003525210 T2 20030826 2001JP-0507436 20000609  
 NZ---516272 A 20031128 2000NZ-0516272 20000609  
 AU---769263 B2 20040122 2000AU-0056027 20000609  
 RU---222315 C2 20040127 2002RU-0102712 20000609  
 AT---292953 E 20050415 2000AT-0941306 20000609  
 ES---2240109 T3 20051016 2000ES-0941306 20000609  
 AU2000059073 A5 20010122 2000AU-0059073 20000630  
 ZA2001010448 A 20020724 2001ZA-0010448 20011220  
 US---6589512 B1 20030708 2001US-0019029 20011220  
 NO2002000005 A 20020228 2002NO-0000005 20020102  
 HK---1046633 A1 20051202 2002HK-0107134 20020926

PRAI 1999WO-US15130 A 19990702  
 1999WO-US15131 A 19990702  
 2000WO-US15890 A 20000609  
 2000WO-US15891 A 20000609  
 2000WO-US18187 W 20000630

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001941	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2001001939	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001940	IPCI	A61K0007-16 [ICM]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19

[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
EP---1196136 ECLA A61K006/02; A61K007/16D14; A61Q011/00  
IPCI A61K0007-16 [ICM,6]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
BR2000012122 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
JP2003525210 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20  
[ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7];  
A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06  
[ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7];  
A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32  
[ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C\*];  
A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C\*];  
A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10  
[ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C\*];  
A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C\*];  
A61P0043-00 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
NZ---516272 IPCI A61K0007-16 [ICM,7]  
IPCR A61K [I,S]  
AU---769263 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
RU---2222315 IPCI A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C\*];  
A61K0007-16 [ICS,7]  
ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22;  
A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/70; A61K008/891; A61Q011/00  
AT---292953 IPCI A61K0007-16 [ICM,7]  
ES---2240109 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-19  
[I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22;

A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/70; A61K008/891; A61Q011/00

AU2000059073 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D

ZA2001010448 IPCI A61K [ICM,7]  
US---6589512 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0008-19 [I,C\*]; A61K0008-26 [I,A]; A61K0008-30  
[I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];  
A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
NCL 424/049.000; 424/052.000; 424/053.000; 424/054.000;  
424/058.000  
ECLA A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/41L; A61K008/891; A61Q011/00

NO2002000005 IPCI A61K [ICM,7]  
HK---1046633 IPCI A61K [ICM,7]  
ECLA A61K006/02; A61K008/19; A61K008/20; A61K008/22;  
A61K008/26; A61K008/31; A61K008/35; A61K008/37;  
A61K008/70; A61K008/891; A61Q011/00

AB Disclosed is a composition for delivering xylitol to the oral cavity,  
comprising: (a) an organosiloxane resin; (b) a volatile carrier capable of  
solubilizing the organosiloxane resin; (c) a rheol. modifier; and (d) an  
effective amount of xylitol. The present invention is also directed to such  
compsns. comprising: (a) an organosiloxane resin; (b) a fluid  
diorganopolysiloxane-based polymer; (c) a volatile carrier capable of  
solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-  
based polymer; (d) a rheol. modifier; and (e) an effective amount of  
xylitol. The compsns. herein may further comprise an addnl. oral care  
substance. Further disclosed is a method of using these compsns. A  
hydrophobic oral care composition contained organosiloxane resin (MQ resin)  
25.5, silicone gum (dimethicone gum) 12.5, xylitol 4.5, volatile carrier  
(isododecane) 56.5, and bentone clay (Bentone 27) 1%.

ST organosiloxane resin xylitol delivery oral cavity

IT Antihistamines  
(H2; compsns. comprising organosiloxane resins for delivering  
xylitol to oral cavity)

IT Analgesics  
Anti-inflammatory agents  
Antimicrobial agents  
Antioxidants  
Antiviral agents  
Chelating agents  
Dentifrices  
Dyes  
Flavoring materials  
Mouth  
Nutrients  
Opacifiers  
Pigments, nonbiological  
Solvents  
Surfactants  
Sweetening agents  
(compsns. comprising organosiloxane resins for delivering xylitol to

oral cavity)  
 IT Clays, biological studies  
 Hydrocarbon oils  
 Polysiloxanes, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (compsns. comprising organosiloxane resins for delivering xylitol to  
 oral cavity)  
 IT 87-99-0, Xylitol 7631-86-9, Silica, biological studies 9002-88-4,  
 Polyethylene 9006-65-9, Dimethicone 9016-00-6,  
 Poly[oxy(dimethylsilylene)] 16984-48-8, Fluoride ion, biological studies  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (compsns. comprising organosiloxane resins for delivering xylitol to  
 oral cavity)  
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE  
 (1) Hill, I; US---4950479 A 1990 HCAPLUS  
 (2) Hill, I; US---5009881 A 1991 HCAPLUS  
 (3) Hill, I; US---5032387 A 1991 HCAPLUS

L34 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:31291 HCAPLUS  
 DN 134:90934  
 ED Entered STN: 12 Jan 2001  
 TI Compositions comprising organosiloxane resins for delivering oral care  
 substances  
 IN Yue, Jiang; Crisanti, Mark Matthew; Majeti, Satyanarayana; Burgess, Steven  
 Carl; Reno, Elizabeth Ann; Li, Li; Mitra, Sekhar  
 PA The Procter & Gamble Company, USA  
 SO PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K-0007/16  
 CC 62-7 (Essential Oils and Cosmetics)  
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2001001939	A1	20010111	2000WO-US15890	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2373867	AA	20010111	2000CA-2373867	20000609
AU2000056026	A5	20010122	2000AU-0056026	20000609
AU---769802	B2	20040205		
BR2000012522	A	20020326	2000BR-0012522	20000609
EP---1196135	A1	20020417	2000EP-0941305	20000609
EP---1196135	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR-200103821	T2	20020422	2001TR-0003821	20000609
AT---252365	E	20031115	2000AT-0941305	20000609
RU---2225706	C2	20040320	2002RU-0102711	20000609
JP2004513065	T2	20040430	2001JP-0507435	20000609
ES---2204630	T3	20040501	2000ES-0941305	20000609
CA---2373983	AA	20010111	2000CA-2373983	20000630
CA---2375093	AA	20010111	2000CA-2375093	20000630
WO2001001941	A1	20010111	2000WO-US18187	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO2001001958 A1 20010111 2000WO-US18188 20000630  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,  
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO2001001942 A1 20010111 2000WO-US18189 20000630  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,  
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU2000059073 A5 20010122 2000AU-0059073 20000630  
AU2000059074 A5 20010122 2000AU-0059074 20000630  
AU---768471 B2 20031211  
AU2000059075 A5 20010122 2000AU-0059075 20000630  
EP---1196137 A1 20020417 2000EP-0945085 20000630  
EP---1196137 B1 20041222  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
BR2000012145 A 20020430 2000BR-0012145 20000630  
EP---1200064 A1 20020502 2000EP-0945084 20000630  
EP---1200064 B1 20030502  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL  
AT---238766 E 20030515 2000AT-0945084 20000630  
JP2003531814 T2 20031028 2001JP-0507453 20000630  
ES---2199168 T3 20040216 2000ES-0945084 20000630  
AT---285220 E 20050115 2000AT-0945085 20000630  
ZA2001010449 A 20020711 2001ZA-0010449 20011220  
ZA2001010447 A 20020930 2001ZA-0010447 20011220  
US---6569408 B1 20030527 2001US-0019038 20011220  
NO2002000004 A 20020228 2002NO-0000004 20020102  
NO2002000006 A 20020228 2002NO-0000006 20020102  
US---6649147 B1 20031118 2002US-0019032 20020320  
US---6692727 B1 20040217 2002US-0019031 20020320  
HK---1047033 A1 20041015 2002HK-0107124 20020926  
HK---1047035 A1 20040305 2002HK-0107161 20020927

PRAI 1999WO-US15130 A 19990702  
1999WO-US15131 A 19990702  
2000WO-US15890 W 20000609  
2000WO-US15891 A 20000609  
2000WO-US18187 W 20000630  
2000WO-US18188 W 20000630  
2000WO-US18189 W 20000630

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001939	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];

		A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373867	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000056026	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
BR2000012522	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1196135	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
TR-200103821	IPCI	A61K0007-16 [ICM,7]

IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D  
 AT---252365 IPCI A61K0007-16 [ICM,7]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D  
 RU---2225706 IPCI A61K0007-16 [ICM,7]; A61K0006-00 [ICS,7]; A61K0009-70 [ICS,7]  
 ECLA A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00  
 JP2004513065 IPCI A61K0007-16 [ICM,7]; A61K0007-00 [ICS,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 FTERM 4C083/AB172; 4C083/AB211; 4C083/AB222; 4C083/AB231; 4C083/AB232; 4C083/AB241; 4C083/AB242; 4C083/AB272; 4C083/AB282; 4C083/AB321; 4C083/AB331; 4C083/AB332; 4C083/AB371; 4C083/AB411; 4C083/AB412; 4C083/AB431; 4C083/AB432; 4C083/AB441; 4C083/AB442; 4C083/AB472; 4C083/AC011; 4C083/AC012; 4C083/AC032; 4C083/AC101; 4C083/AC102; 4C083/AC171; 4C083/AC172; 4C083/AC211; 4C083/AC212; 4C083/AC341; 4C083/AC342; 4C083/AC461; 4C083/AC742; 4C083/AC862; 4C083/AD021; 4C083/AD071; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD151; 4C083/AD152; 4C083/AD162; 4C083/AD241; 4C083/AD261; 4C083/AD451; 4C083/BB60; 4C083/CC41; 4C083/DD22; 4C083/EE32; 4C083/EE33; 4C083/EE34; 4C083/EE35; 4C083/EE36; 4C083/EE37  
 ES---2204630 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D  
 CA---2373983 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22

[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
CA---2375093 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
WO2001001941 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61K006/02; A61K008/02; A61K008/19; A61K008/20;  
A61K008/22; A61K008/25; A61K008/26; A61K008/31;  
A61K008/35; A61K008/37; A61K008/70; A61K008/891;  
A61K009/00M18D; A61K009/00M20B; A61Q011/00  
WO2001001958 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61K006/02; A61K008/02; A61K008/19; A61K008/20;  
A61K008/22; A61K008/25; A61K008/26; A61K008/31;  
A61K008/35; A61K008/37; A61K008/70; A61K008/891;  
A61K009/00M18D; A61K009/00M20B; A61Q011/00  
WO2001001942 IPCI A61K0007-16 [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61K006/02; A61K008/02; A61K008/19; A61K008/20;  
A61K008/22; A61K008/25; A61K008/26; A61K008/31;  
A61K008/35; A61K008/37; A61K008/70; A61K008/891;  
A61K009/00M18D; A61K009/00M20B; A61Q011/00

AU2000059073 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D

AU2000059074 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D

AU2000059075 IPCI A61K0007-16 [ICM,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D

EP---1196137 IPCI A61K0007-16 [ICM,6]  
 IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C\*]

BR2000012145 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D

EP---1200064 IPCI A61K0009-00 [ICM,6]; A61K0007-16 [ICS,6]  
 IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02 [I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A]; A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00

[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
AT----238766 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
JP2003531814 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0009-70  
[ICS,7]; A61K0031-4164 [ICS,7]; A61K0033-40 [ICS,7];  
A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7]; A61K0047-06  
[ICS,7]; A61K0047-08 [ICS,7]; A61K0047-32 [ICS,7];  
A61K0047-34 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00  
[ICS,7,C\*]; A61P0025-04 [ICS,7]; A61P0025-00  
[ICS,7,C\*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];  
A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C\*];  
A61P0043-00 [ICS,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ES---2199168 IPCI A61K0009-00 [ICM,4]; A61K0007-16 [ICS,4]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
AT----285220 IPCI A61K0007-16 [ICM,7]  
ZA2001010449 IPCI A61K [ICM,7]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
ZA2001010447 IPCI A61K [ICM,7]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
US---6569408 IPCI A61K0007-16 [ICM,7]; A61K0006-08 [ICS,7]; A61K0006-02  
[ICS,7,C\*]; A61C0005-00 [ICS,7]; C09K0003-00 [ICS,7]  
IPCR A61K0006-02 [I,C\*]; A61K0006-093 [I,A]; A61K0008-72

[I,C\*]; A61K0008-89 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
NCL 424/049.000; 433/217.100; 433/228.100; 523/116.000;  
523/118.000  
ECLA A61K006/093; A61K008/89; A61Q011/00  
NO2002000004 IPCI A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
NO2002000006 IPCI A61K [ICM,7]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
US---6649147 IPCI A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61C0013-23  
[ICS,7]; A61C0013-225 [ICS,7,C\*]  
IPCR A61C0019-00 [I,C\*]; A61C0019-06 [I,A]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,C\*];  
A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61K0009-00 [I,A];  
A61K0009-00 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00  
[I,C\*]  
NCL 424/049.000; 424/401.000; 424/414.000; 424/443.000;  
424/447.000; 433/217.100; 433/228.100  
ECLA A61C019/06B; A61K008/02; A61K008/25; A61K008/26;  
A61K008/41L; A61K008/891; A61K009/00M18D; A61Q011/00  
US---6692727 IPCI A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0006-08  
[ICS,7]; A61K0006-02 [ICS,7,C\*]  
IPCR A61K0006-02 [I,C\*]; A61K0006-093 [I,A]; A61K0008-19  
[I,C\*]; A61K0008-26 [I,A]; A61K0008-30 [I,C\*];  
A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-72  
[I,C\*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
NCL 424/053.000; 424/049.000; 433/215.000; 433/216.000  
ECLA A61K006/093; A61K008/26; A61K008/31; A61K008/34;  
A61K008/891; A61Q011/00  
HK---1047033 IPCI A61K [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D  
HK---1047035 IPCI A61K [ICM,7]  
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C\*]; A61K0008-02  
[I,A]; A61K0008-02 [I,C\*]; A61K0008-19 [I,A];  
A61K0008-19 [I,C\*]; A61K0008-20 [I,A]; A61K0008-22  
[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];  
A61K0008-30 [I,C\*]; A61K0008-31 [I,A]; A61K0008-35  
[I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];  
A61K0008-72 [I,C\*]; A61K0008-891 [I,A]; A61K0009-00  
[I,A]; A61K0009-00 [I,C\*]; A61Q0011-00 [I,A];  
A61Q0011-00 [I,C\*]  
ECLA A61Q011/00; A61K006/02; A61K008/02; A61K008/19;  
A61K008/20; A61K008/22; A61K008/25; A61K008/26;  
A61K008/31; A61K008/35; A61K008/37; A61K008/70;  
A61K008/891; A61K009/00M18D

AB Disclosed is a composition for delivering an oral care substance to the oral

cavity, comprising: (a) an organosiloxane resin; (b) a volatile carrier capable of solubilizing the organosiloxane resin; (c) a rheol. modifier; and (d) at least one oral care substance. The present invention is also directed to such compns. comprising: (a) an organosiloxane resin; (b) a fluid diorganopolysiloxane polymer; (c) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane polymer; (d) a rheol. modifier; and (e) at least one oral care substance. Further disclosed is a method of using these compns. A hydrophobic oral care composition contained organosiloxane resin (MQ resin) 25, silicone gum (dimethicone gum) 12.5, oral care substance 17, volatile carrier (isododecane) 44.5, and bentone clay (Bentone 27) 1%.

ST oral care organosiloxane resin dentifrice

IT **Antihistamines**

(H2; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Tooth**

(color; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Analgesics**

Antimicrobial agents

Antioxidants

Antiviral agents

Chelating agents

**Dentifrices**

Flavoring materials

Pigments, nonbiological

Surfactants

Sweetening agents

(compns. comprising organosiloxane resins for delivering oral care substances)

IT **Acrylic polymers, biological studies**

Clays, biological studies

Hydrocarbon oils

Mica-group minerals, biological studies

Peroxides, biological studies

Peroxy acids

Peroxy sulfates

Siloxanes (nonpolymeric)

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(compns. comprising organosiloxane resins for delivering oral care substances)

IT **Tooth**

(enamel; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Chlorites**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(metal salts; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Group IIIA element compounds**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(perborates; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Silk**

(powders; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Polyamide fibers, biological studies**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(powders; compns. comprising organosiloxane resins for delivering oral care substances)

IT **Mica-group minerals, biological studies**

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(titanium; compns. comprising organosiloxane resins for delivering oral care substances)

IT 64-17-5, Hydrocarbon oils, biological studies 78-93-3, Hydrocarbon oils, biological studies 87-99-0, Xylitol 109-60-4, Propyl acetate 141-78-6, Ethyl acetate, biological studies 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 563-69-9, Carbonoperoxoic acid 1309-37-1, Red iron oxide, biological studies 1314-13-2, Zinc oxide, biological studies 1327-43-1, Aluminum magnesium silicate 1332-37-2, Iron oxide, biological studies 1343-88-0, Magnesium silicate 7631-86-9, Silica, biological studies 7787-59-9, Bismuth oxychloride 9002-88-4, Polyethylene 9004-34-6, Crystalline cellulose, biological studies 9005-25-8, Starch, biological studies 9006-65-9, Dimethicone 9016-00-6, Dimethylpolysiloxane 9016-00-6D, Polydimethylsiloxane, polyalkylene oxide-modified 12227-89-3, Black iron oxide 12691-60-0, (Bentone 27) 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 16984-48-8, Fluoride ion, biological studies 31807-55-3, (Isododecane) 31900-57-9, Polydimethylsiloxane 31900-57-9D, Polydimethylsiloxane, polyalkylene oxide-modified 51274-00-1, Yellow iron oxide 56091-38-4, Bentone gel ipm 57455-37-5, Ultramarine 163702-07-6, Methyl nonafluorobutyl ether 163702-08-7, Methyl nonafluoroisobutyl ether 219484-64-7, Hfe 7100

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(compns. comprising organosiloxane resins for delivering oral care substances)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Hill, I; US---5651959 A 1997 HCAPLUS
- (2) Kedrowski, B; US---5866630 A 1999 HCAPLUS
- (3) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:144704 HCAPLUS

DN 132:185445

ED Entered STN: 03 Mar 2000

TI Oral liquid mucoadhesive compositions

IN Dobrozsi, Douglas Joseph

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0009/10

ICS A61K-0047/02

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2000010529	A1	20000302	1999WO-US19202	19990824
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
US---6319513	B1	20011120	1999US-0361533	19990727
CA---2338704	AA	20000302	1999CA-2338704	19990824
CA---2338704	C	20041102		
AU---9955809	A1	20000314	1999AU-0055809	19990824
AU---761968	B2	20030612		
BR---9913178	A	20010515	1999BR-0013178	19990824
EP---1107733	A1	20010620	1999EP-0942429	19990824
EP---1107733	B1	20050727		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	

	IE, SI, LT, LV, FI, RO			
TR-200100628	T2	20011022	TR 2001-200100628	19990824
JP2002523354	T2	20020730	2000JP-0565851	19990824
AT----300282	E	20050815	1999AT-0942429	19990824
NO2001000832	A	20010219	2001NO-0000832	20010219
PRAI 1998US-097578P	P	19980824		
1999WO-US19202	W	19990824		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000010529	ICM	A61K-0009/10
	ICS	A61K-0047/02
	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
US---6319513	ECLA	A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
	IPCI	A61F0013-02 [ICM,7]
	IPCR	A61K0047-02 [I,A]; A61K0047-02 [I,C*]
	NCL	424/434.000; 424/435.000
	ECLA	A61K047/02
CA---2338704	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
AU---9955809	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
BR---9913178	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
EP---1107733	IPCI	A61K0009-10 [ICM,6]; A61K0047-02 [ICS,6]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
	ECLA	A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
TR-200100628	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
JP2002523354	IPCI	A61K0045-08 [ICM,7]; A61K0045-00 [ICM,7,C*]; A61K0047-02 [ICS,7]; A61P0001-00 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-04 [ICS,7]; A61P0009-00 [ICS,7]; A61P0011-00 [ICS,7]; A61P0011-08 [ICS,7]; A61P0011-10 [ICS,7]; A61P0011-14 [ICS,7]; A61P0023-00 [ICS,7]; A61P0025-04 [ICS,7]; A61P0025-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]
AT----300282	IPCI	A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
	ECLA	A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
NO2001000832	IPCI	A61K0009-10 [ICM,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02 [I,A]; A61K0047-02 [I,C*]

AB The present invention relates to a oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising 2-50%, by weight of the composition, of colloidal particles of silica, titanium dioxide, clay, and mixts. and a safe and effective amount of a drug selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixts. The composition has a sedimentation volume ratio of >0.90 and the triggered viscosity ratio of the composition is at least about 1.2. The present invention further relates to a method of coating the alimentary canal or nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amount of the above composition. Thus, a formulation contained dried Al(OH)<sub>3</sub> gel powder antacid 7, Cab-O-Sil M5 8.3, and water to 100%.

ST oral liq mucoadhesive titanium dioxide; silica oral liq mucoadhesive

IT Antihistamines  
(H2; oral liquid mucoadhesive compns.)

IT Drugs  
 (gastrointestinal; oral liquid mucoadhesive compns.)  
 IT Drug delivery systems  
 (liqs., oral; oral liquid mucoadhesive compns.)  
 IT Plant (Embryophyta)  
 (medicinal, exts.; oral liquid mucoadhesive compns.)  
 IT Drug delivery systems  
 (nasal sprays; oral liquid mucoadhesive compns.)  
 IT Analgesics  
 Antacids  
 Antidiarrheals  
 Antihistamines  
 Antitussives  
 Bronchodilators  
 Cholinergic antagonists  
 Decongestants  
 Expectorants  
 Laxatives  
 Mouthwashes  
 Particle size distribution  
 Viscosity  
 (oral liquid mucoadhesive compns.)  
 IT Esophagus  
 (sphincter; oral liquid mucoadhesive compns.)  
 IT Drug delivery systems  
 (syrups; oral liquid mucoadhesive compns.)  
 IT Anesthetics  
 (topical; oral liquid mucoadhesive compns.)  
 IT 125-69-9, Dextromethorphan hydrobromide 2315-02-8, Oxymetazoline  
 hydrochloride 7631-86-9, Silica, biological studies 13463-67-7,  
 Titanium oxide, biological studies 14882-18-9, Bismuth subsalicylate  
 21645-51-2, Aluminum hydroxide (Al(OH)<sub>3</sub>), biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oral liquid mucoadhesive compns.)  
 IT 9000-83-3  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proton-translocating, inhibitors; oral liquid mucoadhesive compns.)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Cedona Pharmaceuticals; EP---0517274 A 1992 HCAPLUS
- (2) Laboratoires Human-Pharm SA; EP---0062578 A 1982 HCAPLUS
- (3) The Procter & Gamble Company; US---5458879 A 1995 HCAPLUS
- (4) The Procter & Gamble Company; WO---9523591 A 1995 HCAPLUS

L34 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:124044 HCAPLUS

DN 128:196683

ED Entered STN: 28 Feb 1998

TI Inhibiting undesirable taste in oral compositions

IN Nelson, Sandra Lynn

PA Procter & Gamble Company, USA

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0047/00

ICS A61K-0007/00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17, 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9806436	A2	19980219	1997WO-US13472	19970728
	WO---9806436	A3	20001221		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,  
 VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

US---	5766622	A	19980616	1996US-0696711	19960814
AU---	9739676	A1	19980306	1997AU-0039676	19970728
AU---	724235	B2	20000914		
BR---	9711159	A	19990817	1997BR-0011159	19970728
EP---	1077726	A2	20010228	1997EP-0937072	19970728
EP---	1077726	B1	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
CN---	1306440	A	20010801	1997CN-0197342	19970728
JP2001527518		T2	20011225	1998JP-0509785	19970728
AT---	234115	E	20030315	1997AT-0937072	19970728
CA---	2263297	C	20031028	1997CA-2263297	19970728
CA---	2263297	AA	19980219		
ZA---	9707082	A	19980304	1997ZA-0007082	19970808
NO---	9900685	A	19990412	1999NO-0000685	19990212
KR2000030006		A	20000525	1999KR-0701291	19990218
PRAI	1996US-0696711	A	19960814		
	1997WO-US13472	W	19970728		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9806436	ICM	A61K-0047/00
	ICS	A61K-0007/00
	IPCI	A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A23L001/227; A61Q011/00; A61K008/44; A61K008/55; A61K009/00M18B; A61K009/00N2; A61K047/24
US---5766622	IPCI	A61K0031-74 [ICM,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/440.000; 441/048.000; 441/049.000; 441/054.000; 514/974.000
	ECLA	A23L001/227; A61K008/44; A61K008/55; A61K009/00M18B; A61K009/00N2; A61K047/24; A61Q011/00
AU---9739676	IPCI	A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR---9711159	IPCI	A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
EP---1077726	IPCI	A61K0047-24 [ICM,6]; A61K0009-00 [ICS,6]; A61K0007-16 [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];

A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 CN---1306440 IPCI A61K0047-24 [ICM,7]; A61K0009-00 [ICS,7]; A61K0007-16 [ICS,7]  
 IPCR A23L0001-226 [I,C\*]; A23L0001-227 [I,A]; A61K0008-30 [I,C\*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 JP2001527518 IPCI A61K0047-24 [ICM,7]; A61K0007-16 [ICS,7]  
 AT----234115 IPCI A61K0047-24 [ICM,7]; A61K0009-00 [ICS,7]; A61K0007-16 [ICS,7]  
 IPCR A23L0001-226 [I,C\*]; A23L0001-227 [I,A]; A61K0008-30 [I,C\*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 CA---2263297 IPCI A61K0047-24 [ICM,6]; A61K0007-16 [ICS,6]  
 ZA---9707082 IPCI A23L [ICM,6]; A61K [ICS,6]  
 IPCR A23L0001-226 [I,C\*]; A23L0001-227 [I,A]; A61K0008-30 [I,C\*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 NO---9900685 IPCI A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]  
 IPCR A23L0001-226 [I,C\*]; A23L0001-227 [I,A]; A61K0008-30 [I,C\*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 KR2000030006 IPCI A61K0047-24  
 IPCR A23L0001-226 [I,C\*]; A23L0001-227 [I,A]; A61K0008-30 [I,C\*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C\*]; A61K0047-16 [N,C\*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C\*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C\*]  
 AB The present invention relates to a method for inhibiting an undesirable taste in oral compns. such as foods, beverages, and pharmaceuticals. The present invention also relates to oral and pharmaceutical compns. comprising undesirable tasting compds. wherein undesirable tastes are inhibited by the addition of a phosphorylated amino acid, such as phosphotyrosine, phosphoserine, phosphothreonine, and mixts. thereof, to the oral and pharmaceutical compns. Liquid cough/cold compns. for oral administration contained ibuprofen arginate 1, chlorpheniramine maleate 0.02, pseudoephedrine·HCl 0.3, phosphotyrosine 2, ethanol (95%) 25, propylene glycol 25, Na citrate 2, citric acid 0.25, liquid sugar 25, glycerin 7, colorants 0.009, flavors 0.5, and water to 100 % weight/volume  
 ST taste masking phosphorylated amino acid; phosphotyrosine antitussive liq taste masking  
 IT Antihistamines  
 (H2; taste masking in oral compns. using phosphorylated amino acids)  
 IT Drug delivery systems  
 Drug delivery systems  
 (liqs., oral; taste masking in oral compns. using phosphorylated amino acids)  
 IT Amino acids, biological studies  
 RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphorylated; taste masking in oral compns. using phosphorylated amino acids)

IT Nutrients  
(supplements; taste masking in oral compns. using phosphorylated amino acids)

IT Analgesics  
Anesthetics  
Antacids  
Anti-inflammatory agents  
Antibacterial agents  
Antidiarrheals  
Antiemetics  
Antihistamines  
Antimicrobial agents  
Antipyretics  
Antitussives  
Antiviral agents  
Appetite depressants  
Beverages  
Bronchodilators  
Cholinergic antagonists  
Decongestants  
Dentifrices  
Expectorants  
Food  
Fungicides  
Laxatives  
Mouthwashes  
(taste masking in oral compns. using phosphorylated amino acids)

IT Peroxides, biological studies  
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(taste masking in oral compns. using phosphorylated amino acids)

IT 407-41-0 1114-81-4 21820-51-9, Phosphotyrosine 57469-82-6  
RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(taste masking in oral compns. using phosphorylated amino acids)

IT 93-14-1, Glyceryl guaiacolate 103-90-2, Acetaminophen 113-92-8, Chlorpheniramine maleate 125-69-9, Dextromethorphan hydrobromide 345-78-8, Pseudoephedrine hydrochloride  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(taste masking in oral compns. using phosphorylated amino acids)

L34 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN  
AN 1998:13835 HCAPLUS  
DN 128:93192  
ED Entered STN: 10 Jan 1998  
TI Use of H2-antagonists for the manufacture of a topical composition for the treatment of colds  
IN Singer, Robert Ernest, Jr.  
PA Procter and Gamble Company, USA  
SO PCT Int. Appl., 14 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K-0031/00  
CC 63-6 (Pharmaceuticals)  
Section cross-reference(s): 1  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9747292	A1	19971218	1997WO-US09977	19970610
	W: AU, BR, CA, CN, JP, KR, MX, SG				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA---2257990	AA	19971218	1997CA-2257990	19970610
	AU---9733069	A1	19980107	1997AU-0033069	19970610

CN---	1221338	A	19990630	1997CN-0195430	19970610
BR---	9709792	A	19990810	1997BR-0009792	19970610
JP---	11513035	T2	19991109	1997JP-0501751	19970610
EP----	954294	A1	19991110	1997EP-0928916	19970610

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

PRAI	1996US-0662389	A	19960612		
	1997WO-US09977	W	19970610		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9747292	ICM	A61K-0031/00
	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
	ECLA	A61K031/341; A61K031/426
CA---2257990	IPCI	A61K0045-00 [ICM,6]; A61K0007-16 [ICS,6]; A61K0031-34 [ICS,6]; A61K0031-415 [ICS,6]
AU---9733069	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
CN---1221338	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
BR---9709792	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
JP--11513035	IPCI	A61K0045-00 [ICM,6]; A61K0007-16 [ICS,6]; A61K0009-06 [ICS,6]; A61K0031-00 [ICS,6]; A61K0031-34 [ICS,6]; A61K0031-415 [ICS,6]; A61K0031-425 [ICS,6]; A61K0031-435 [ICS,6]; A61K0047-32 [ICS,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
EP----954294	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
AB	Oral compns. for topical application contain an H2 antagonist to provide protection against colds and flu. A toothpaste containing cimetidine and a tooth gel containing mifentidine were prepared	
ST	H2 antagonist pharmaceutical cold flu	
IT	Common cold	
	Dentifrices	
	Influenza	
	Mouthwashes	
	(H2-antagonists for the manufacture of a topical composition for the treatment of colds)	
IT	Antihistamines	
	(H2; H2-antagonists for the manufacture of a topical composition for the treatment of colds)	
IT	Polyesters, biological studies	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(dilactone-based; H2-antagonists for the manufacture of a topical composition for the treatment of colds)	
IT	Drug delivery systems	
	(topical; H2-antagonists for the manufacture of a topical composition for the treatment of colds)	
IT	26780-50-7, Glycolide-lactide copolymer 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine 73278-54-3, Lamtidine 75438-42-5, ORF-17578 76824-35-6, Famotidine 76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine 80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine 84071-15-8, Ramixotidine 84545-30-2, ICI-162846 85195-15-9, L-643728 85604-00-8, Zaltidine 86134-80-7, SKF-94482 87107-94-6, BL-6548 89077-71-4, BMY-25405 89250-13-5, DA-4634 90287-93-7, SR 58042 93064-63-2, D-16637 94662-53-0, WY-45727 96153-56-9, Bisfentidine 99248-32-5,	

Donetidine 100981-43-9, Ebrotidine 104428-51-5 105805-28-5  
108498-50-6, FRG-8701 118288-08-7, FRG-8813

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(H2-antagonists for the manufacture of a topical composition for the treatment of  
colds)

L34 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:540271 HCAPLUS

DN 127:140227

ED Entered STN: 25 Aug 1997

TI Oral care compositions containing peptides with anti-adherence activity

IN Charbonneau, Duane Larry; Baker, Timothy Robert; Murawaski, Sandra Lou;  
Ward, Susan Ruth

PA Procter & Gamble Company, USA

SO Brit. UK Pat. Appl., 42 pp.

CODEN: BAXXDU

DT Patent

LA English

IC ICM C07K-0007/06

ICS A61K-0007/16; C07K-0007/64

CC 62-7 (Essential Oils and Cosmetics)

Section cross-reference(s): 34

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB---2307476	A1	19970528	1996GB-0011500	19960603
PRAI	1995US-0466542	A	19950606		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
GB 2307476	ICM	C07K-0007/06
	ICS	A61K-0007/16; C07K-0007/64
	IPCI	C07K0007-06 [ICM,6]; A61K0007-16 [ICS,6]; C07K0007-64 [ICS,6]; C07K0007-00 [ICS,6,C*]
	IPCR	C07K0007-00 [I,C*]; C07K0007-06 [I,A]
	ECLA	A61K008/64; A61Q011/00; C07K007/06A

AB There is a number of peptides which prevent bacteria adhering to teeth are disclosed. Dimers and/or cyclomonomers of these peptides are preferred because they have enhanced stability in the acid conditions of the mouth. The peptides may be employed in oral compns. such as dentifrices and mouth-washes to inhibit the growth of dental plaque. A tooth paste contained Tyr-Trp-Phe-Trp-Tyr-Gln (preparation given) 0.10, sorbitol 42.00, saccharin sodium 0.13, FD&C Blue 0.05, precipitated silica 20.00, sodium fluoride 0.24, flavor 0.900, sodium alkyl sulfate 1.00, phosphoric acid 0.4, Carbomer 940 0.25, xanthan gum 0.5, titanium oxide 0.5, and water q.s. 100%.

ST oral care compn peptide prepn antiadherence; antiplaque toothpaste peptide prepn

IT Antihistamines

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(H2; oral care compns. containing peptides with anti-adherence activity)

IT Chewing gum

(antiplaque dentifrices; oral care compns. containing peptides with anti-adherence activity)

IT Dentifrices

Mouthwashes

Mouthwashes

(antiplaque; oral care compns. containing peptides with anti-adherence activity)

IT Dentifrices

Dentifrices

(chewing gums, antiplaque; oral care compns. containing peptides with anti-adherence activity)

IT Chewing gum

(dentifrices, antiplaque; oral care compns. containing peptides with anti-adherence activity)

IT Adhesion, biological  
(inhibitors; oral care compns. containing peptides with anti-adherence activity)

IT Tooth  
(oral care compns. containing peptides with anti-adherence activity)

IT Anti-inflammatory agents  
Peptides, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(oral care compns. containing peptides with anti-adherence activity)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 644-62-2, Meclofenamic acid 5104-49-4, Flurbiprofen 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 74103-06-3, Ketorolac  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(oral care compns. containing peptides with anti-adherence activity)

IT 193199-43-8P 193199-47-2P 193199-51-8P 193199-56-3P 193199-60-9P  
193199-63-2P 193199-66-5P 193199-69-8P 193199-72-3P 193199-75-6P  
193199-78-9P 193199-81-4P 193199-84-7P 193199-87-0P 193199-89-2P  
193199-92-7P 193199-97-2P 193200-01-0P 193200-05-4P 193200-09-8P  
193200-12-3P 193200-16-7P 193200-20-3P 193200-22-5P 193200-25-8P  
193200-27-0P  
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(oral care compns. containing peptides with anti-adherence activity)

IT 13726-85-7 13734-34-4 13734-41-3 15761-38-3 18942-46-6  
47355-10-2 193200-36-1 193200-39-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(oral care compns. containing peptides with anti-adherence activity)

L34 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:307478 HCAPLUS

DN 120:307478

ED Entered STN: 11 Jun 1994

TI Use of histamine H-2 antagonists for treatment of gingivitis or periodontitis

IN Singer, Robert E.; Ebel, James P.

PA Procter and Gamble Co., USA

SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 868,805.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K-0007/16

ICS A61K-0007/18; A61K-0007/22

INCL 424052000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---5294433	A	19940315	1993US-0019782	19930305
	WO---9320815	A1	19931028	1993WO-US02673	19930324
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU---9339304	A1	19931118	1993AU-0039304	19930324
	CN---1082400	A	19940223	1993CN-0105692	19930415
	US---5364616	A	19941115	1993US-0171494	19931222
PRAI	1992US-0868805	A2	19920415		
	1993US-0019782	A	19930305		
	1993WO-US02673	A	19930324		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

```

-----
US 5294433      ICM      A61K-0007/16
                  ICS      A61K-0007/18; A61K-0007/22
                  INCL     424052000
                  IPCI     A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22
                           [ICS,5]
                  IPCR     A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41
                           [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A];
                           A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425
                           [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
                           A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505
                           [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*];
                           A61K0045-06 [I,A]
WO---9320815    NCL      424/052.000; 424/049.000; 424/054.000
                  IPCI     A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34
                           [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5];
                           A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
                  IPCR     A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41
                           [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A];
                           A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425
                           [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
                           A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505
                           [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*];
                           A61K0045-06 [I,A]
AU---9339304    IPCI     A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34
                           [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5];
                           A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
                  IPCR     A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41
                           [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A];
                           A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425
                           [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
                           A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505
                           [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*];
                           A61K0045-06 [I,A]
CN---1082400    IPCI     A61K0007-16 [ICM,5]; A61K0031-275 [ICS,5]; A61K0031-415
                           [ICS,5]; A61K0031-155 [ICS,5]; A61K0031-44 [ICS,5]
                  IPCR     A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41
                           [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A];
                           A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425
                           [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
                           A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505
                           [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*];
                           A61K0045-06 [I,A]
US---5364616    IPCI     A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22
                           [ICS,5]
                  IPCR     A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41
                           [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A];
                           A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425
                           [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
                           A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505
                           [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*];
                           A61K0045-06 [I,A]
                  NCL      424/052.000; 424/049.000; 424/054.000; 514/399.000;
                           514/406.000; 514/900.000; 514/902.000
AB      Gingivitis or periodontitis is treated by topical administration, to
gingival tissues of the oral cavity, of a composition comprising a safe and
effective amount of a selective histamine H-2 receptor antagonist. Oral
care comps. (toothpastes, etc.) containing the H-2 antagonists are disclosed.
The H-2 antagonist may be cimetidine, ranitidine, famotidine, nizatidine,
etc.
ST      gingivitis treatment histamine H2 antagonist; toothpaste histamine H2
antagonist gingivitis
IT      Dentifrices
        Mouthwashes
        (with histamine H2 antagonist, for gingivitis or periodontitis
        treatment)

```

IT Antihistaminics  
(H2, for gingivitis or periodontitis treatment)

IT Pharmaceutical dosage forms  
(controlled-release, polymers, with histamine H2 antagonist, for gingivitis or periodontitis treatment)

IT Gingiva  
(disease, gingivitis, treatment of, histamine H2 antagonist for)

IT Periodontium  
(disease, periodontitis, treatment of, histamine H2 antagonist for)

IT Dentifrices  
(gels, with histamine H2 antagonist, for gingivitis or periodontitis treatment)

IT 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine 73278-54-3, Lamtidine 75438-42-5, ORF-17578 76824-35-6, Famotidine 76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine 80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine 84071-15-8, Ramixotidine 84545-30-2, ICI-162846 85195-15-9, L 643728 85604-00-8, Zaltidine 86134-80-7, BMY-25368 87107-94-6, BL-6548 89077-71-4, BMY-25405 89250-13-5, DA-4634 90287-93-7, SR 58042 93064-63-2, D 16637 94662-53-0, Wy-45727 96153-56-9, Bisfentidine 99248-32-5, Donetidine 100981-43-9, Ebrotidine 104428-51-5, HB 408 105805-28-5, HE 30256 108498-50-6, FRG-8701 118288-08-7, FRG-8813  
RL: BIOL (Biological study)  
(for gingivitis or periodontitis treatment)

IT 155057-88-8 155057-90-2  
RL: BIOL (Biological study)  
(mouthwash with, for gingivitis or periodontitis treatment)

IT 155057-87-7 155057-89-9  
RL: BIOL (Biological study)  
(toothpaste with, for gingivitis or periodontitis treatment)

L34 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:678396 HCAPLUS

DN 119:278396

ED Entered STN: 25 Dec 1993

TI Dental compositions containing H2 histamine antagonists for treatment of gingivitis and periodontitis

IN Singer, Robert E.; Ebel, James P.

PA Procter and Gamble Co., USA

SO PCT Int. Appl., 38 pp.  
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K-0031/41  
ICS A61K-0031/415; A61K-0031/34; A61K-0031/425; A61K-0031/44;  
A61K-0031/445; A61K-0031/505

CC 62-7 (Essential Oils and Cosmetics)  
Section cross-reference(s): 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO---9320815	A1	19931028	1993WO-US02673	19930324
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US---5294433	A	19940315	1993US-0019782	19930305
AU---9339304	A1	19931118	1993AU-0039304	19930324
PRAI 1992US-0868805	A	19920415		
1993US-0019782	A	19930305		
1993WO-US02673	A	19930324		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
-----	-----	-----

WO 9320815 ICM A61K-0031/41  
 ICS A61K-0031/415; A61K-0031/34; A61K-0031/425;  
 A61K-0031/44; A61K-0031/445; A61K-0031/505  
 IPCI A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34  
 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5];  
 A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]  
 IPCR A61K0031-34 [I,A]; A61K0031-34 [I,C\*]; A61K0031-41  
 [I,A]; A61K0031-41 [I,C\*]; A61K0031-415 [I,A];  
 A61K0031-415 [I,C\*]; A61K0031-425 [I,A]; A61K0031-425  
 [I,C\*]; A61K0031-44 [I,A]; A61K0031-44 [I,C\*];  
 A61K0031-445 [I,A]; A61K0031-445 [I,C\*]; A61K0031-505  
 [I,A]; A61K0031-505 [I,C\*]; A61K0045-00 [I,C\*];  
 A61K0045-06 [I,A]  
 US---5294433 IPCI A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22  
 [ICS,5]  
 IPCR A61K0031-34 [I,A]; A61K0031-34 [I,C\*]; A61K0031-41  
 [I,A]; A61K0031-41 [I,C\*]; A61K0031-415 [I,A];  
 A61K0031-415 [I,C\*]; A61K0031-425 [I,A]; A61K0031-425  
 [I,C\*]; A61K0031-44 [I,A]; A61K0031-44 [I,C\*];  
 A61K0031-445 [I,A]; A61K0031-445 [I,C\*]; A61K0031-505  
 [I,A]; A61K0031-505 [I,C\*]; A61K0045-00 [I,C\*];  
 A61K0045-06 [I,A]  
 AU---9339304 NCL 424/052.000; 424/049.000; 424/054.000  
 IPCI A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34  
 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5];  
 A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]  
 IPCR A61K0031-34 [I,A]; A61K0031-34 [I,C\*]; A61K0031-41  
 [I,A]; A61K0031-41 [I,C\*]; A61K0031-415 [I,A];  
 A61K0031-415 [I,C\*]; A61K0031-425 [I,A]; A61K0031-425  
 [I,C\*]; A61K0031-44 [I,A]; A61K0031-44 [I,C\*];  
 A61K0031-445 [I,A]; A61K0031-445 [I,C\*]; A61K0031-505  
 [I,A]; A61K0031-505 [I,C\*]; A61K0045-00 [I,C\*];  
 A61K0045-06 [I,A]  
 AB Dental compns. containing H2 histamine antagonists are used for treatment of  
 gingivitis and periodontitis. A dental solution contained ranitidine 1.00,  
 flavors 0.10, Polysorbate-80 0.25, Na saccharin 0.05, methylparaben 0.20,  
 propylparaben 0.10, and water q.s. 100%.  
 ST dental compn H2 histamine antagonists gingivitis; periodontitis dental  
 compn H2 histamine antagonists; ranitidine dental soln periodontitis  
 gingivitis  
 IT **Dentifrices**  
**Mouthwashes**  
 (H2 histamine antagonists in, for treatment of gingivitis and  
 periodontitis)  
 IT Bactericides, Disinfectants, and Antiseptics  
 Inflammation inhibitors  
 Diphosphates  
 Fluorides, biological studies  
 RL: BIOL (Biological study)  
 (dental composition containing H2 histamine antagonists and, for treatment of  
 gingivitis and periodontitis)  
 IT **Antihistaminics**  
 (H2, dental composition containing, for treatment of gingivitis and  
 periodontitis)  
 IT Pharmaceutical dosage forms  
 (controlled-release, for placement in periodontal pocket, H2 histamine  
 antagonists in)  
 IT Gingiva  
 (disease, gingivitis, treatment of, with dental composition containing H2  
 histamine antagonists)  
 IT Periodontium  
 (disease, periodontitis, treatment of, with dental composition containing H2  
 histamine antagonists)  
 IT **Dentifrices**  
 (gels, H2 histamine antagonists in, for treatment of  
 gingivitis and periodontitis)

IT Periodontium  
 (pocket, placement of H2 histamine antagonists in, controlled-release  
 pharmaceutical containing)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 644-62-2, Meclofenamic acid  
 5104-49-4, Flurbiprofen 15687-27-1 22071-15-4 22204-53-1, Naproxen  
 36322-90-4, Piroxicam 74103-06-3, Ketorolac  
 RL: BIOL (Biological study)  
 (dental composition containing H2 histamine antagonists and, for treatment of  
 gingivitis and periodontitis)

IT 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine  
 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine  
 73278-54-3, Lamtidine 75438-42-5, ORF-17578 76824-35-6, Famotidine  
 76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine  
 78441-82-4, BMV-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine  
 80343-63-1 83184-43-4, Mifentidine 83903-06-4, Lupitidine  
 84071-15-8, Ramixotidine 84545-30-2, ICI-162846 85195-15-9  
 85604-00-8, Zaltidine 86134-80-7, SKF-94482 87107-94-6, BL-6548  
 89077-71-4, BMV-25405 89250-13-5, DA-4634 90287-93-7, SR 58042  
 93064-63-2, D 16637 94662-53-0, Wy-45727 96153-56-9 99248-32-5,  
 Donetidine 100981-43-9, Ebrotidine 104428-51-5, HB 408 105805-28-5,  
 HE 30256 108498-50-6, FRG-8701 118288-08-7, FRG-8813  
 RL: BIOL (Biological study)  
 (dental composition containing, for treatment of gingivitis and periodontitis)

=> d his

(FILE 'HOME' ENTERED AT 09:22:39 ON 06 JUL 2006)

FILE 'HCAPLUS' ENTERED AT 09:22:55 ON 06 JUL 2006

L1 1 US2000-607602/AP,PRN  
 E DOYLE M/AU

L2 75 E3,E13  
 E DOYLE MATT/AU

L3 26 E4-6  
 E HUNTER RINDERLE/AU

L4 8 E5  
 E SINGER R/AU

L5 105 E3,E7  
 E SINGER ROB/AU

L6 67 E4,E11-14

L7 12952 (PROCTER (L) GAMBLE)/CS,PA  
 E TOOTHPASTE/CT  
 E E3+ALL  
 E E2

L8 9351 E3-13  
 E E3+ALL

L9 9351 E2  
 E TOOTH, DISEASE/CT

L10 2230 E3-13  
 E E3+ALL

L11 5601 E11+OLD

L12 539 L10-11 (L) (INHIBIT? OR SUPPRESS? OR MODULAT? OR DOWNREGULAT? O

L13 9787 L8-9,L12  
 E DENTAL FLOSS/CT  
 E E3+ALL  
 E MOUTHWASH/CT  
 E E3+ALL  
 E MOUTHWASH/CT

L14 3858 E3-9  
 E E4+ALL

L15 3898 E2+OLD  
 E MOUTH, DISEASE/CT

L16 1398 E3-16  
 E E3+ALL

L17 8646 E10+NT

```

L18      1200 L16-17 (L) (INHIBIT? OR SUPPRESS? OR MODULAT? OR DOWNREGULAT? O
L19      12282 L13-15,L18
L20      6381 L19 AND PHARM?/SC,SX
L21      163 L20 AND L1-7
          E H2/CT
          E H2 ANTAG/CT
          E E5+ALL
          E E2
          E ANTIHISTAMINES/CT
          E E3+ALL
L22      1994 E4+OLD,NT (L)H2
          E H2 ANTAG/CT
L23      16 L21 AND L22
L24      28 L20 AND L22
L25      16 L24 AND L1-7
L26      12 L24 NOT L25
L27      4 L26 AND (PY<=2000 OR AY<=2000 OR PRY<=2000)
L28      36 L19 AND L22
L29      24 L28 AND L1-7
L30      12 L28 NOT L29
L31      12 L26-27,L30
          SEL AN 1-4 7 10-11
L32      7 E1-14 AND L31
          SEL AN 3-5 7
L33      4 E15-22 AND L32
L34      24 L25,L29

```

=> b wpix

FILE 'WPIX' ENTERED AT 14:19:17 ON 06 JUL 2006  
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 3 JUL 2006 <20060703/UP>  
 MOST RECENT DERWENT UPDATE: 200642 <200642/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE  
[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) and  
<http://scientific.thomson.com/media/scpdf/ipcrdwpf.pdf> <<<

>>> FOR FURTHER DETAILS ON THE FORTHCOMING DERWENT WORLD PATENTS  
 INDEX ENHANCEMENTS PLEASE VISIT:  
[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<  
 'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all abex tech l18 tot

```

L18 ANSWER 1 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-439858 [41] WPIX
CR 2004-439857 [41]
DNC C2004-164676
TI Oral care dentifrice composition for treatment of oral conditions,
includes particulate retentive agent comprising water-soluble hydrophilic
gums and/or polymers, and oral care carrier.
DC A96 B06 B07 D21
IN BEST, J M; BURGESS, S C; EVERSOLE, S L; FALLER, R V; SCOTT, D C
PA (PROC) PROCTER & GAMBLE CO; (BEST-I) BEST J M;
(BURG-I) BURGESS S C; (EVER-I) EVERSOLE S L; (FALL-I) FALLER R V; (SCOT-I)
SCOTT D C
CYC 108

```

PI US--2004101494 A1 20040527 (200441)\* 21 A61K-009-68  
 WO--2004047785 A1 20040610 (200441) EN A61K-007-16 <--  
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE  
 LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE  
 DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG  
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM  
 PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ  
 VC VN YU ZA ZM ZW  
 AU--2003293110 A1 20040618 (200471) A61K-007-16 <--  
 EP-----1565154 A1 20050824 (200556) EN A61K-007-16 <--  
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV  
 MC MK NL PT RO SE SI SK TR  
 JP--2006509768 W 20060323 (200623) 40 A61K-008-00  
 ADT US--2004101494 A1 Provisional 2002US-429234P 20021126, 2003US-0706104  
 20031112; WO--2004047785 A1 2003WO-US37880 20031125; AU--2003293110 A1  
 2003AU-0293110 20031125; EP-----1565154 A1 2003EP-0790102 20031125,  
 2003WO-US37880 20031125; JP--2006509768 W 2003WO-US37880 20031125,  
 2004JP-0555783 20031125  
 FDT AU--2003293110 A1 Based on WO--2004047785; EP-----1565154 A1 Based on  
 WO--2004047785; JP--2006509768 W Based on WO--2004047785  
 PRAI 2002US-429234P 20021126; 2003US-0706104 20031112  
 IC ICM A61K-007-16; A61K-008-00; A61K-009-68  
 ICS A61K-009-00; A61K-009-20; A61Q-011-00  
 AB US2004101494 A UPAB: 20060405  
 NOVELTY - An oral care dentifrice composition comprises a retentive agent  
 comprising water soluble hydrophilic gums and/or polymers, and having a  
 property of hydrating upon exposure to water or saliva forming an intact  
 hydrated mass to provide a retention index of 1-4; and an oral care  
 carrier. The composition is a non-cariogenic, chewable solid unit dosage  
 form, and comprises water insoluble particulates.  
 DETAILED DESCRIPTION - An oral care dentifrice composition comprises  
 a retentive agent (1-40 weight%) comprising water soluble hydrophilic gums  
 and/or polymers, and having a property of hydrating upon exposure to water  
 or saliva forming an intact hydrated mass to provide a retention index of  
 1-4; and an oral care carrier. The composition is a non-cariogenic,  
 chewable solid unit dosage form, and comprises water insoluble  
 particulates (less than 65 weight%).  
 INDEPENDENT CLAIMS are also included for:  
 (a) an oral care kit comprising an oral care dentifrice composition  
 for topical, oral administration in a human or other animal, instructions,  
 and a container;  
 (b) a method of buffering the oral cavity saliva or environment on or  
 at the tooth surfaces of a subject, to a pH of 7-12, for at least 2  
 minutes, by administering topically to the oral cavity, an oral care  
 composition;  
 (c) a method of providing sustained delivery of an oral care active,  
 flavor, sensate or buffer, in the oral cavity of a subject, by  
 administering topically, an oral care dentifrice composition.  
 USE - For treatment of oral conditions.  
 ADVANTAGE - The composition provides mechanical shear by chewing the  
 solid unit dosage form and using a retentive agent. The retentive agent  
 enhances deposition and adhesion of the composition to the teeth surfaces.  
 The composition also provides pH buffering on or at the tooth surfaces,  
 especially the sites where most caries form, the pits, fissures and  
 occlusal surfaces of the teeth.  
 Dwg.0/3  
 FS CPI  
 FA AB; DCN  
 MC CPI: A12-V04B; B03-L; B04-C02A; B04-C02B; B04-C02B2; B04-C02D;  
 B04-C02F; B04-C03; B04-N02; B05-A01B; B05-A02; B05-C04; B05-C07;  
 B10-A07; B10-B02J; B10-B03B; B12-M10A; B12-M11B; B14-A01; B14-A04;  
 B14-C03; B14-C08; B14-L11; B14-N06A;  
 D08-A05; D08-B08  
 ABEX UPTX: 20040629  
 EXAMPLE - A chewable compressed tablet was prepared by mixing (wt.%)

sodium fluoride (0.243), sodium lauryl sulfate (1.5), silica (20), sodium saccharin (0.5), flavor (1.5), xanthan gum (2), microcrystalline cellulose (5), polyvinyl pyrrolidone (3), crosslinked sodium carboxymethyl (2), sorbitol (30), mannitol (33.257), and zinc stearate (1).

TECH UPTX: 20040629

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Property: The retention index is 2-4.

Preferred Composition: The retentive agent is present at 7-30 (preferably 11-18) wt. %.

Preferred Agent: The oral care active agent is anticalculus agent, anticaries agent (xylitol), fluoride ion source (stannous fluoride, sodium fluoride, indium fluoride, sodium monofluorophosphate), antimicrobial agents, dentinal desensitizing agents, anesthetic agents, antifungal agents, anti-inflammatory agents, selective H-2 antagonists, anticaries agents, remineralization agents, whitening agents, anti-erosion agents, vitamins, and/or minerals.

Preferred Concentration: The active agent is a fluoride ion source providing 200-300 ppm of fluoride ion. Preferred Form: The solid unit dosage form is a compressed tablet.

TECHNOLOGY FOCUS - POLYMERS - Preferred Material: The retentive agent is acacia, karaya gum, guar gum, gelatin, alginic acid or its salts, tragacanth, polyethylene glycol, polyethylene oxide, acrylamide polymers, cross linked polyacrylic acid, polyvinyl alcohol, ethylene oxide polymers, polyvinylpyrrolidone, cationic polyacrylamide polymers, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan, locust bean gum, gum Arabic, tragacanth gum, pullulan, pre-gelatinized and partially pre-gelatinized starch, hydrolyzed starch, maltodextrin and corn syrup solids, hydrogenated maltodextrin, hydrogenated starch hydrosylates, amylose, and/or amylopectin.

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Material: The carrier can be water soluble buffers, sodium bicarbonate, sodium carbonate, phosphate buffer, trisodium phosphate, disodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, tetrasodium pyrophosphate, disodium pyrophosphate, tetrapotassium pyrophosphate, and/or salts of tripolyphosphates.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Material: The carrier can be amino acid buffers, alanine, glycine, and/or tris(hydroxymethyl)aminomethane.

L18 ANSWER 2 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 2004-141600 [14] WPIX  
 CR 1998-312139 [27]; 2000-412119 [35]; 2000-422852 [36]; 2001-417614 [44];  
 2002-147973 [19]; 2002-266603 [31]; 2003-016005 [01]; 2004-388565 [36]  
 DNC C2004-056534  
 TI Promoting whole body health in human and animal subjects by topical  
 administration of oral composition comprising stannous ion source,  
 polymeric mineral surface active agent and oral carrier.  
 DC A96 B05 C03 D21  
 IN DOYLE, M J; GLANDORF, W M; HUNTER-RINDERLE, S J;  
 WHITE, D J  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 1  
 PI US--2003206874 A1 20031106 (200414)\* 17 A61K-007-16 <--  
 ADT US--2003206874 A1 CIP of 1996US-0754577 19961121, CIP of 1998US-0203216  
 19981130, Div ex 1999US-0451420 19991130, CIP of 2000US-0607240 20000630,  
 CIP of 2000US-0710440 20001110, CIP of 2001US-0039620 20011024,  
 2003US-0454843 20030605  
 FDT US--2003206874 A1 CIP of US-----5939052, Div ex US-----6350436, CIP of  
 US-----6555094  
 PRAI 2003US-0454843 20030605; 1996US-0754577 19961121;  
 1998US-0203216 19981130; 1999US-0451420 19991130;  
 2000US-0607240 20000630; 2000US-0710440 20001110;

2001US-0039620      20011024

IC ICM A61K-007-16  
ICS A61K-007-28

AB US2003206874 A UPAB: 20041203  
NOVELTY - Promoting whole body health in human and animal subjects comprises topically administering oral composition to the subject's oral cavity comprising stannous ion source, polymeric mineral surface-active agent and oral carrier.  
USE - For promoting whole body health in human and animal subjects.  
ADVANTAGE - Topical administration of oral composition inhibits the spread of pathogenic oral bacteria, associated bacterial toxins and endotoxins and resultant inflammatory cytokines and mediators into the bloodstream. It reduces the risk in developing cardiovascular disease, stroke, atherosclerosis, diabetes, severe respiratory infections, premature births and low-birth weight, post-partum dysfunction in neurologic and developmental functions and associated increased risk of mortality.  
Dwg. 0/0

FS CPI  
FA AB; DCN

MC CPI: A12-V01; B03-L; B04-C01G; B04-C02A2; B04-C02V; B04-C03; B04-H06; B04-J01; B05-A03A; B05-A03B; B05-B01N; B05-C05; B05-C07; B06-E05; B06-F01; B07-H; B10-A07; B10-A17; B10-A22; B10-C02; B10-C04C; B10-C04D; B10-D03; B10-E02; B10-E04C; B14-A01; B14-A02; B14-C01; B14-C03; B14-D07C; B14-G01; B14-L06; B14-L11; B14-N06; C03-L; C04-C01G; C04-C02A2; C04-C02V; C04-C03; C04-H06; C04-J01; C05-A03A; C05-A03B; C05-B01N; C05-C05; C05-C07; C06-E05; C06-F01; C07-H; C10-A07; C10-A17; C10-A22; C10-C02; C10-C04C; C10-C04D; C10-D03; C10-E02; C10-E04C; C14-C01; C14-D07C; C14-G01; C14-L06; C14-L11; C14-N06; D08-A05; D08-B08

ABEX UPTX: 20040226  
EXAMPLE - A dual phase dentifrice was formed from a first phase containing (wt.%) water (2.768), glycerin (36.432), polyethylene glycol (1.500), propylene glycol (8.000), hydrated silica (28.000), xanthan gum (0.300), carboxymethyl cellulose (0.500), sodium alkylsulfate (4.000), sodium saccharin (1.000), glass H polyphosphate (1.000), flavor (0.300), benzoic acid (0.600) and sodium benzoate (0.600) and a second phase containing stannous fluoride (0.908), stannous chloride (3.000), sodium gluconate (4.160), color (0.300), water (21.840), flavor (1.000), glycerin (28.992), silica (23.000), sodium saccharin (0.300), 50% sodium hydroxide solution (1.000) and poloxamer (15.500).

TECH UPTX: 20040226  
TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The stannous ion source is stannous fluoride, stannous chloride, stannous acetate, stannous gluconate, stannous oxalate, stannous sulfate, stannous lactate and/or stannous tartrate. The stannous ion source provides 3000-15000 ppm stannous ions.  
  
TECHNOLOGY FOCUS - POLYMERS - Preferred Components: The polymeric surface-active agent is phosphorylated polymer, preferably condensed polyphosphate having an average chain length of at least 4 (preferably 21). The polyphosphate is present at 1-35 wt.%.  
TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The composition also contains additional therapeutic agent(s), e.g. antimicrobial agent, anti-inflammatory agent, hydrogen antagonist, metalloproteinase inhibitor, cytokine receptor antagonist, lipopolysaccharide complexing agent, tissue growth factor, immunostimulatory agent, cellular redox modifier, analgesic, hormone, vitamin and/or mineral. The antimicrobial agent is triclosan, triclosan monophosphate, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride, tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyridinium chloride, octenidine, delmopinol, octapinol, nisin, zinc ion source, copper ion source, essential oil, furanone, bacteriocin and/or their salts.

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition may be in the form of mouth rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge or pet-chew product.

L18 ANSWER 3 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 2001-112498 [12] WPIX  
 CR 2001-102981 [11]; 2001-102982 [11]; 2001-102983 [11]; 2001-112494 [12]  
 DNC C2001-033516  
 TI Delivery system for delivering a substance to the oral cavity, comprising a removable backing strip and a composition comprising an organosiloxane resin, a rheology modifier and an oral care substance.  
 DC A26 A96 B07 C07 D21  
 IN BUCKLEY, C D; YE, H; YUE, J; CRISANTI, M M; JIANG, Y; MAJETI, S  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 92  
 PI WO---200101958 A1 20010111 (200112)\* EN 39 A61K-009-00  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TZ UG ZW  
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES  
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS  
 LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL  
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU---200059074 A 20010122 (200125) A61K-009-00  
 NO---200200004 A 20020228 (200223) A61K-000-00  
 EP-----1200064 A1 20020502 (200236) EN A61K-009-00  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI  
 BR---200012145 A 20020430 (200237) A61K-009-00  
 SK---200101941 A3 20020806 (200261) A61K-009-00  
 CZ---200104709 A3 20020911 (200268) A61K-009-00  
 CN-----1360494 A 20020724 (200269) A61K-009-00  
 HU---200201620 A2 20020930 (200272) A61K-009-00  
 EP-----1200064 B1 20030502 (200330) EN A61K-009-00  
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 DE---60002471 E 20030605 (200345) A61K-009-00  
 JP--2003531814 W 20031028 (200373) 50 A61K-007-16 <--  
 US-----6649147 B1 20031118 (200376) A61K-007-16 <--  
 AU-----768471 B 20031211 (200404) A61K-009-00  
 ES-----2199168 T3 20040216 (200416) A61K-009-00  
 RU-----2223746 C2 20040220 (200424) A61K-007-16 <--  
 CN-----1200684 C 20050511 (200641) A61K-007-16 <--  
 ADT WO---200101958 A1 2000WO-US018188 20000630; AU---200059074 A  
 2000AU-0059074 20000630; NO---200200004 A 2000WO-US018188 20000630,  
 2002NO-0000004 20020102; EP-----1200064 A1 2000EP-0945084 20000630,  
 2000WO-US18188 20000630; BR---200012145 A 2000BR-0012145 20000630,  
 2000WO-US18188 20000630; SK---200101941 A3 2000WO-US18188 20000630,  
 2001SK-0001941 20000630; CZ---200104709 A3 2000WO-US18188 20000630,  
 2001CZ-0004709 20000630; CN-----1360494 A 2000CN-0809984 20000630;  
 HU---200201620 A2 2000WO-US18188 20000630, 2002HU-0001620 20000630;  
 EP-----1200064 B1 2000EP-0945084 20000630, 2000WO-US18188 20000630;  
 DE---60002471 E 2000DE-0602471 20000630, 2000EP-0945084 20000630,  
 2000WO-US18188 20000630; JP--2003531814 W 2000WO-US18188 20000630,  
 2001JP-0507453 20000630; US-----6649147 B1 2000WO-US18188 20000630,  
 2002US-0019032 20020320; AU-----768471 B 2000AU-0059074 20000630;  
 ES-----2199168 T3 2000EP-0945084 20000630; RU-----2223746 C2  
 2000WO-US18188 20000630, 2002RU-0102710 20000630; CN-----1200684 C  
 2000CN-0809937 20000609  
 FDT AU---200059074 A Based on WO---200101958; EP-----1200064 A1 Based on  
 WO---200101958; BR---200012145 A Based on WO---200101958; SK---200101941  
 A3 Based on WO---200101958; CZ---200104709 A3 Based on WO---200101958;  
 HU---200201620 A2 Based on WO---200101958; EP-----1200064 B1 Based on  
 WO---200101958; DE---60002471 E Based on EP-----1200064, Based on  
 WO---200101958; JP--2003531814 W Based on WO---200101958; US-----6649147  
 B1 Based on WO---200101958; AU-----768471 B Previous Publ.

AU---200059074, Based on WO---200101958; ES-----2199168 T3 Based on EP-----1200064; RU-----2223746 C2 Based on WO---200101958

PRAI 2000WO-US15891 20000609; 1999WO-US15130 19990702;  
1999WO-US15131 19990702; 2000WO-US15890 20000609

IC ICM A61K-000-00; A61K-007-16; A61K-009-00  
ICS A61C-013-23; A61K-007-18; A61K-009-20; A61K-009-70;  
A61K-031-4164; A61K-033-40; A61K-047-02; A61K-047-04; A61K-047-06;  
A61K-047-08; A61K-047-32; A61K-047-34; A61P-001-02; A61P-025-04;  
A61P-029-00; A61P-031-04; A61P-031-12; A61P-043-00

AB WO 200101958 A UPAB: 20060629  
NOVELTY - A new delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip and an oral care composition applied to the backing strip so that when the delivery system is placed on the oral surface, the oral care composition contacts the oral surface and remains on the surface after the backing strip is removed.  
DETAILED DESCRIPTION - A new delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip and an oral care composition applied to the backing strip so that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface and remains on the surface after the backing strip is removed. The backing strip has sufficient flexibility to be readily conformable to the oral surface. The oral care composition comprises an organosiloxane resin, a fluid diorganopolysiloxane-based polymer (optional), a rheology modifier and at least one oral care substance.  
An INDEPENDENT CLAIM is included for a method for delivering an oral care substance to at least one surface of the oral cavity, comprising:  
(a) applying the backing strip of the delivery system with the oral care composition coated to the surface(s) of the oral cavity;  
(b) removing the backing strip from the surface(s) of the oral cavity or allowing the backing strip to dissolve in situ, where the oral care composition remains on the surface(s) of the oral cavity after the backing strip is removed.  
ACTIVITY - Antimicrobial; analgesic; antiviral; antiinflammatory.  
No biological data given.  
MECHANISM OF ACTION - None given.  
No biological data given.  
USE - The delivery system is useful for delivering an oral care substances to the oral cavity.  
Dwg.0/11

FS CPI  
FA AB; DCN

MC CPI: A06-A00E3; A12-V04B; B04-C02; B04-C03B; B04-C03D; B05-A01B;  
B05-C07; B10-A17; B12-M05; B14-A01; B14-A02; B14-C01; B14-C03;  
B14-L11; B14-N06; C04-C02; C04-C03B; C04-C03D;  
C05-A01B; C05-C07; C10-A17; C12-M05; C14-A01; C14-A02; C14-C01;  
C14-C03; C14-L11; C14-N06; D08-A

ABEX UPTX: 20010302  
ADMINISTRATION - The delivery system delivers the oral care composition orally.

EXAMPLE - Organosiloxane resin solution (43.7% MQ resin in isododecane) (25% parts resin) was mixed with fluid diorganopolysiloxane polymer solution (50% SE30 silicone gum in isododecane) (12.5 parts silicone gum). Sodium percarbonate (17 parts) as a dry powder, isododecane (44.5 parts) and bentone clay (1 part) were dispersed in the mixture to give a hydrophobic oral care composition which was used with a backing strip consisting of a piece of polyethylene film 0.013 mm. thick.

TECH UPTX: 20010302  
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The organosiloxane resin is present at a level of 5-70%. The oral care substance comprises 0.01-50% of the oral care composition. The rheology modifier is present in the oral care composition at a level of about 0.1-30%. The composition further comprises a fluid diorganopolysiloxane-based polymer and a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The ratio of

organosiloxane resin to fluid diorganopolysiloxane-based polymer is 10:1-1:10.

The oral care substance includes at least one oral care active selected from a teeth whitening active, an anti-tartar agent, a fluoride ion source, an anti-microbial agent, an anti-inflammatory agent, one or more nutrients, a mouth and throat product, an antioxidant, an H<sub>2</sub> antagonist, an analgesic active, an anti-viral agent, flavoring agents, sweetening agents, sweetening agents, xylitol, opacifiers, coloring agents, surfactants, chelants, pigments or their mixtures. Preferably the oral care substance is a teeth whitening active selected from peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates or their mixtures.

The composition further comprises a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The carrier is selected from hydrocarbon oils, volatile silicones, non-hydrocarbon solvents or their mixtures. The backing strip is water insoluble or water soluble. The water insoluble backing strip is a polymer film of nominal thickness less than about 0.1 mm., selected from polyethylene, ethylvinylacetate, polyesters, ethylvinyl alcohol, pullulan film or combinations of these and has a peel force of less than 50 g. The water soluble backing strip is selected from rice paper, pullulan paper, agar film, starch paper, natural gum or their mixtures.

Preferred Method: The oral care composition comprises a teeth whitening active and the oral cavity surface to which the composition is applied is the enamel of the teeth.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The organosiloxane resin is present at a level of 5-70%. The oral care substance comprises 0.01-50% of the oral care composition. The rheology modifier is present in the oral care composition at a level of about 0.1-30%. The composition further comprises a fluid diorganopolysiloxane-based polymer and a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The ratio of organosiloxane resin to fluid diorganopolysiloxane-based polymer is 10:1-1:10.

The organosiloxane resin is selected from (CH<sub>3</sub>)<sub>3</sub>SiO)0.5 'M' units, (CH<sub>3</sub>)<sub>2</sub>SiO 'D' units, (CH<sub>3</sub>)SiO<sub>1.5</sub> 'T' units, SiO<sub>2</sub> 'Q' units or their mixtures. The rheology modifier is selected from organo modified clays, silica, polyethylene and mixtures of these. The fluid diorganopolysiloxane-based polymer comprises repeating units formula (R<sub>2</sub>SiO)<sub>n</sub>.

R = 1-6C monovalent hydrocarbon radical.

Preferably the fluid diorganopolysiloxane-based polymer is poly(dimethylsiloxane). The oral care substance includes at least one oral care active selected from a teeth whitening active, an anti-tartar agent, a fluoride ion source, an anti-microbial agent, an anti-inflammatory agent, one or more nutrients, a mouth and throat product, an antioxidant, an H<sub>2</sub> antagonist, an analgesic active, an anti-viral agent, flavoring agents, sweetening agents, sweetening agents, xylitol, opacifiers, coloring agents, surfactants, chelants, pigments or their mixtures. Preferably the oral care substance is a teeth whitening active selected from peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates or their mixtures.

The composition further comprises a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The carrier is selected from hydrocarbon oils, volatile silicones, non-hydrocarbon solvents or their mixtures. The backing strip is water insoluble or water soluble. The water insoluble backing strip is a polymer film of nominal thickness less than about 0.1 mm, selected from polyethylene, ethylvinylacetate, polyesters, ethylvinyl alcohol, pullulan film or combinations of these and has a peel force of less than 50 g. The water soluble backing strip is selected from rice paper, pullulan paper, agar film, starch paper, natural gum or their mixtures.

L18 ANSWER 4 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
AN 2000-224523 [19] WPIX  
DNC C2000-068607

TI Oral mucoretentive composition for treating symptoms of upper respiratory tract infections comprises titanium dioxide and e.g. gastrointestinal agents, analgesics, decongestants and/or expectorants.

DC B07 P32

IN DOBROZSI, D J; DOBROZSI, J

PA (PROC) PROCTER & GAMBLE CO

CYC 88

PI WO---200010529 A1 20000302 (200019)\* EN 35 A61K-009-10

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL  
OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB  
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU  
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
TT UA UG UZ VN YU ZA ZW

AU-----9955809 A 20000314 (200031) A61K-009-10

NO---200100832 A 20010219 (200128) A61K-000-00

BR-----9913178 A 20010515 (200130) A61K-009-10

EP-----1107733 A1 20010620 (200135) EN A61K-009-10

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI

CZ---200100339 A3 20010613 (200138) A61K-009-10

US-----6319513 B1 20011120 (200174) A61F-013-02

CN-----1313756 A 20010919 (200202) A61K-009-10

KR--2001072678 A 20010731 (200209) A61K-047-02

HU---200103388 A2 20020128 (200222) A61K-009-10

MX--2001002001 A1 20010801 (200238) A61K-047-02

JP--2002523354 W 20020730 (200264) 51 A61K-045-08

AU-----761968 B 20030612 (200349) A61K-009-10

KR-----413877 B 20040107 (200427) A61K-047-02

CA-----2338704 C 20041102 (200474) EN A61K-009-10

EP-----1107733 B1 20050727 (200549) EN A61K-009-10

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

IN---200100061 P1 20050311 (200555) EN A61K-009-10

DE---69926377 E 20050901 (200558) A61K-009-10

PH--1199902125 B1 20050103 (200629) A61K-009-10

CN-----1195494 C 20050406 (200641) A61K-009-10

ADT WO---200010529 A1 1999WO-US019202 19990824; AU-----9955809 A  
1999AU-0055809 19990824; NO---200100832 A 1999WO-US019202 19990824,  
2001NO-0000832 20010219; BR-----9913178 A 1999BR-0013178 19990824,  
1999WO-US19202 19990824; EP-----1107733 A1 1999EP-0942429 19990824,  
1999WO-US19202 19990824; CZ---200100339 A3 1999WO-US19202 19990824,  
2001CZ-0000339 19990824; US-----6319513 B1 Provisional 1998US-097578P  
19980824, 1999US-0361533 19990727; CN-----1313756 A 1999CN-0809860  
19990824; KR--2001072678 A 2001KR-0701965 20010215; HU---200103388 A2  
1999WO-US19202 19990824, 2001HU-0003388 19990824; MX--2001002001 A1  
2001MX-0002001 20010223; JP--2002523354 W 1999WO-US19202 19990824,  
2000JP-0565851 19990824; AU-----761968 B 1999AU-0055809 19990824;  
KR-----413877 B 1999WO-US19202 19990824, 2001KR-0701965 20010215;  
CA-----2338704 C 1999CA-2338704 19990824, 1999WO-US19202 19990824;  
EP-----1107733 B1 1999EP-0942429 19990824, 1999WO-US19202 19990824;  
IN---200100061 P1 2001IN-DN00061 20010123, 1999WO-US19202 ;  
DE---69926377 E 1999DE-0626377 19990824, 1999EP-0942429 19990824,  
1999WO-US19202 19990824; PH--1199902125 B1 1999PH-0002125 19990823;  
CN-----1195494 C 1999CN-0809860 19990824

FDT AU-----9955809 A Based on WO---200010529; BR-----9913178 A Based on  
WO---200010529; EP-----1107733 A1 Based on WO---200010529; CZ---200100339  
A3 Based on WO---200010529; HU---200103388 A2 Based on WO---200010529;  
JP--2002523354 W Based on WO---200010529; AU-----761968 B Previous Publ.  
AU-----9955809, Based on WO---200010529; KR-----413877 B Previous Publ.  
KR--2001072678, Based on WO---200010529; CA-----2338704 C Based on  
WO---200010529; EP-----1107733 B1 Based on WO---200010529; DE---69926377  
E Based on EP-----1107733, Based on WO---200010529

PRAI 1998US-097578P 19980824; 1999US-0361533 19990727

IC ICM A61F-013-02; A61K-000-00; A61K-009-10; A61K-045-08; A61K-047-02  
ICS A61P-001-00; A61P-001-02; A61P-001-04; A61P-009-00; A61P-011-00;  
A61P-011-08; A61P-011-10; A61P-011-14; A61P-023-00; A61P-025-04;

A61P-043-00

AB WO 200010529 A UPAB: 20021105

NOVELTY - Oral mucoretentive pharmaceutical composition comprises titanium dioxide and e.g. gastrointestinal agents, analgesics, decongestants and/or expectorants.

DETAILED DESCRIPTION - A per oral or oral mucoretentive, aqueous liquid, pharmaceutical composition comprises:

(a) 2-50 weight% of the composition, of colloidal particles of titanium dioxide; and

(b) gastrointestinal agents, analgesics, decongestants, expectorants, antitussives, antihistamines, bronchodilators, topical anesthetics, sensory agents, oral care agents and/or miscellaneous respiratory agents.

The composition has a sedimentation volume ratio of greater than 0.90 when measured after 48 hours, a triggered viscosity ratio of at least 1.2. The gastrointestinal agent is selected from anticholinergics, H<sub>2</sub>-receptor antagonists, laxatives, gastroprotectants, gastrokinetic and prokinetic agents, proton pump inhibitors, antidiarrheals, agents effective for the treatment of *H. pylori*, polyanionic agents and/or plant extracts effective for the treatment of gastrointestinal disorders.

An INDEPENDENT CLAIM is also included for an intranasal mucoretentive, aqueous liquid, pharmaceutical composition comprising:

(a) 2-50 weight% of the composition, of colloidal particles of titanium dioxide; and (b) gastrointestinal agents, analgesics, decongestants, expectorants, antitussives, antihistamines, bronchodilators, topical anesthetics, sensory agents, oral care agents and/or miscellaneous respiratory agents. The composition has a sedimentation volume ratio of greater than 0.90 when measured after 48 hours and triggered viscosity ratio of at least 1.2.

ACTIVITY - Drug-Delivery; Oral; Gastrointestinal-Gen.; Analgesic; Expectorant; Antitussive; Anesthetic; Antidiarrheic; Laxative; Antibacterial; Respiratory-Gen.

A mucoretentive intranasal spray decongestant composition comprised (weight%): oxymetazoline. HCl (0.05), titanium dioxide (6.8), tyloxapol (0.035), dibasic sodium phosphate (0.02), monobasic potassium phosphate (0.065), xanthan gum (0.025), benzalkonium chloride (0.04), chlorhexidine gluconate (0.26), disodium EDTA (0.01) and purified water (qs. 100%). A subject with congestion sprayed 5-500 micro l of the above solution into each nostril 3 times daily. The flow properties and triggering of the formulation with the mucus lining in the nasal passage caused the formulation and active oxymetazoline to be retained within the region of the inflamed nasal turbinates, providing a more prolonged decongesting effect on the intranasal blood vessels.

MECHANISM OF ACTION - Antihistamine-H<sub>2</sub>; Bronchodilator; Parasympatholytic; H-ATPase-Inhibitor.

USE - The composition is useful for coating the alimentary canal or nasal mucosa in particular for preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage. The formulations provide coating and protection of the mouth, esophagus, oropharynx and/or the stomach for relief of irritation, pain and discomfort associated with ailments of the gastrointestinal tract such as sore throat. The formations can also provide a matrix to deliver an active ingredient in more intimate, concentrated and sustained contact with the irritated area.

ADVANTAGE - The formulations provide prolonged and improved coating and protection.

Dwg. 0/1

FS CPI GMPI

FA AB; DCN

MC CPI: B04-A10; B05-A02; B05-A03B; B07-D09; B10-A17; B10-A22; B10-C02; B10-E02; B12-M07; B14-A01; B14-C01; B14-C08; B14-E02; B14-E09; B14-E10; B14-K01; B14-L11; B14-N05

ABEX UPTX: 20000419

ADMINISTRATION - Dosage is 1-300 mg/kg/day administered orally, topically applied to the oral cavity or intranasally.

TECH UPTX: 20000419

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The

composition has a sedimentation volume ratio of greater than 0.95 (preferably greater than 0.98) when measured after 48 hours. The composition has a triggered viscosity ratio of at least 1.4 (preferably at least 1.5). The level of titanium dioxide is 3-15 wt.%. The titanium dioxide has a mean particle size of less than 1 microm. The composition has a shear viscosity of greater than 2000 (preferably greater than 7500) Pa.s.

L18 ANSWER 5 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1998-052011 [05] WPIX

DNC C1998-017800

TI Use of H2-antagonist especially cimetidine or ranitidine - in formulations to reduce incidence of colds and similar illnesses.

DC A96 B03 B05

IN SINGER, R E

PA (PROC) PROCTER & GAMBLE CO

CYC 26

PI WO-----9747292 A1 19971218 (199805)\* EN 15 A61K-031-00

RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AU BR CA CN JP KR MX SG

AU-----9733069 A 19980107 (199820) A61K-031-00

CN-----1221338 A 19990630 (199944) A61K-031-00

EP-----954294 A1 19991110 (199952) EN A61K-031-00

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

BR-----9709792 A 19990810 (199953) A61K-031-00

JP-----11513035 W 19991109 (200004) 18 A61K-045-00

MX-----9810660 A1 19990401 (200055) A61K-031-00

ADT WO-----9747292 A1 1997WO-US009977 19970610; AU-----9733069 A

1997AU-0033069 19970610; CN-----1221338 A 1997CN-0195430 19970610;

EP-----954294 A1 1997EP-0928916 19970610, 1997WO-US009977 19970610;

BR-----9709792 A 1997BR-0009792 19970610, 1997WO-US009977 19970610;

JP-----11513035 W 1997WO-US009977 19970610, 1998JP-0501751 19970610;

MX-----9810660 A1 1998MX-0010660 19981214

FDT AU-----9733069 A Based on WO-----9747292; EP-----954294 A1 Based on

WO-----9747292; BR-----9709792 A Based on WO-----9747292; JP-----11513035 W

Based on WO-----9747292

PRAI 1996US-0662389 19960612

IC ICM A61K-031-00; A61K-045-00

ICS A61K-007-16; A61K-009-06; A61K-031-34; A61K-031-415;

A61K-031-425; A61K-031-435; A61K-047-32

AB WO 9747292 A UPAB: 19980202

Use of an H2 antagonist in the manufacture of topical formulations to reduce the incidence of colds and similar illnesses is new.

The antagonist is preferably cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, luptidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 or HB-4-08 (especially cimetidine or ranitidine)

USE - Topical application of an H2 antagonist to the gingival or oral mucosal tissues reduces the incidence of colds in susceptible individuals. Effective amounts are 5 g mouthwash or 0.5 g toothpaste. Contact of the composition with oral cavity soft tissue afflicted with gingivitis or periodontitis should be for at least 15 (especially 30-60) seconds. The composition is rinsed out with water following contact. Frequency of contact is once per week to four times per day, especially once or twice per day.

ADVANTAGE - For individuals with heart disease, hypertension, diabetes or thyroid disorders, oral drugs such as decongestants could pose a risk of unfavourable drug interactions and may cause an adverse reaction. It is therefore desirable to deliver relief from specific nasal symptoms via compositions without the need for such active agents.

Dwg.0/0

FS CPI

FA AB; DCN  
MC CPI: A12-V01; B07-D09; B14-L11; B14-N05; B14-N06B

=> d all abex tech l24 tot

L24 ANSWER 1 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2005-057753 [06] WPIX

DNC C2005-019961

TI Use of composition comprising purified enantiomer of chiral phenothiazine, in medicament for inhibiting osteoclasts for treating or preventing e.g. osteoporosis.

DC B02 D21

IN BOLAND, E J; MCDONOUGH, J

PA (SWRI) SOUTHWEST RES INST; (TEXA) UNIV TEXAS SYSTEM

CYC 108

PI WO--2004110458 A1 20041223 (200506)\* EN 48 A61K-031-5415

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE

LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE

DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG

KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ

OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG

US UZ VC VN YU ZA ZM ZW

ADT WO--2004110458 A1 2004WO-US015416 20040517

PRAI 2003US-471155P 20030516

IC ICM A61K-031-5415

ICS A61P-019-10

AB WO2004110458 A UPAB: 20050126

NOVELTY - Use of a composition (A) comprising a purified enantiomer of a chiral phenothiazine (A1), is claimed in a medicament for inhibiting osteoclasts for treating or preventing a disease or condition associated with bone loss.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for

(1) inhibiting osteoclasts which comprises contacting a population of cells (having osteoclasts) in vitro with a composition which comprises a purified enantiomer of a chiral phenothiazine;

(2) inhibiting osteoclastic resorption of bone tissue which comprises contacting an in vitro bone tissue sample with a composition which comprises a purified enantiomer of a chiral phenothiazine, to inhibit osteoclasts in the bone tissue sample, and

(3) a therapeutic kit which comprises at least a first container, a purified enantiomer of a chiral phenothiazine to inhibit osteoclasts and a second, distinct anti-osteoclastic or anti-osteoporotic agent.

ACTIVITY - Osteopathic; Antiinflammatory; Antiasthmatic; Antiallergic; Respiratory-Gen.; Antiparkinsonian; Antiemetic.

Tests are described, but no results are given.

MECHANISM OF ACTION - Osteoclast inhibitor; Histamine H1 receptor antagonist; Histamine H2 receptor antagonist.

USE - (A1) are useful for the inhibition of osteoclastic resorption of bone and for the treatment or prevention of bone loss (periodontitis and osteoporosis) or conditions associated with bone loss in post-menopausal female and for the treatment or prevention of bone loss in an animal having or at risk for developing bone loss (all claimed).

Promethazine is used as an antiemetic, antihistamine and antipsychotic agent. Promethazine is also useful for the treatment of asthma, allergic conditions, respiratory tract diseases and Parkinson's diseases.

ADVANTAGE - The method reduces bone loss and treats or prevents periodontitis, osteoporosis and associated disorders with higher efficacy and lower risk of side effects.

Dwg.0/6

FS CPI

FA AB; GI; DCN

MC CPI: B06-F04; B14-E05; B14-G02A; B14-J01A3; B14-J01B3; B14-K01; B14-K01A; B14-L06; B14-L09; B14-L10; B14-L11; B14-N01; B14-N06B; D08-A05

ABEX UPTX: 20050126  
 ADMINISTRATION - The dosage of (A1) is 0.5 mg/day, orally.

TECH UPTX: 20050126  
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method : (A) comprises an enantiomerically pure enantiomer of a chiral phenothiazine. (A1) is a substantially or enantiomerically purified (-) enantiomer of ethopropazine or (+) enantiomer of promethazine. (A1) is a phenothiazine derivative of formula (I), preferably promethazine, ethopropazine, propiomazine or trimeprazine.  
 R1-R3 = upto 6C alkyl;  
 X = 1-5C alkyl or 1-5C alkenyl, and  
 R4 = N-(R5)3 or S-R5, and  
 R5 = H, 1-4C alkyl or 1-4C alkenyl, cyclic alkylene or heterocyclic alkylene comprising a N or S heteroatom.  
 The population of cells comprising osteoclasts is an in vitro bone tissue sample. (A1) and the second, distinct anti-osteoclastic or anti-osteoporotic agent are within a single container or distinct containers in the kit. The kit further comprises instructions for using the kit in the manufacture of a medicament for treating or preventing bone loss.

L24 ANSWER 2 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 2004-690507 [67] WPIX  
 DNC C2004-244692  
 TI Prophylactic or therapeutic agent of teeth grinding or its related disease e.g. dropping off or headache caused by breaking/shaking of temporomandibular arthrosis, contains gastric acid secretion inhibitor as active ingredient.

DC B02  
 IN MIYAWAKI, S; YAMAMOTO, T  
 PA (EISA) EISAI CO LTD; (MIYA-I) MIYAWAKI S; (YAMA-I) YAMAMOTO T  
 CYC 109  
 PI WO--2004080487 A1 20040923 (200467)\* JA 28 A61K-045-00  
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE  
 LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE  
 DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG  
 KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ  
 OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG  
 US UZ VC VN YU ZA ZM ZW  
 EP-----1611901 A1 20060104 (200603) EN A61K-045-00  
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV  
 MC MK NL PT RO SE SI SK TR  
 JP--2005503460 X 20060608 (200638) 17 A61K-045-00

ADT WO--2004080487 A1 2004WO-JP000939 20040130; EP-----1611901 A1  
 2004EP-0706869 20040130, 2004WO-JP000939 20040130; JP--2005503460 X  
 2004WO-JP000939 20040130, 2005JP-0503460 20040130

FDT EP-----1611901 A1 Based on WO--2004080487; JP--2005503460 X Based on  
 WO--2004080487

PRAI 2003JP-0068755 20030313  
 IC ICM A61K-045-00  
 ICS A61K-031-4427; A61K-031-4439; A61P-001-00; A61P-001-02; A61P-001-04;  
 A61P-019-00; A61P-019-02; A61P-019-08; A61P-021-00; A61P-025-00;  
 A61P-025-04; A61P-029-00; A61P-043-00; C07D-401-00; C07D-401-12

AB WO2004080487 A UPAB: 20041019  
 NOVELTY - A prophylactic or therapeutic agent for treating teeth grinding or its related diseases contains a proton pump-inhibitor, a histamine H2 receptor antagonist and/or an acid pump antagonist as an active ingredient.  
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:  
 (1) prevention or treatment of tooth grinding and its related diseases by administering an agent as above; and  
 (2) use of a gastric acid secretion inhibitor for the manufacture of a prophylactic or therapeutic agent for tooth grinding and its related diseases.

ACTIVITY - Analgesic; Antiarthritic; Antiallergic; Vulnerary; Osteopathic.

Change of pH of esophagus in a teeth grinding patient while sleeping, and temporal muscle activity were measured and the effect of proton pump inhibitor (sodium salt of rabeprazole) was evaluated by a double blind test. The frequency of jaw movement accompanied by rhythmic temporal muscle activity decreased remarkably by the administration of the proton pump inhibitor.

MECHANISM OF ACTION - Gastric-Secretion-Inhibitor; Proton-Pump-Inhibitor; Antihistamine-H2; Acid-Pump-Inhibitor.

No suitable test details are given.

USE - For preventing and treating teeth grinding and its related diseases e.g. dropping off or headaches caused by breaking/shaking of temporomandibular arthrosis, hypersensitivity of teeth, occlusal trauma, occlusal wear of teeth, wedge-shaped defect of teeth, gingival retraction, odontoschism, root resorption, alveolar-bone absorption, masseter enlargement, mastication, myalgia and crown repair (claimed).

ADVANTAGE - The agent suppresses the backflow of gastric acid into the esophagus. The combination of proton pump inhibitor and histamine H2 receptor antagonist has a synergistic effect.

DESCRIPTION OF DRAWING(S) - The graph (A) shows the temporal muscle activity while sleeping (4 hours) after administering proton pump inhibitor and (B) the frequency of pH episode per hour in each case after administering the proton pump inhibitor, where p value is less than 0.0001 on left side indicated by four stars and p value is less than 0.001 on right side indicated by three stars, in 8 patients.

Dwg.2/3

FS CPI

FA AB; GI; DCN

MC CPI: B06-D05; B06-D08; B07-A01; B07-D05; B07-D09; B07-F01; B14-C01;

B14-E07; B14-L11; B14-N06B; B14-S09

ABEX UPTX: 20041019

ADMINISTRATION - Administration of proton pump inhibitor is 0.01-100 mg/day/adult, orally. Administration of sodium salt of rabeprazole is 0.1-10 mg/day/adult. Administration of omeprazole is 0.1-20 mg/day, magnesium salt of esomeprazole is 0.1-20 mg/day, lansoprazole is 0.1-30 mg/day, and pantoprazole is 0.1-40 mg/day. Administration of histamine H2 receptor antagonist is 1-800 mg/day/adult, orally. Administration of cimetidine is 1-800 (50-400) mg/day/adult. Administration of ranitidine is 5-300 (30-150) mg/day/adult. Administration of famotidine is 1-40 (5-20) mg/day/adult. Administration of roxatidine acetate hydrochloride is 5-150 (25-75) mg/day/adult. Administration of nizatidine is 30-300 (50-150) mg/day/adult. Administration of lafutidine is 0.5-20 (2.5-10) mg/day/adult.

EXAMPLE - No relevant examples given.

TECH UPTX: 20041019

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Active Ingredients: The agent preferably contains a proton pump inhibitor, a histamine H2 receptor antagonist and/or an acid pump antagonist, preferably a proton pump inhibitor and a histamine H2 receptor antagonist, more preferably a proton pump inhibitor as active ingredient.

The proton pump inhibitor is rabeprazole, omeprazole, esomeprazole, lansoprazole, pantoprazole, tenatoprazole, its salts and/or hydrates, preferably sodium salt of rabeprazole.

The histamine H2 receptor antagonist is cimetidine, ranitidine, famotidine, roxatidine, nizatidine and/or its salt.

L24 ANSWER 3 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2001-122754 [13] WPIX

DNC C2001-035515

TI Treatment of inflammation, e.g. psoriasis, asthma, cancer or infections, comprises administration of alcoholic curcumin composition to inhibit phosphorylase kinase.

DC B05 C03

IN HENG, M C Y

PA (HENG-I) HENG M C Y  
CYC 91  
PI WO---200070949 A1 20001130 (200113)\* EN 169 A01N-031-00  
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TZ UG ZW  
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES  
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS  
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL  
TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
AU---200050353 A 20001212 (200115) A01N-031-00  
US--2001051184 A1 20011213 (200204) A61K-009-00  
ADT WO---200070949 A1 2000WO-US013929 20000519; AU---200050353 A  
2000AU-0050353 20000519; US--2001051184 A1 1999US-0315856 19990520  
FDT AU---200050353 A Based on WO---200070949  
PRAI 1999US-0315856 19990520  
IC ICM A01N-031-00; A61K-009-00  
ICS A01N-031-14; A01N-033-02; A01N-035-00; A01N-043-08; A01N-055-08;  
A61K-009-16; A61K-009-26; A61K-009-50; A61K-009-62; A61K-031-045;  
A61K-031-075; A61K-031-12; A61K-031-135; A61K-031-34; A61K-033-00;  
A61K-033-14; A61K-033-26; A61K-035-78  
AB WO 200070949 A UPAB: 20010307  
NOVELTY - Treating inflammation by administering soluble curcumin in  
solutions containing alcohol(s) to mammals to detectably inhibit  
phosphorylase kinase in mammalian blood or tissues.  
DETAILED DESCRIPTION - Inflammation in mammals is treated by  
inhibiting glycogen breakdown and generation of adenosine triphosphate  
(ATP) through phosphorylase kinase inhibition in order to inhibit the  
energy supply for cellular activities such as cell migration and  
proliferation, cytokine and growth factor secretion and gene transcription  
by administering soluble curcumin in solutions containing alcohol(s) to  
detectably inhibit phosphorylase kinase in mammalian blood or tissues.  
An INDEPENDENT CLAIM is included for compositions comprising:  
(a) curcumin, a curcuminoid or a curcumin derivative in a solution  
containing alcohol(s);  
(b) an additional component(s) chosen from vitamin D3 or its analogs,  
vitamin A or its derivatives or analogs, a calmodulin inhibitor, an  
antiinflammatory drug, a calcium channel blocker, an H1 or H2 histamine  
blocker, an antioxidant or free radical scavenger, a polyphenolic  
compound, a monoterpene, genistein, a soybean-derived lectin or  
dehydrozingerone; and  
(c) a pharmaceutically acceptable carrier.  
ACTIVITY - Antiinflammatory; antipsoriatic; vulnerary;  
dermatological; antiallergic; antibacterial; fungicide; virucide;  
antiarthritic; immunosuppressive; arteriosclerotic; nootropic;  
neuroprotective; hepatotrophic; osteopathic; gynecological; cytostatic;  
antiparasitic; antidiabetic; protozoacide; anthelmintic; anti-HIV.  
MECHANISM OF ACTION - The soluble curcumin inhibits:  
(1) migration of gamma / delta T cells occurring 30 minutes-4 hours  
after the inflammatory stress;  
(2) migration of neutrophils beginning 18-24 hours after the  
inflammatory stress;  
(3) migration of macrophages beginning about 24 hours after the  
inflammatory stress; and/or  
(4) migration of alpha / beta T cells and other cells such as  
eosinophils beginning 48-72 hours after the inflammatory stress.  
Glycogen breakdown inhibitor; phosphorylase kinase inhibitor; ATP  
generation inhibitor (all claimed).  
USE - The methods are used to treat inflammation in mammals,  
especially humans or socially or economically important animals such as  
cows, horses, sheep, pigs, goats, dogs or cats. They are used to treat  
conditions or diseases including psoriasis, skin wounds, burns, scalds,  
scars, chemical-, radiation- and sun-induced skin injury, smoking-induced  
skin injury, allergic and hypersensitive reactions, hay fever, periodontal  
disease, gingivitis, eczema, skin infections (bacterial, viral, fungal,  
mycoplasma), arthritis, systemic lupus erythematosus, connective tissue  
diseases, atherosclerosis, Alzheimer's disease, the inflammatory process

that occurs during partial or complete blockage of an artery such as a coronary artery, gastritis, chronic hepatitis, chronic diverticulitis, osteomyelitis, inflammatory bowel diseases, pelvic inflammatory disease, chronic prostatitis, sinusitis, neuritis, neuropathies, radiation- and smoking-induced injury, benign and malignant tumors, including metastatic tumors, of tissues such as breast, prostate, lung, skin, brain, liver, pancreas, gastric, intestinal, colon, kidney, bladder, cervix, ovary, uterus, central nervous system, sinuses, ears, eyes, bone and thyroid, melanomas, leukemias, lymphomas, infections caused by bacteria, superficial fungi, deep fungi, viruses, mycoplasmas and parasites, diabetes and neurodegenerative conditions (claimed). They may be used to treat infections caused by dermatophytes, sporotrichium, Histoplasma, blastomyces, herpes simplex virus, varicella zoster virus, adenovirus, human immunodeficiency virus (HIV), nematodes, other worms, other pathogenic parasites such as organisms causing filariasis, schistosomiasis and malaria.

Dwg.0/16

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-G; B03-L; B04-A10; B04-B01B; B05-B01A; B05-B02C; B06-A02; B07-A01; B10-B01B; B10-B03B; B10-B04B; B10-E04C; B10-E04D; B10-F01; B10-F02; B10-J02; B14-A01; B14-A02; B14-A03; B14-A04; B14-B02; B14-B03; B14-C03; B14-C09; B14-D06; B14-E10B; B14-E10C; B14-F01E; B14-F02B2; B14-F07; B14-G02A; B14-H01; B14-J01; B14-J01A4; B14-L06; B14-L10; B14-L11; B14-M01; B14-N01; B14-N04; B14-N06B; B14-N07A; B14-N12; B14-N17; B14-S04; B14-S08; B14-S12; C03-A; C03-G; C03-L; C04-A10; C04-B01B; C05-B01A; C05-B02C; C06-A02; C07-A01; C10-B01B; C10-B03B; C10-B04B; C10-E04C; C10-E04D; C10-F01; C10-F02; C10-J02; C14-A01; C14-A02; C14-A03; C14-A04; C14-B02; C14-B03; C14-C03; C14-C09; C14-D06; C14-E10B; C14-E10C; C14-F01E; C14-F02B2; C14-F07; C14-G02A; C14-H01; C14-J01; C14-J01A4; C14-L06; C14-L10; C14-L11; C14-M01; C14-N01; C14-N04; C14-N06B; C14-N07A; C14-N12; C14-N17; C14-S04; C14-S08; C14-S12

ABEX UPTX: 20010307

ADMINISTRATION - Administration may be in liposomes and may be topical, ocular, nasal, oral, pharyngeal, rectal, vaginal, bladder, urethral, bronchial or parenteral (claimed). Dosage is 250 mg-2 g curcumin daily orally or in topical gels at concentrations of 0.1-2% concentration. . Administration may be in combination with vitamin D3 or its analogs, vitamin A or its derivatives or analogs, a calmodulin inhibitor, an antiinflammatory drug, a calcium channel blocker, an H1 or H2 histamine blocker, an antioxidant or free radical scavenger, a polyphenolic compound, a monoterpene, genistein, a soybean-derived lectin or dehydrozingerone (claimed).

TECH UPTX: 20010307

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The alcohol is a 1-6 (especially 1-3) C alcohol, that is preferably saturated or monohydric, especially ethanol (preferred), 1-propanol or 2-propanol. The curcumin is administered as a boron complex, preferably a difluoroboron complex, a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with the carboxyl oxygens of oxalic acid, a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with a carboxyl group and a hydroxyl group of citric acid, a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with the two hydroxyl groups of dibenzyl tartrate or a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with a second molecule of curcumin. The soluble curcumin is curcumin or a curcuminoid derivative.

L24 ANSWER 4 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1988-316468 [45] WPIX

CR 1988-355373 [50]; 1990-009109 [02]

DNC C1988-139816

TI Cimetidine containing methacrylate copolymer to improve palatability - comprise copolymer of di methylamino ethyl methacrylate and neutral methacrylic acid ester(s).

DC A96 B03  
 IN FRANCE, G; LEONARD, G S; PEARMAIN, K E  
 PA (SMIK) SMITH KLINE FRENCH LAB  
 CYC 21  
 PI EP-----290229 A 19881109 (198845)\* EN 11  
     R: AT BE CH DE ES FR GB GR IT LI LU NL SE  
 GB-----2204489 A 19881116 (198846)  
 WO-----8808703 A 19881117 (198847) EN  
     W: AU DK JP KR US  
 WO-----8808704 A 19881117 (198847) EN  
     W: AU DK JP KR US  
 AU-----8817140 A 19881206 (198913)  
 AU-----8817141 A 19881206 (198913)  
 ZA-----8803212 A 19890329 (198918)  
 DK-----8807264 A 19881228 (198920)  
 DK-----8807265 A 19881228 (198920)  
 PT-----87422 A 19890531 (198925)  
 PT-----87423 A 19890531 (198925)  
 JP-----01503385 W 19891116 (199001)  
 JP-----02500747 W 19900315 (199017)  
 GB-----2204489 B 19901114 (199046)  
 EP-----290229 B 19910731 (199131)  
     R: AT BE CH DE ES FR GB GR IT LI LU NL SE  
 DE-----3863963 G 19910905 (199137)  
 CA-----1304685 C 19920707 (199233) A61K-031-415  
 CA-----1304686 C 19920707 (199233) A61K-031-415  
 US-----5169640 A 19921208 (199252) 4 A61K-009-26  
 US-----5188839 A 19930223 (199310) 4 A61K-009-16  
 ES-----2040339 T3 19931016 (199346) A61K-031-415  
 JP-----94045540 B2 19940615 (199422) 5 A61K-031-415  
 JP-----2721219 B2 19980304 (199814) 3 A61K-031-415  
 KR-----9611236 B1 19960821 (199924) A61K-031-415  
 ADT EP-----290229 A 1988EP-0304007 19880504; GB-----2204489 A 1988GB-0010477  
     19880504; WO-----8808703 A 1988WO-GB000350 19880504; WO-----8808704 A  
     1988WO-GB000349 19880504; ZA-----8803212 A 1988ZA-0003212 19880505;  
     JP-----01503385 W 1988JP-0503930 19880504; JP-----02500747 W 1988JP-0503931  
     19880504; CA-----1304685 C 1988CA-0566093 19880506; CA-----1304686 C  
     1988CA-0566094 19880506; US-----5169640 A 1988WO-GB000350 19880504,  
     1989US-0297197 19890104; US-----5188839 A 1988WO-GB00349 19880504,  
     1989US-0295190 19890104; ES-----2040339 T3 1988EP-0304007 19880504;  
     JP-----94045540 B2 1988JP-0503931 19880504, 1988WO-GB00350 19880504;  
     JP-----2721219 B2 1988JP-0503930 19880504, 1988WO-GB00349 19880504;  
     KR-----9611236 B1 1988WO-GB00349 19880504, 1989KR-0700007 19890106  
 FDT US-----5169640 A Based on WO-----8808704; US-----5188839 A Based on  
     WO-----8808703; ES-----2040339 T3 Based on EP-----290229; JP-----94045540  
     B2 Based on JP-----02500747, Based on WO-----8808704; JP-----2721219 B2  
     Previous Publ. JP-----01503385, Based on WO-----8808703  
 PRAI 1988GB-0010477 19880504; 1987GB-0010965 19870508;  
     1987GB-0010966 19870508  
 REP 5.Jnl.Ref; No-SR.Pub  
 IC ICM A61K-009-16; A61K-009-26; A61K-031-415  
 ICS A61K-009-20; A61K-031-41  
 AB EP 290229 A UPAB: 19970502  
 Pharmaceutical granule comprises cimetidine (I) and 2-20 (5-15), especially 10  
 weight % (on (I)) of a copolymer of dimethylaminoethyl methacrylate and  
 neutral methacrylic acid esters. Also claimed is a solid pharmaceutical  
 dosage form comprising the granule and opt. also an antacid or alginate.  
 USE/ADVANTAGE - (I) is a histamine H2-antagonist, useful in treatment  
 of duodenal, gastric, recurrent and stomal ulceration, and reflux  
 oesophagitis, and in the management of patients at high risk from  
 haemorrhage of the upper gastrointestinal tract. The granule is palatable  
 and has good dissolution characteristics in the stomach, and is especially  
 useful in production of chewable tablets. The granule does not need to  
 contain a high loading of sugar, and advantageously contains no sugar at  
 all.  
 Dwg.0/0

FS CPI  
 FA AB; DCN  
 MC CPI: A04-D09; A04-F06E5; A12-V01; B04-C03B; B07-D09; B12-D06A;  
 B12-D07; B12-E08; B12-L04; B12-M11D

L24 ANSWER 5 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 1987-110237 [16] WPIX  
 DNC C1987-045823  
 TI New 2-substd.-quinoline derivs. - having leukotriene antagonist activity,  
 useful as anti-asthmatic, antiinflammatory, anti-allergic and  
 cyto-protective agents.  
 DC B02  
 IN LEGER, S; YOUNG, R N; ZAMBONI, R  
 PA (MERI) MERCK FROSST CANADA INC  
 CYC 15  
 PI EP-----219308 A 19870422 (198716)\* EN 23  
 R: AT BE CH DE FR GB IT LI LU NL SE  
 JP-----62093277 A 19870428 (198722)  
 DK-----8604875 A 19870417 (198746)  
 ES-----2002037 A 19880701 (198924)  
 EP-----219308 B 19911023 (199143)  
 R: AT BE CH DE FR GB IT LI LU NL SE  
 DE-----3682160 G 19911128 (199149)  
 CA-----1298838 C 19920414 (199224) C07D-215-02  
 ADT EP-----219308 A 1986EP-0307785 19861008; JP-----62093277 A 1986JP-0244299  
 19861016; ES-----2002037 A 1985ES-0787942 19851016; CA-----1298838 C  
 1986CA-0520525 19861015  
 PRAI 1985US-0787942 19851016  
 REP 8.Jnl.Ref; A3...8741; EP----110405; EP----181568; FR---2445319;  
 FR---2578540; GB---2002764; GB---321738; JP--61246164; No-SR.Pub;  
 US---4325959; US---4464533; EP----200101  
 IC ICM C07D-215-02  
 ICS A61K-031-47; C07D-215-14; C07D-307-00; C07D-405-10  
 AB EP 219308 A UPAB: 19930922  
 Quinoline derivs. of formula (I) and their pharmaceutically acceptable  
 salts are new. Y = -(CR2=CR2)n-, -(CC)n-, -CR2R2-X-, -X-CR2R2-,  
 -CR2R2-X-CR2R2-, X, CO, -N(R2)-CO-, -CO-N(R2)- or a gp. of formula (a);  
 each R1 = H, halo, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, OR2, SR2,  
 SOR2, SO2R2, N(R2)2, CHO, COOR2, COR2, C(OH)(R2)2, CN, NO2, or opt.  
 substd. phenyl, benzyl or phenethyl; each R2 = H, 1-8C alkyl, 2-8C  
 alkenyl, 2-8C alkynyl, CF3; or opt. substd. phenyl, benzyl or phenethyl;  
 R3 = -(A)m-(CR6=CR6)p-(CR2R4)m-Q; R4 = H, halo, NO2, CN, OR2, SR2, N(R2)2  
 or 1-8C alkyl; R5 = -(CH2)s-C(R6)2-(CH2)s-R7; each R6 = H or 1-4C alkyl;  
 R7 = mono- or bi-cyclic heterocyclyl containing 3-12C and 1-2 of N, S and/or  
 O, each ring being 5- or 6-membered; or W-R8; R8 = hydrocarbyl or acyl  
 (derived from an organic acyclic or monocyclic carboxylic acid containing not  
 more than 1 heteroatom) and contains up to 21C; R9 = OR10, SR10 or N(R10)2  
 (SiC); R10 = H, 1-6C alkyl, COR11, phenyl or benzyl; R11 = H, 1-8C alkyl,  
 2-8C alkenyl, 2-8C alkynyl, CF3, phenyl, benzyl or phenethyl; R12 = R2 gp.  
 or halo; m = 0-8; n = 1-2; p = 0-1; s = 0-3; A = -C(R4)2- or CO; Q =  
 COOR2, tetrazolyl, COOR5, CONHSO2R11, CN or CON(R10)2; it can also be  
 NHSO2R11 when, in R3, m+m+p is greater than 0; or, when Q = COOH and R3  
 contains R4 where R4 = OH, SH or NHR2, then Q+R4 completes a heterocyclic  
 ring (with loss of H2O); W = O, S or NH; X = O, S, SO, SO2 or NR2.  
 USE - (I) are antagonists of the slow reacting substance of  
 anaphylaxis (SRS-A), especially leukotriene D4. They also exhibit moderate  
 inhibition of leukotriene biosynthesis. Thus (I) can be used as  
 antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents,  
 and for treating allergic rhinitis, chronic bronchitis and skin diseases  
 such as psoriasis and atopic exzema.  
 0/0  
 FS CPI  
 FA AB  
 MC CPI: B06-D02; B12-A07; B12-C10; B12-D01; B12-D02; B12-D06;  
 B12-D06A; B12-D07; B12-E08; B12-F01B; B12-F02; B12-G01A;  
 B12-G01B1; B12-G02; B12-G03; B12-J01; B12-J05; B12-K02; B12-K06;

## B12-L04; N02-F02

L24 ANSWER 6 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1987-110236 [16] WPIX

DNC C1987-045822

TI New 2-phenyl alkenyl or alkynyl-quinoline derivs. - having leukotriene antagonist activity, useful as e.g. anti-asthmatic, antiinflammatory, anti-allergic and cyto-protective agents.

DC B02

IN LEGER, S; YOUNG, R N; ZAMBONI, R

PA (MERI) MERCK FROSST CANADA INC

CYC 13

PI EP-----219307 A 19870422 (198716)\* EN 13

R: AT BE CH DE FR GB IT LI NL SE

JP----62093276 A 19870428 (198722)

DK----8604876 A 19870417 (198746)

ES-----2002038 A 19880701 (198924)

ADT EP-----219307 A 1986EP-0307779 19861008; JP----62093276 A 1986JP-0244300 19861016; ES-----2002038 A 1985ES-0788180 19851016

PRAI 1985US-0788180 19851016

REP A3...8741; EP----110405; EP----181568; No-SR.Pub

IC A61K-031-47; C07D-215-14

AB EP 219307 A UPAB: 19930922

Quinoline derivs. of formula (I) and their pharmaceutically acceptable salts are new. Y is -(CR<sub>2</sub>:CR<sub>2</sub>)<sub>n</sub>- or (C:C)<sub>n</sub>; each R<sub>1</sub> is H, halo, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF<sub>3</sub>, OR<sub>2</sub>, SR<sub>2</sub>, SO<sub>2</sub>R<sub>2</sub>, N(R<sub>2</sub>)<sub>2</sub>, CHO or COOR<sub>2</sub>, COR<sub>2</sub>, C(OH)(R<sub>2</sub>)<sub>2</sub>, CN, NO<sub>2</sub> or opt. substd. phenyl, benzyl or phenethyl; each R<sub>2</sub> is H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF<sub>3</sub> or opt. substd. phenyl, benzyl or phenethyl; R<sub>3</sub> is -(A)<sub>m</sub>-(CR<sub>2</sub>R<sub>2</sub>)<sub>m</sub>-(CR<sub>2</sub>R<sub>4</sub>)<sub>m</sub>-CR<sub>2</sub>R (sic); provided that R<sub>3</sub> is not CHO when it is para to Y; each R<sub>4</sub> is H, halo, NO<sub>2</sub>, OR<sub>2</sub>, SR<sub>2</sub>, N(R<sub>2</sub>)<sub>2</sub> or 1-8C alkyl or (R<sub>4</sub>)<sub>2</sub> is O:, A is CO or C(R<sub>2</sub>)(OR<sub>6</sub>), R<sub>6</sub> is H, 1-6C alkyl, COR<sub>7</sub>, phenyl or benzyl, R<sub>7</sub> is H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF<sub>3</sub>, phenyl, benzyl or phenethyl; each m is 0-8, provided that at least one is not 0; n is 1-2.

USE - (I) are antagonists of the slow reacting substance of araphylaxis (SR<sub>5</sub>-A), especially leukotriene D<sub>4</sub>. They also exhibit moderate inhibition of leukotriene biosynthesis. Thus (I) can be used as antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents and for treating allergic rhinitis, chronic bronchitis and skin diseases such as psoriasis and atopic eczema.

0/0

FS CPI

FA AB

MC CPI: B06-D02; B12-A07; B12-C10; B12-D01; B12-D02; B12-D06;  
B12-D06A; B12-D07; B12-E08; B12-F01C; B12-F02; B12-G01;  
B12-G01A; B12-G01B1; B12-G02; B12-G03; B12-J01; B12-J05; B12-K02;  
B12-K06; B12-L04

L24 ANSWER 7 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1986-126580 [20] WPIX

DNC C1986-053995

TI Heterocyclic phenoxy derivs. - are histamine hydrogen receptor antagonists used for treatment of e.g. vascular headache.

DC B03

IN BROWN, T H; MITCHELL, R C; SMITH, I R; YOUNG, R C

PA (SMIK) SMITH KLINE FRENCH LAB; (YOUN-I) YOUNG R C

CYC 29

PI EP-----181163 A 19860514 (198620)\* EN 30

R: AT BE CH DE FR GB IT LI LU NL SE

AU----8549113 A 19860508 (198626)

JP----61115069 A 19860602 (198628)

NO----8504368 A 19860526 (198628)

DK----8505009 A 19860504 (198631)

HU-----38926 T 19860728 (198635)

FI----8504275 A 19860504 (198636)

PT-----81405 A 19861105 (198650)

CN----85108132 A 19860716 (198713)  
 ES-----8702385 A 19870316 (198716)  
 ZA-----8508400 A 19870504 (198729)  
 US-----4681883 A 19870721 (198731)  
 ES-----8706643 A 19870916 (198741)  
 CA-----1260468 A 19890926 (198944)  
 EP-----181163 B 19891220 (198951) EN  
 R: AT BE CH DE FR GB IT LI LU NL SE  
 DE-----3574872 G 19900125 (199005)  
 IL-----76871 A 19900429 (199026)  
 US-----4952589 A 19900828 (199037)  
 KR-----9302490 B1 19930402 (199419) C07D-401-12  
 DK-----168763 B 19940606 (199426) C07D-277-82  
 JP-----95064816 B2 19950712 (199532) 1 C07D-213-74  
 ADT EP-----181163 A 1985EP-0307929 19851031; JP----61115069 A 1985JP-0248670  
 19851105; ES-----8702385 A 1985ES-0548448 19851031; ZA-----8508400 A  
 1985ZA-0008400 19851101; US-----4681883 A 1985US-0788261 19851017;  
 ES-----8706643 A 1986ES-0555013 19860516; US-----4952589 A 1987US-0057470  
 19870603; KR-----9302490 B1 1985KR-0008130 19851101; DK-----168763 B  
 1985DK-0005009 19851031; JP----95064816 B2 1985JP-0248670 19851105  
 FDT DK-----168763 B Previous Publ. DK-----8505009; JP----95064816 B2 Based on  
 JP----61115069  
 PRAI 1984GB-0027878 19841103; 1985GB-0017714 19850713  
 REP A3...8708; EP-----143630; EP-----50407; No-SR.Pub; US---4447611  
 IC A61K-031-33; A61K-031-41; A61K-031-42; A61K-031-43; A61K-031-44;  
 C07D-013-60; C07D-015-16; C07D-031-12; C07D-213-74; C07D-215-38;  
 C07D-217-22; C07D-219-08; C07D-231-12; C07D-233-88; C07D-235-30;  
 C07D-239-42; C07D-263-48; C07D-263-58; C07D-277-82; C07D-295-08;  
 C07D-401-10; C07D-401-12; C07D-403-12; C07D-413-12; C07D-417-12  
 ICM C07D-213-74; C07D-277-82; C07D-401-12  
 ICS A61K-031-33; A61K-031-41; A61K-031-415; A61K-031-42; A61K-031-425;  
 A61K-031-43; A61K-031-44; A61K-031-445; A61K-031-47; C07D-013-60;  
 C07D-015-16; C07D-031-12; C07D-213-89; C07D-215-38; C07D-215-42;  
 C07D-217-22; C07D-219-08; C07D-231-12; C07D-233-64; C07D-233-88;  
 C07D-235-12; C07D-235-30; C07D-239-42; C07D-239-86; C07D-239-94;  
 C07D-263-48; C07D-263-58; C07D-277-42; C07D-295-08; C07D-401-10;  
 C07D-403-12; C07D-413-12; C07D-417-12  
 AB EP 181163 A UPAB: 19930922  
 (A) Heterocyclic phenoxy derivs. of formula (I) and their salts are used  
 in the mfr. of a medicament for the treatment of vascular headache. R1,  
 R2=1-4C alkyl or NR1R2 is a pyrrolidino, piperidino or hexahydroazepino  
 ring; Y=1-4C alkyl; n=2-5; m= 0-1; provided that when m=1, z=gp. (a) or  
 (b). X=N or CR6; X1=O, S or NR9; R3-R8=H, 1-6C alkyl, 1-6C alkoxy,  
 phenyl, halo, benzyl or benzyloxy; R9=H or 1-6C alkyl; any two of R3-R8 on  
 adjacent atoms may form a benzene ring opt. substd. by 1-3 of 1-6C alkyl,  
 1-6C alkoxy, halo, phenyl, benzyl or benzyloxy; provided that when X'=O,  
 R7, R8=H, 1-6C alkyl, phenyl or benzyl or are joined to form an opt.  
 substd. benzene ring; when m=0, z=gp. (c). one of V and W is N and the  
 other is C; R10, R11=H, 1-6C alkyl, phenyl, benzyl, 1-6C alkoxy or halo or  
 when W is N and the O(CH2)n chain is joined to V, R10, R11=joined to form  
 a benzene ring opt. substd. by 1-3 of 1-6C alkyl, 1-6C alkoxy, halo,  
 phenyl or benzyl. (B) Also claimed are cpds. of formula (I) with the  
 additional proviso that R9 is not H, when R7, R8 are joined to form a  
 benzene ring (i.e. (Ia)).  
 27 Cpds. (I) and their salts are specifically claimed e.g. 2-(3-(3  
 -(piperidinomethyl) phenoxy) propylamino) benzoxazole (Ib),  
 3-(3-(3-(piperidinomethyl) phenoxy) propylamino) pyridine; and  
 2-(3-(3-(piperidinomethyl) phenoxy) propyl)-1H-benzimidazole.  
 USE - (I) are histamine H2-receptor antagonists (used for the  
 treatment of vascular headache (claimed)) and/or cerebral conditions. (I)  
 can be used to treat skin inflammation, ocular inflammation and  
 inflammatory bowel disease. Unit dose of (I) is 10-1000 mg, 1-100 mg,  
 0.1-5 mg, by oral, parenteral, inhalation admin. respectively. The daily  
 adult dose of (Ia) is 10-1000 (pref. 50-500) mg orally or 0.1-100 mg by  
 inhalation.  
 0/0

FS CPI  
 FA AB  
 MC CPI: B06-H; B07-H02; B07-H03; B12-A07; B12-C10; B12-D06A;  
 B12-D07; B12-E01; B12-J01; B12-L04

=> d all abex tech l61 tot

L61 ANSWER 1 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 2004-154370 [15] WPIX  
 CR 1999-045477 [04]; 2000-523864 [47]; 2000-628197 [60]; 2002-187718 [24];  
 2002-195694 [25]; 2002-215675 [27]; 2002-239190 [29]; 2005-766005 [78]  
 DNC C2004-061365  
 TI Tooth whitening substance formed into thin layer, comprises polyox resin  
 and tooth whitening active.  
 DC A96 B07 D21 E37  
 IN DIRKSING, R S; MAJETI, S; RENO, E A; ROHMAN, F J; SAGEL, P A  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 1  
 PI US--2003211056 A1 20031113 (200415)\* 12 A61K-007-20 <--  
 ADT US--2003211056 A1 CIP of 1997US-0870664 19970606, CIP of 1998US-0042909  
 19980317, Cont of 1998US-0196364 19981119, Cont of 2000US-0605220  
 20000628, Cont of 2001US-0681729 20010529, 2003US-0410037 20030409  
 FDT US--2003211056 A1 CIP of US-----5894017, Cont of US-----6096328, CIP of  
 US-----6136297, Cont of US-----6551579  
 PRAI 1998US-0196364 19981119; 1997US-0870664 19970606;  
 1998US-0042909 19980317; 2000US-0605220 20000628;  
 2001US-0681729 20010529; 2003US-0410037 20030409  
 IC ICM A61K-007-20  
 AB US2003211056 A UPAB: 20060106  
 NOVELTY - A tooth whitening substance (14) formed into a thin layer,  
 comprises a polyox resin and a tooth whitening active. The poloyox resin  
 adheres the thin layer to teeth for a time to allow the tooth whitening  
 active to act upon the teeth.  
 USE - For whitening a tooth.  
 ADVANTAGE - The invention is low cost, is comfortable to wear, can  
 deliver a sufficient amount of tooth whitening active to teeth, and allows  
 the tooth whitening active to act upon the teeth.  
 DESCRIPTION OF DRAWING(S) - The figure is a perspective view of the  
 flat strip of material coated with an oral care substance for treating  
 teeth and gums.  
 Delivery system 10  
 Strip of material 12  
 Tooth whitening substance 14  
 Dwg.2/10  
 FS CPI  
 FA AB; GI; DCN  
 MC CPI: A12-V04B; B04-C02A; B04-C03; B05-A01B; B05-B02C; B05-C07;  
 B05-C08; B06-F01; B07-A01; B10-A07; B10-E04C; B12-M02A;  
 B14-N06; D08-A; D08-B08; E05-A; E06-F01; E07-A01;  
 E31-A05; E31-E; E33-B  
 ABEX UPTX: 20040302  
 SPECIFIC COMPOUNDS - The tooth whitening active is hydrogen peroxide.  
 EXAMPLE - An oral composition comprising 2.5% hydroxyethyl cellulose,  
 0.09% sodium fluoride, 0.05% sodium saccharin, 0.1% ranitidine and  
 purified water (balance) was prepared by routine processing methods.  
 TECH UPTX: 20040302  
 TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Material: The tooth  
 whitening active is peroxides, metal chlorites, perborates, percarbonates  
 and/or peroxyacids.  
 Preferred Composition: The tooth whitening substance comprises 0.5-20 wt.%  
 tooth whitening active and 10-95 wt.% of material from glycerin, sorbitol,  
 polyethylene glycol, propylene glycol, or polyhydric alcohols.  
 Preferred Component: The tooth whitening substance further comprises  
 water.

Preferred Parameter: The thin layer has a length of 2-12 cm.

L61 ANSWER 2 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 2002-154684 [20] WPIX  
 DNC C2002-048360  
 TI Topical oral composition useful for promoting whole body health in humans and other animals comprises a host-response modulating agent and a carrier.  
 DC B05 C03 D21  
 IN DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 95  
 PI WO---200202096 A2 20020110 (200220)\* EN 47 A61K-031-00  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
 SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
 AU---200171544 A 20020114 (200237) A61K-031-00  
 EP-----1294367 A2 20030326 (200323) EN A61K-031-00  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI TR  
 JP--2004501966 W 20040122 (200411) 89 A61K-045-00  
 MX--2003000043 A1 20031201 (200470) A61K-031-00  
 CN-----1536989 A 20041013 (200508) A61K-031-00  
 AU--2001271544 A8 20050915 (200569) A61K-031-00  
 ADT WO---200202096 A2 2001WO-US020515 20010628; AU---200171544 A  
 2001AU-0071544 20010628; EP-----1294367 A2 2001EP-0950569 20010628,  
 2001WO-US20515 20010628; JP--2004501966 W 2001WO-US20515 20010628,  
 2002JP-0506718 20010628; MX--2003000043 A1 2001WO-US20515 20010628,  
 2003MX-0000043 20021219; CN-----1536989 A 2001CN-0811860 20010628;  
 AU--2001271544 A8 2001AU-0271544 20010628  
 FDT AU---200171544 A Based on WO---200202096; EP-----1294367 A2 Based on  
 WO---200202096; JP--2004501966 W Based on WO---200202096; MX--2003000043  
 A1 Based on WO---200202096; AU--2001271544 A8 Based on WO---200202096  
 PRAI 2000US-0607602 20000630  
 IC ICM A61K-031-00; A61K-045-00  
 ICS A61K-007-16; A61K-009-06; A61K-009-08; A61K-009-12;  
 A61K-009-20; A61K-009-68; A61K-031-341; A61K-031-407; A61K-031-4164;  
 A61K-031-426; A61K-031-662; A61K-045-06; A61P-001-02; A61P-003-02;  
 A61P-029-00; A61P-043-00  
 AB WO 200202096 A UPAB: 20020402  
 NOVELTY - A topical oral composition comprises a host-response modulating agent and carrier. The host-response modulating agent is anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamin and nutrient key to maintenance of a host response balance and/or inhibitor of activation of NF-kB.  
 ACTIVITY - Cardiant; Cerebroprotective; Antiarteriosclerotic; Antidiabetic.  
 MECHANISM OF ACTION - None given.  
 USE - For the manufacture of a medicament for promoting whole body health in human and animal subjects (claimed); in mediating host reaction to the presence of periodontal pathogen in oral cavity as well as toxins and endotoxin released by these pathogens and the inflammatory cytokines and mediators promoted by these pathogens; to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, serve respiratory infections, premature births and low birth weight, post-partum dysfunction in neurologic and development functions and associated increased risk of mortality.  
 ADVANTAGE - The composition reduces the development of fatty arterial streaks, atherosclerotic plaques, progressive plate development, thinning of the fibrous cap on atherosclerotic plaques, etc; reduces carotid arterial (intimal) wall thickness; reduces the exposure of the lower respiratory track to the inhalation of bacterial pathogens; reduces alterations in circulating hematocrit, hemoglobin, while blood cell count

and/or platelet counts; reduces the incidence of dis-regulation in blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha, IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of blood/serum levels of acute phase reactants and markers of metabolic dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-F; B03-H; B06-D01; B06-D04; B06-D16; B06-F03; B07-H; B10-B02A; B10-C04B; B10-C04C; B10-E02; B14-A01; B14-F01; B14-F07; B14-K01; B14-N05; B14-N16; B14-P03; B14-S04; C03-A; C03-F; C03-H; C06-D01; C06-D04; C06-D16; C06-F03; C07-H; C10-B02A; C10-C04B; C10-C04C; C10-E02; C14-A01; C14-F01; C14-F07; C14-K01; C14-N05; C14-N16; C14-P03; C14-S04; D08-B08

ABEX UPTX: 20020402

ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, mouth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet care product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - A sub-gingival gel was prepared by dissolving (wt.%) poly(lactyl-co-glycolide)/50:50 copolymer (20) into propylene carbonate (68) and adding ranitidine (12) to the mixture. Subjects diagnosed to have both periodontitis and significantly elevated systemic blood levels of the apolipoprotein B associated with blood LDL levels were treated daily with the gel (0.35%) or with a placebo as control for 6 months. Analysis blood sample taken at a baseline before initiation of the study's treatment phase and again following 6 months of product usage, for levels of the apolipoprotein B showed a significant decrease for the subjects using the ranitidine dentifrice as compared to the placebo group.

TECH UPTX: 20020402

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises a therapeutic active agent. The H2-antagonist is cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamitidine, BL-6548, BMY-25271, zaitidine, nizatidine, mifentidine, BMY-25368 (SKF-94482), BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 and/or HB-408. The antiinflammatory agent is aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, ketoprofen, piroxicam, meclofenamic acid, nordihydroguaiaretic acid and/or triclosan. The cell redox status modifier is Co-enzyme Q10, PQQ, Vitamin C, Vitamin E, Vitamin A, epi-gallo catechin gallate and/or anethole-dithiothione. The therapeutic active agent is antimicrobial/antiplaque agent, biofilm inhibiting agent, antibiotic, analgesic and local anesthetic agent, dentinal desensitizing agent and/or odor masking agent.

L61 ANSWER 3 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-147973 [19] WPIX

CR 1998-312139 [27]; 2000-412119 [35]; 2000-422852 [36]; 2002-266603 [31]; 2004-141600 [14]; 2004-388565 [36]

DNC C2002-045968

TI Topical oral composition useful for promoting whole body health in humans and other animals comprises an antimicrobial agent and a carrier.

DC B05 C03 D21

IN DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E  
; HUNTNER-RINDERLE, S J

PA (PROC) PROCTER & GAMBLE CO; (DOYL-I) DOYLE M J;  
(HUNT-I) HUNTER-RINDERLE S J; (SING-I) SINGER R E

CYC 96

PI WO---200202128 A2 20020110 (200219)\* EN 40 A61K-033-00  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
 SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
 AU---200171545 A 20020114 (200237) A61K-033-00  
 EP-----1294383 A2 20030326 (200323) EN A61K-033-00  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI TR  
 JP--2004517038 W 20040610 (200438) 75 A61K-031-14  
 MX--2003000041 A1 20031201 (200470) A61K-031-05  
 CN-----1522149 A 20040818 (200477) A61K-033-00  
 US--2005163727 A1 20050728 (200550) A61K-009-68  
 IN---200201484 P2 20050311 (200555) EN A61K-007-16 <--  
 ADT WO---200202128 A2 2001WO-US020516 20010628; AU---200171545 A  
 2001AU-0071545 20010628; EP-----1294383 A2 2001EP-0950570 20010628,  
 2001WO-US20516 20010628; JP--2004517038 W 2001WO-US20516 20010628,  
 2002JP-0506749 20010628; MX--2003000041 A1 2001WO-US20516 20010628,  
 2003MX-0000041 20021219; CN-----1522149 A 2001CN-0812035 20010628;  
 US--2005163727 A1 Cont of 2000US-0607240 20000630, 2004US-0854065  
 20040525; IN---200201484 P2 2001WO-US20516 20010628, 2002IN-KN01484  
 20021202  
 FDT AU---200171545 A Based on WO---200202128; EP-----1294383 A2 Based on  
 WO---200202128; JP--2004517038 W Based on WO---200202128; MX--2003000041  
 A1 Based on WO---200202128  
 PRAI 2000US-0607240 20000630; 2004US-0854065 20040525  
 IC ICM A61K-007-16; A61K-009-68; A61K-031-05; A61K-031-14;  
 A61K-033-00  
 ICS A01N-033-12; A61K-007-20; A61K-007-22;  
 A61K-031-085; A61K-031-155; A61K-031-44; A61K-031-4425; A61K-033-24;  
 A61K-033-30; A61K-033-34; A61K-045-00; A61K-045-06; A61P-001-02;  
 A61P-003-10; A61P-009-00; A61P-009-10; A61P-011-00; A61P-015-00;  
 A61P-031-02  
 AB WO 200202128 A UPAB: 20051019  
 NOVELTY - A topical oral composition comprises an antimicrobial agent and  
 a carrier.  
 DETAILED DESCRIPTION - A topical oral composition comprises an  
 antimicrobial agent and carrier. The antimicrobial agent is stannous ion  
 agent, triclosan, triclosan monophosphate, chlorhexidine, alexidine,  
 hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen  
 bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride  
 (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine,  
 delmopinol, octapinol, nisin, zinc ion agent, copper ion agent, essential  
 oil, furanones, bacteriocins and/or its analog or salt (preferably  
 stannous ion agent, triclosan, triclosan monophosphate, chlorhexidine,  
 domiphen bromide, CPC, zinc ion agent, copper ion agent and/or essential  
 oil).  
 ACTIVITY - Cardiant; Cerebroprotective; Antiarteriosclerotic;  
 Antidiabetic; Antibacterial.  
 MECHANISM OF ACTION - Pathogenic oral bacteria inhibitor.  
 USE - For the manufacture of a medicament for promoting whole body  
 health in human and animal subjects (claimed); for controlling bacterial  
 mediated diseases and conditions present in the oral cavity and inhibiting  
 spread into the bloodstream of pathogenic oral bacteria and associated  
 bacterial toxins and endotoxin as well as the inflammatory cytokines and  
 mediators promoted by these pathogens; to reduce the risk in development  
 of cardiovascular disease, stroke, atherosclerosis, diabetes, serve  
 respiratory infections, premature births and low birth weight, post-partum  
 dysfunction in neurologic and development functions and associated  
 increased risk of mortality.  
 ADVANTAGE - The composition reduces the development of fatty arterial  
 streaks, atherosclerotic plaques, progressive plate development, thinning  
 of the fibrous cap on arteriosclerotic plaques, etc; reduces carotid  
 arterial (intimal) wall thickness; reduces the exposure of the lower

respiratory track to the inhalation of bacterial pathogens; reduces alterations in circulating hematocrit, hemoglobin, while blood cell count and/or platelet counts; reduces the incidence of dis-regulation in blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha, IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of blood/serum levels of acute phase reactants and markers of metabolic dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B01-C02; B02-C01; B02-K; B02-N; B02-P03; B02-T; B03-A; B03-F; B03-H; B04-B01B; B04-B01C1; B04-C01B; B05-A01B; B05-C02; B05-C07; B06-H; B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-B02; B10-B04A; B10-C03; B10-C04B; B10-C04C; B10-D03; B10-E02; B14-A01; B14-F01; B14-F07; B14-K01; B14-N16; B14-P03; B14-S04; C01-C02; C02-C01; C02-K; C02-N; C02-P03; C02-T; C03-A; C03-F; C03-H; C04-B01B; C04-B01C1; C04-C01B; C06-H; C07-H; C10-A04; C10-A08; C10-A17; C10-A18; C10-B02; C10-B04A; C10-C03; C10-C04B; C10-C04C; C10-D03; C10-E02; C14-A01; C14-F01; C14-F07; C14-K01; C14-N16; C14-P03; C14-S04; D08-B08

ABEX UPTX: 20020321

ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet core product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - A mouthwash composition comprised (wt.%): stannous chloride (0.519), sodium gluconate (0.521), ethanol (10), glycerin (8), dibasic sodium phosphate heptahydrate (0.18), saccharin sodium (0.05), polysorbate 80 (0.3), FD and C Blue (0.02), flavor (0.15), sodium hydroxide (0.02) and water (balance) was prepared. No test was carried out.

TECH UPTX: 20020321

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises therapeutic agent (A). (A) is anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor, cytokine receptor antagonist, lipopolysaccharide complexing agent, tissue growth factor, immunostimulatory agent, cellular redox modifier, analgesic, hormone, vitamin and/or mineral (preferably anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor and/or cellular redox modifier, especially augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamide, mercurial, bisbiguanide, phenolic, neomycin, kanamycin, clindamycin, eugenol, hydrocortisone, methotrexate, levamisole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigen, lidocaine, benzocaine, amino acid, essential fat, vitamin C, a-tocopherol, co-enzyme Q10, PQQ, Vitamin A, folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene, polymyxin, urea peroxide, hydroxamic acid derivative and/or phosphinic acid amide). The H2-antagonist is cimetidine, ranitidine, famotidine, roxatidine, nizatidine and/or mifentidine.

L61 ANSWER 4 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-147964 [19] WPIX

CR 1999-518721 [43]; 1999-540489 [45]; 1999-550822 [46]; 2002-147963 [19]

DNC C2002-045959

TI Topical oral composition useful for promoting whole body health in humans and other animals comprises chlorite ion and a carrier.

DC B05 C03 D21

IN DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E  
; WIMALASENA, R L

PA (PROC) PROCTER &amp; GAMBLE CO

CYC 96

PI WO---200202063 A2 20020110 (200219)\* EN 40 A61K-007-16 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
 SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU---200170218 A 20020114 (200237) A61K-007-16 &lt;--

EP-----1294345 A2 20030326 (200323) EN A61K-007-16 &lt;--

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI TR

CN-----1440268 A 20030903 (200380) A61K-007-16 &lt;--

JP--2004501944 W 20040122 (200411) 76 A61K-007-16 &lt;--

MX--2003000044 A1 20031201 (200470) A61K-007-16 &lt;--

US-----6846478 B1 20050125 (200508) A61K-007-16 &lt;--

AU--2001270218 A8 20050908 (200568) A61K-007-16 &lt;--

IN---200201483 P2 20051202 (200623) EN A61K-007-16 &lt;--

ADT WO---200202063 A2 2001WO-US020517 20010628; AU---200170218 A  
 2001AU-0070218 20010628; EP-----1294345 A2 2001EP-0948785 20010628,  
 2001WO-US20517 20010628; CN-----1440268 A 2001CN-0812028 20010628;  
 JP--2004501944 W 2001WO-US20517 20010628, 2002JP-0506686 20010628;  
 MX--2003000044 A1 2001WO-US20517 20010628, 2003MX-0000044 20021219;  
 US-----6846478 B1 Div ex 1998US-0032234 19980227, Div ex 1998US-0032237  
 19980227, Div ex 1998US-0032238 19980227, CIP of 2000US-0481624 20000112,  
 2000US-0607729 20000630; AU--2001270218 A8 2001AU-0270218 20010628;  
 IN---200201483 P2 2001WO-US20517 20010628, 2002IN-KN01483 20021202

FDT AU---200170218 A Based on WO---200202063; EP-----1294345 A2 Based on  
 WO---200202063; JP--2004501944 W Based on WO---200202063; MX--2003000044  
 A1 Based on WO---200202063; US-----6846478 B1 Div ex US-----6077502, Div  
 ex US-----6132702, Div ex US-----6251372, CIP of US-----6264924;  
 AU--2001270218 A8 Based on WO---200202063

PRAI 2000US-0607729 20000630; 1998US-0032234 19980227;  
 1998US-0032237 19980227; 1998US-0032238 19980227;  
 2000US-0481624 20000112

IC ICM A61K-007-16  
 ICS A61K-007-20

AB WO 200202063 A UPAB: 20060405

NOVELTY - A topical oral composition comprises chlorite ion and a carrier.  
 The final composition has a final pH greater than 7 and free of chlorine  
 dioxide or chlorous acid and is free of hypochlorite ions or hypochlorite  
 salt.

ACTIVITY - Cardiant; Cerebroprotective; Antiartherosclerotic;  
 Antidiabetic; Antibacterial.

MECHANISM OF ACTION - Pathogenic oral bacteria inhibitor.

USE - For the manufacture of a medicament for promoting whole body  
 health in human and animal subjects (claimed); for controlling bacterial  
 mediated diseases and conditions present in the oral cavity and inhibiting  
 spread into the bloodstream of pathogenic oral bacteria and associated  
 bacterial toxins and endotoxin as well as the inflammatory cytokines and  
 mediators promoted by these pathogens; to reduce the risk in development  
 of cardiovascular disease, stroke, atherosclerosis, diabetes, serve  
 respiratory infections, premature births and low birth weight, post-partum  
 dysfunction in neurologic and development functions and associated  
 increased risk of mortality.

ADVANTAGE - The composition reduces the development of fatty arterial  
 streaks, atherosclerotic plaques, progressive plate development, thinning  
 of the fibrous cap on atherosclerotic plaques, etc; reduces carotid  
 arterial (intimal) wall thickness; reduces the exposure of the lower  
 respiratory track to the inhalation of bacterial pathogens; reduces  
 alterations in circulating hematocrit, hemoglobin, while blood cell count  
 and/or platelet counts; reduces the incidence of dis-regulation in  
 blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha,  
 IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of  
 blood/serum levels of acute phase reactants and markers of metabolic

dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B01-C02; B02-P03; B02-T; B03-A; B03-F; B03-H; B04-B01B; B04-B01C1; B04-C01B; B04-C01G; B05-A01B; B05-C02; B05-C07; B06-H; B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-A22; B10-B02; B10-C04B; B10-C04C; B10-D03; B10-H01; B14-A01; B14-F01; B14-F07; B14-K01; B14-N16; B14-S04; C01-C02; C02-P03; C02-T; C03-A; C03-F; C03-H; C04-B01B; C04-B01C1; C04-C01B; C04-C01G; C05-A01B; C05-C02; C05-C07; C06-H; C07-H; C10-A04; C10-A08; C10-A17; C10-A18; C10-A22; C10-B02; C10-C04B; C10-C04C; C10-D03; C10-H01; C14-A01; C14-F01; C14-F07; C14-K01; C14-N16; C14-S04; D03-E09; D08-A

ABEX UPTX: 20020321

ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet core product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - An oral spray contained (wt.%) sodium chlorite (1.25), sodium bicarbonate (0.192), sodium carbonate (0.289) and water (balance) was prepared having a pH of approximately 10. Beagle dogs were applied with the spray (30 ml) through-out the mouth twice daily. After 9 months significant reduction in attachment loss were observed in the treated animals compared to those receiving the spray without sodium chlorite.

TECH UPTX: 20020321

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition comprises the chlorite ion (0.02 - 6 wt.%) and further comprises a therapeutic active agent (A). Preferred Components: (A) is antimicrobial/antiplaque agents, biofilm inhibiting agents, anti-inflammatory agents, H2-antagonists, metalloproteinase inhibitors, cytokine receptor antagonists, lipopolysaccharide complexing agents, tissue growth factors, immunostimulatory agents, cellular redox modifiers, analgesics, hormones, vitamins and/or minerals (preferably triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine, delmopinol, octapinol, nisin, zinc ion agents, stannous ion agents, essential oils, augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole; Aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamides, mercurials, bisbiguanides, phenolics, neomycin, kanmycins, clindamycin, eugenol, hydrocortisone, methotrexate, levamasole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigens, lidocaine, benzocaine, amino acids, essential fats, vitamin C, alpha-tocopherol, Co-enzyme Q10, pyrroloquinoline quinone (PQQ), vitamin A, Folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene, polymyxin, urea peroxide, hydroxamic acid derivatives, phosphinic acid amides, furanones, lysozyme, dextranases, mutanases and/or bacteriocins.

L61 ANSWER 5 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-147963 [19] WPIX

CR 1999-518721 [43]; 1999-540489 [45]; 1999-550822 [46]; 2002-147964 [19]

DNC C2002-045958

TI Composition for treating and preventing oral cavity disease e.g. inflammation of gingiva comprises chlorite ion and carrier.

DC B05 D21 P32 P34

IN DOYLE, M J; GOULBOURNE, E A; WIMALASENA, R L; WITT, J J; WONG, A

L

PA (PROC) PROCTER &amp; GAMBLE CO

CYC 96

PI WO---200202061 A2 20020110 (200219)\* EN 37 A61K-007-00

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TR TZ UG ZWW: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

US-----6350438 B1 20020226 (200220) A61K-007-16 &lt;--

AU---200168743 A 20020114 (200237) A61K-007-00

EP-----1294347 A2 20030326 (200323) EN A61K-007-20 &lt;--

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
RO SE SI TR

CN-----1446075 A 20031001 (200382) A61K-007-20 &lt;--

JP--2004501942 W 20040122 (200411) 71 A61K-007-20 &lt;--

MX--2003000042 A1 20031201 (200470) A61K-007-16 &lt;--

IN---200201514 P2 20050311 (200555) EN A61K-007-00

ADT WO---200202061 A2 2001WO-US020614 20010628; US-----6350438 B1 CIP of

1998US-0032234 19980227, CIP of 1998US-0032237 19980227, CIP of

1998US-0032238 19980227, 2000US-0607242 20000630; AU---200168743 A

2001AU-0068743 20010628; EP-----1294347 A2 2001EP-0946731 20010628,

2001WO-US20614 20010628; CN-----1446075 A 2001CN-0811974 20010628;

JP--2004501942 W 2001WO-US20614 20010628, 2002JP-0506684 20010628;

MX--2003000042 A1 2001WO-US20614 20010628, 2003MX-0000042 20021219;

IN---200201514 P2 2001WO-US20614 20010628, 2002IN-KN01514 20021210

FDT US-----6350438 B1 CIP of US-----6077502, CIP of US-----6132702, CIP of

US-----6251372; AU---200168743 A Based on WO---200202061; EP-----1294347

A2 Based on WO---200202061; JP--2004501942 W Based on WO---200202061;

MX--2003000042 A1 Based on WO---200202061

PRAI 2000US-0607242 20000630; 1998US-0032234 19980227;

1998US-0032237 19980227; 1998US-0032238 19980227

IC ICM A61K-007-00; A61K-007-16; A61K-007-20

ICS A61C-017-00; A61K-007-22; A61K-007-24;

A61L-002-18

AB WO 200202061 A UPAB: 20050826

NOVELTY - A composition comprises chlorite ion (0.02 - 6 weight%) and a  
topical or oral carrier. The composition has a final pH of greater than 7.

ACTIVITY - Antiinflammatory.

MECHANISM OF ACTION - None given.

USE - For the manufacture of a medicament, as mouthrinse, toothpaste,  
non-abrasive gel or toothgel for treating and preventing oral cavity  
diseases in human and animal, e.g. at least one of inflammation of  
gingiva, inflammation of periodontal ligament, formation of periodontal  
pockets, bleeding and/or pus discharge from periodontal pockets,  
resorption of alveolar bone, loose teeth and loss of teeth; for aiding  
periodontal tissue healing and regeneration (all claimed).ADVANTAGE - The composition is completely free of chlorine dioxide or  
chlorous acid and hypochlorite ions or hypochlorite salts. The composition  
has capability to retain in the tissue and slowly releases the chlorite  
ion to the tissue. The composition is also suitable for placing at the  
site in need of periodontal tissue healing or regeneration.

Dwg.0/0

FS CPI GMPI

FA AB; DCN

MC CPI: B01-C02; B02-C; B02-K; B02-N; B02-P03; B02-T; B03-A; B03-F; B03-H;  
B04-B01C1; B04-C01B; B04-L04; B05-A01B; B05-B02A3; B05-C02; B06-H;  
B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-A22; B10-B02;  
B10-C04B; B10-C04C; B10-E02; B14-N05; D08-B08

ABEX UPTX: 20020321

WIDER DISCLOSURE - The composition contains a minimal amount of chlorite  
ion.ADMINISTRATION - The composition is administered orally. The composition  
is delivered as the mouthrinse to the periodontal pockets using a syringe,  
applicator or electromechanical device and is suitable for swishing in the  
mouth to cover other oral cavity tissues including tongue, gingival and

mucosal surfaces. The composition is also delivered in the form of toothpaste, non-abrasive gel or tooth gel by brushing teeth and tongue, gingival and mucosal surfaces (all claimed).

EXAMPLE - An oral spray formulation was prepared by mixing (wt%) 80%-sodium chlorite (1.25), sodium bicarbonate (0.192), sodium carbonate (0.289) and water (balance). The spray formulation had a pH of approximately 10. In an animal clinical study conducted among Beagle dogs, 30 ml of the spray formulation was applied evenly throughout the dog's mouth twice daily. After 9 months, significant reductions in attachment loss were observed in the treated animals compared to those receiving placebo(n=30), i.e. a spray solution containing the same above ingredients, but without sodium chlorite.

TECH

UPTX: 20020321

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises a therapeutic active selected from antimicrobial/antiplaque agents, anti-inflammatory agents, H2-antagonists, metalloproteinase inhibitors, cytokine receptor antagonists, lipopolysaccharide complexing agents, tissue growth factors, immunostimulatory agents, cellular redox modifiers, biofilm inhibiting agents, analgesics, hormones, vitamins and/or minerals (preferably triclosan, chlorhexidine, alexidine; hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine, delmopinol, octapinol, nicin preparations, zinc ion agents, stannous ion agents, essential oils, augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole; aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamides, mercurials, bisbiguanides, phenolics, neomycin, kanamycin, clindamycin, eugenol, hydrocortisone, methotrexate, levamasole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigens, lidocaine, benzocaine, amino acids, essential fats, vitamin C, alpha-tocopherol, Co-enzyme Q10, PQQ, Vitamin A, folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene, polymyxin, urea peroxide, hydroxamic acid derivatives, phosphinic acid amides, furanones, lysozyme, dextranases, mutanases and/or bacteriocins).

L61 ANSWER 6 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2000-564614 [52] WPIX

DNC C2000-168133

TI Composition for treating allergic diseases, e.g. asthma, allergic rhinitis, sneezing and itching runny nose, comprising neurokinin antagonist, H-3 antagonist and H-1 antagonist.

DC B03

IN ASLANIAN, R G; PIWINSKI, J J

PA (SCHE) SCHERING CORP

CYC 1

PI US-----6103735 A 20000815 (200052)\* 9 A61K-031-44

ADT US-----6103735 A Provisional 1998US-103757P 19981009, 1999US-0412621 19991006

PRAI 1998US-103757P 19981009; 1999US-0412621 19991006

IC ICM A61K-031-44

ICS A61K-031-415; A61K-031-445

AB US 6103735 A UPAB: 20001018

NOVELTY - Antiallergic composition comprises a neurokinin antagonist or a derivative, an H-3 antagonist or a derivative and an H-1 antagonist or a derivative.

DETAILED DESCRIPTION - Pharmaceutical composition comprises a neurokinin antagonist or a derivative, an H-3 antagonist or a derivative and an H-1 antagonist or a derivative.

ACTIVITY - Anti-allergic; antiasthmatic; antitussive; antiinflammatory

MECHANISM OF ACTION - Neurokinin antagonist; H3 antagonist; H1 antagonist.

USE - The composition is useful for treating asthma, allergic rhinitis, sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, wheezing, sinusitis, coughs associated with postnasal drip symptoms and respiratory disorders associated with allergy. No activity examples given.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B06-D13; B07-D05; B07-D09; B14-K01; B14-L09; B14-N02; B14-N03; B14-N04; B14-N05

ABEX UPTX: 20001018

ADMINISTRATION - Each unit dose preferably contains 1 to 1000 (especially 50 to 2000 mg, of neurokinin antagonist, 1 to 1000 (especially 1 to 50) mg of H-3 antagonist and 1 to 200 mg (especially 2 to 10) mg, of H-1 antagonist. Administration is e.g. oral.

TECH UPTX: 20001018

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The neurokinin antagonist is preferably a piperidino-piperidine derivative of formula (I):

R = H, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CONHCH<sub>3</sub>, CH<sub>2</sub>CON(CH<sub>3</sub>)<sub>2</sub> or a 4-hydroxypiperidine group of formula (i);

The H3 antagonist is preferably impromidine, burimamide, clobenpropit, impentamine, mifetidine, thioperamide, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, GT2331, UCL-1199, 1H-imidazole-4-pentanamine, clozapine or N-(3,5-dichlorophenyl)-N'-((4-(1H-imidazol-4-yl)-methyl)-phenyl)-methyl)-urea. The H1 antagonist is preferably an ethanolamine, ethylenediamine, alkylamine, phenothiazine or piperidine, especially ceterizine, astemizole, azatadine, azelastine, acrivastine, bromopheniramine, chlorpheniramine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrillamine, promethazine, terfenadine, tripeleminamine, temelastine, trimeprazine or tripolidine. The composition may also include a decongestant, a cough suppressant and an expectorant.

L61 ANSWER 7 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1998-052011 [05] WPIX

DNC C1998-017800

TI Use of H2-antagonist especially cimetidine or ranitidine - in formulations to reduce incidence of colds and similar illnesses.

DC A96 B03 B05

IN SINGER, R E

PA (PROC) PROCTER & GAMBLE CO

CYC 26

PI WO-----9747292 A1 19971218 (199805)\* EN 15 A61K-031-00

RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AU BR CA CN JP KR MX SG

AU-----9733069 A 19980107 (199820) A61K-031-00

CN-----1221338 A 19990630 (199944) A61K-031-00

EP-----954294 A1 19991110 (199952) EN A61K-031-00

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

BR-----9709792 A 19990810 (199953) A61K-031-00

JP-----11513035 W 19991109 (200004) 18 A61K-045-00

MX-----9810660 A1 19990401 (200055) A61K-031-00

ADT WO-----9747292 A1 1997WO-US009977 19970610; AU-----9733069 A

1997AU-0033069 19970610; CN-----1221338 A 1997CN-0195430 19970610;

EP-----954294 A1 1997EP-0928916 19970610, 1997WO-US009977 19970610;

BR-----9709792 A 1997BR-0009792 19970610, 1997WO-US009977 19970610;

JP-----11513035 W 1997WO-US009977 19970610, 1998JP-0501751 19970610;

MX-----9810660 A1 1998MX-0010660 19981214

FDT AU-----9733069 A Based on WO-----9747292; EP-----954294 A1 Based on

WO-----9747292; BR-----9709792 A Based on WO-----9747292; JP-----11513035 W

Based on WO-----9747292

PRAI 1996US-0662389 19960612

IC ICM A61K-031-00; A61K-045-00  
 ICS A61K-007-16; A61K-009-06; A61K-031-34; A61K-031-415;  
 A61K-031-425; A61K-031-435; A61K-047-32

AB WO 9747292 A UPAB: 19980202  
 Use of an H2 antagonist in the manufacture of topical formulations to reduce the incidence of colds and similar illnesses is new.  
 The antagonist is preferably cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, luptidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 or HB-4-08 (especially cimetidine or ranitidine)  
 USE - Topical application of an H2 antagonist to the gingival or oral mucosal tissues reduces the incidence of colds in susceptible individuals. Effective amounts are 5 g mouthwash or 0.5 g toothpaste. Contact of the composition with oral cavity soft tissue afflicted with gingivitis or periodontitis should be for at least 15 (especially 30-60) seconds. The composition is rinsed out with water following contact. Frequency of contact is once per week to four times per day, especially once or twice per day.  
 ADVANTAGE - For individuals with heart disease, hypertension, diabetes or thyroid disorders, oral drugs such as decongestants could pose a risk of unfavourable drug interactions and may cause an adverse reaction. It is therefore desirable to deliver relief from specific nasal symptoms via compositions without the need for such active agents.  
 Dwg.0/0

FS CPI  
 FA AB; DCN  
 MC CPI: A12-V01; B07-D09; B14-L11; B14-N05; B14-N06B

L61 ANSWER 8 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 1997-271850 [24] WPIX  
 DNC C1997-087391

TI Antiinflammatory oral composition for treatment of, e.g., gingivitis or periodontitis - comprises a histamine H2 receptor antagonist, such as ranitidine, and antimicrobial oils, such as methyl salicylate or eucalyptol.

DC B05 D21 E19 E37  
 IN PAN, P; RUBIN, M; STURDIVANT, L D  
 PA (WARN) WARNER LAMBERT CO  
 CYC 58

PI WO-----9716159 A1 19970509 (199724)\* EN 22 A61K-007-16 <--  
 RW: AT BE CH DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE  
 W: AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KE KR LK LR LS LT LV MG  
 MK MN MW MX NO NZ PL RO SD SG SI SK TR TT UA UG UZ VN  
 AU-----9674680 A 19970522 (199739) A61K-007-16 <--

ADT WO-----9716159 A1 1996WO-US016948 19961023; AU-----9674680 A  
 1996AU-0074680 19961023

FDT AU-----9674680 A Based on WO-----9716159

PRAI 1995US-0550045 19951030

REP US---5294433; US---5364616; WO---9204893; WO---9408560; WO---9418939

IC ICM A61K-007-16  
 ICS A61K-007-26; A61K-035-78

AB WO 9716159 A UPAB: 19970612  
 Antiinflammatory oral composition comprises a histamine H2 receptor antagonist and antimicrobial oils. Pref. the H2 receptor antagonist is selected from ranitidine, cimetidine, nizatidine, famotidine and salts of these; and the antimicrobial oils are selected from thymol, methyl salicylate, menthol, eucalyptol, spearmint oil, cinnamon oil, clove oil, rosemary oil and peppermint oil.  
 USE - The composition is useful for treating inflammation of the oral cavity, such as gingivitis or periodontitis. The composition is in a form suitable for oral topical administration, e.g., a toothpaste, mouthwash, spray or gel.

Dwg.0/0  
 FS CPI  
 FA AB; DCN  
 MC CPI: B06-A02; B07-A01; B10-C03; B10-G02; B14-L09; B14-N06B;  
 D08-B08; E06-A02; E07-A01; E10-E02E1; E10-E02F1

L61 ANSWER 9 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 1993-351341 [44] WPIX  
 DNC C1993-155879  
 TI Treatment of gingivitis or soft tissue aspects of periodontitis - by  
 admin. of a selective H-2 antagonist especially cimetidine.  
 DC B05 D21  
 IN EBEL, J P; SINGER, R E  
 PA (PROC) PROCTER & GAMBLE CO  
 CYC 44  
 PI WO-----9320815 A1 19931028 (199344)\* EN 36 A61K-031-41  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE  
 W: AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD  
 SK UA VN  
 AU-----9339304 A 19931118 (199410) A61K-031-41  
 US-----5294433 A 19940315 (199411) 14 A61K-007-16 <--  
 US-----5364616 A 19941115 (199445) 14 A61K-007-16 <--  
 CN-----1082400 A 19940223 (199523) A61K-007-16 <--  
 BR-----1101010 A3 19991026 (200013) A61K-007-18 <--  
 ADT WO-----9320815 A1 1993WO-US002673 19930324; AU-----9339304 A  
 1993AU-0039304 19930324; US-----5294433 A CIP of 1992US-0868805 19920415,  
 1993US-0019782 19930305; US-----5364616 A CIP of 1992US-0868805 19920415,  
 Div ex 1993US-0019782 19930305, 1993US-0171494 19931222; CN-----1082400 A  
 1993CN-0105692 19930415; BR-----1101010 A3 1997BR-1101010 19970514  
 FDT AU-----9339304 A Based on WO-----9320815; US-----5364616 A Div ex  
 US-----5294433  
 PRAI 1992US-0868805 19920415; 1993US-0019782 19930305  
 REP 1.Jnl.Ref; WO---8904178  
 IC ICM A61K-007-16; A61K-007-18; A61K-031-41  
 ICS A61K-007-22; A61K-031-155; A61K-031-275; A61K-031-34;  
 A61K-031-415; A61K-031-425; A61K-031-44; A61K-031-445; A61K-031-505  
 AB WO 9320815 A UPAB: 19931213  
 Prevention or treatment of gingivitis or soft tissue aspects of  
 periodontitis comprises topical admin. to afflicted gingival mucosa of  
 0.01-10% of a selective H-2 antagonist.  
 Also claimed is (a) toothpaste or tooth gel compsn. comprising  
 0.1-10% H-2 antagonist and a carrier comprising a dental abrasive,  
 surfactant, humectant, flavouring, or sweetener and water; and (b) a  
 dentifrice compsn. comprising H-2 antagonist and a carrier comprising a  
 dental abrasive and a flavouring or sweetener.  
 The pref. H-2 antagonist is e.g., cimetidine, etintidine, ranitidine,  
 ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine,  
 roxatidine, pifatidine, lamtidine, BL-6548, etc., especially cimetidine or  
 ranitidine.  
 USE - For treatment and prevention of gingivitis and the soft tissue  
 aspects of periodontitis.  
 Dwg.0/0  
 FS CPI  
 FA AB; DCN  
 MC CPI: B07-A01; B12-G01; B12-L04; D08-A05; D08-B06

L61 ANSWER 10 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 1992-331482 [40] WPIX  
 DNC C1992-147361  
 TI Medicaments containing salts of non-steroidal antiinflammatory drugs - with  
 antihistamine(s) or sympathomimetic drugs and have enhanced stability  
 yielding multi-symptom relief properties.  
 DC B05  
 IN FAWZI, M B; MAHJOUR, M  
 PA (WARN) WARNER LAMBERT CO  
 CYC 20

PI WO-----9215332 A1 19920917 (199240)\* EN 40 A61K-045-06  
 RW: AT BE CH DE DK ES FR GB GR IT LU MC NL SE  
 W: AU CA JP  
 AU-----9212526 A 19921006 (199301) A61K-045-06  
 ZA-----9201583 A 19921125 (199302) 37 A61K-000-00  
 EP-----574424 A1 19931222 (199351) EN A61K-045-06  
 R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE  
 JP-----06506198 W 19940714 (199432) 12 A61K-045-06  
 US-----5373022 A 19941213 (199504) 26 A61K-031-19  
 US-----5385941 A 19950131 (199511) 10 A61K-031-195  
 ADT WO-----9215332 A1 1992WO-US000164 19920110; AU-----9212526 A  
 1992AU-0012526 19920110, 1992WO-US00164 19920110; ZA-----9201583 A  
 1992ZA-0001583 19920303; EP-----574424 A1 1992EP-0904732 19920110,  
 1992WO-US00164 19920110; JP-----06506198 W 1992JP-0505311 19920110,  
 1992WO-US00164 19920110; US-----5373022 A Cont of 1991US-0664018 19910304,  
 1992US-0942108 19920908; US-----5385941 A Cont of 1991US-0664018 19910304,  
 Div ex 1992US-0942108 19920908, 1993US-0076910 19930615  
 FDT AU-----9212526 A Based on WO-----9215332; EP-----574424 A1 Based on  
 WO-----9215332; JP-----06506198 W Based on WO-----9215332  
 PRAI 1991US-0664018 19910304  
 REP GB---2120938; WO---8503443; WO---8504589; WO---8808302  
 IC ICM A61K-031-19; A61K-031-195; A61K-045-06  
 ICS A61K-031-135; A61K-031-415; A61K-031-445; A61K-031-55; A61K-031-60;  
 A61K-031-62  
 ICI A61K-031-19, A61K-031:135; A61K-031-60, A61K-031:135, A61K-031:19,  
 A61K-031:34, A61K-031:415, A61K-031:445, A61K-031:55; A61K-031-19,  
 A61K-031:135; A61K-031-60, A61K-031:135, A61K-031:19, A61K-031:34,  
 A61K-031:415, A61K-031:445, A61K-031:55; A61K-031-19, A61K-031:135;  
 A61K-031-60, A61K-031:135, A61K-031:19, A61K-031:34, A61K-031:415,  
 A61K-031:445, A61K-031:  
 AB WO 9215332 A UPAB: 19931115  
 New pharmaceutical compns. contain salts of nonsteroidal antiinflammatory  
 drugs (I) with antihistamines (II) or sympathomimetic drugs (III). The  
 salts may be in crystalline form or in the form of an amorphous semisolid  
 mass (so-called 'ion-pairs').  
 (I) is meclofenamic acid, salicylic acid (sic), sulindac, ibuprofen,  
 naproxen or dichlorfinac. (II) is diphenhydramine, pseudoephedrine,  
 ranitidine, loratidine, cimetidine, hismanal or terfenadine. (III) is a  
 nasal decongestant or bronchodilator (no examples given). The salts are  
 1:1 salts.  
 USE/ADVANTAGE - The compns. may be used to treat cough, cold,  
 cold-like and/or flu symptoms. The salts avoid drug incompatibility  
 problems and have different solubilities from the individual drugs,  
 facilitating the preparation of sustained- or enhanced-release dosage form  
 Dwg.0/11  
 FS CPI  
 FA AB; DCN  
 MC CPI: B10-A10; B10-B03B; B12-D06; B12-D07; B12-K01; B12-K02; B12-K05;  
 B12-L04  
 L61 ANSWER 11 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN  
 AN 1992-147543 [18] WPIX  
 TI Polymorphonuclear leukocyte activator - contains histamine H1 and/or H2  
 receptor blocker for treating tinea pedis, haemorrhoids, periodontal  
 diseases and intractable infections.  
 DC B04 C03 D21  
 PA (KAOS) KAO CORP  
 CYC 1  
 PI JP----04089428 A 19920323 (199218)\* 6  
 ADT JP----04089428 A 1990JP-0199186 19900730  
 PRAI 1990JP-0199186 19900730  
 IC A61K-031-13; A61K-045-06  
 AB JP 04089428 A UPAB: 19931006  
 Polymorphonuclear leukocyte activator contains histamine H1 receptor  
 blocker and/or histamine H2 receptor blocker.  
 USE/ADVANTAGE - Used for prevention and treatment of periodontal

diseases, tinea pedis, haemorrhoids, etc. The drug recovers the depressed phagocytosis in guinea pigs and cures experimentally induced periodontal diseases in dogs.

In an example, the drug for periodontal diseases comprises 0.1 weight% mepiramine HCl, 0.1 weight% ranitidine HCl, 1.0 weight% hydroxyethylcellulose and distilled water.va

0/0

FS CPI

FA AB; DCN

MC CPI: B07-A01; C07-A01; B07-D04C; C07-D04C; B12-A07; C12-A07; B12-D06; C12-D06; B12-J04; C12-J04; B12-L03; C12-L03; D08-A05; D08-B08

L61 ANSWER 12 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1991-177535 [24] WPIX

CR 1994-263304 [32]

DNC C1991-076655

TI Treatment and prevention of retinopathy associated with diabetes - by administration to a mammal of antihistamine(s).

DC B05

IN GARDNER, T W; HOLLIS, T M

PA (PENN-N) PENNSYLVANIA RES CO

CYC 1

PI US-----5019591 A 19910528 (199124)\*

ADT US-----5019591 A 1989US-0312693 19890217

PRAI 1989US-0312693 19890217

IC A61K-031-34

AB US 5019591 A UPAB: 19941010

Retinopathy associated with diabetes is treated and prevented by administration to a mammal of at least one antihistamine selected from diphenhydramine, terfenadine, mequitazine, astemizole, activastine, SCH 29851, SK & F 93944, clemastine, ketotifen, azatadine, oxatomide, azelastine, doxepine, piperoxan (933F), 929F, 1571F, mepyramine, chlorpheniramine, triprolidine, promethazine, burimamide, cimetidine, ranitidine, famotidine and nizatidine, and their derivs.

USE - Antihistamine is used in the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus.

In an example, in tests on rats having streptozotocin-induced diabetes, treatment with diphenhydramine hydrochloride (50 mg/kg. at 12 h. i.m.) or ranitidine (5 mg/kg. at 6 h. i.p.) or both concurrently indicates that activation of retinal histamine receptors is an important component of vitreal fluorescein isothiocyanate conjugated to bovine serum albumin (FITCBSA; accumulation in experimental diabetes. @ (4pp Dwg.No.0/0)

0/0

FS CPI

FA AB; DCN

MC CPI: B06-H; B07-H; B10-B03B; B12-D06; B12-H05; B12-L04

L61 ANSWER 13 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1988-316468 [45] WPIX

CR 1988-355373 [50]; 1990-009109 [02]

DNC C1988-139816

TI Cimetidine containing methacrylate copolymer to improve palatability - comprise copolymer of di methylamino ethyl methacrylate and neutral methacrylic acid ester(s).

DC A96 B03

IN FRANCE, G; LEONARD, G S; PEARMAIN, K E

PA (SMIK) SMITH KLINE FRENCH LAB

CYC 21

PI EP-----290229 A 19881109 (198845)\* EN 11

R: AT BE CH DE ES FR GB GR IT LI LU NL SE

GB-----2204489 A 19881116 (198846)

WO-----8808703 A 19881117 (198847) EN

W: AU DK JP KR US

WO-----8808704 A 19881117 (198847) EN

W: AU DK JP KR US

AU-----8817140 A 19881206 (198913)  
 AU-----8817141 A 19881206 (198913)  
 ZA-----8803212 A 19890329 (198918)  
 DK-----8807264 A 19881228 (198920)  
 DK-----8807265 A 19881228 (198920)  
 PT-----87422 A 19890531 (198925)  
 PT-----87423 A 19890531 (198925)  
 JP----01503385 W 19891116 (199001)  
 JP----02500747 W 19900315 (199017)  
 GB-----2204489 B 19901114 (199046)  
 EP-----290229 B 19910731 (199131)  
 R: AT BE CH DE ES FR GB GR IT LI LU NL SE  
 DE-----3863963 G 19910905 (199137)  
 CA-----1304685 C 19920707 (199233) A61K-031-415  
 CA-----1304686 C 19920707 (199233) A61K-031-415  
 US-----5169640 A 19921208 (199252) 4 A61K-009-26  
 US-----5188839 A 19930223 (199310) 4 A61K-009-16  
 ES-----2040339 T3 19931016 (199346) A61K-031-415  
 JP----94045540 B2 19940615 (199422) 5 A61K-031-415  
 JP----2721219 B2 19980304 (199814) 3 A61K-031-415  
 KR-----9611236 B1 19960821 (199924) A61K-031-415  
 ADT EP-----290229 A 1988EP-0304007 19880504; GB-----2204489 A 1988GB-0010477  
 19880504; WO-----8808703 A 1988WO-GB000350 19880504; WO-----8808704 A  
 1988WO-GB000349 19880504; ZA-----8803212 A 1988ZA-0003212 19880505;  
 JP----01503385 W 1988JP-0503930 19880504; JP----02500747 W 1988JP-0503931  
 19880504; CA-----1304685 C 1988CA-0566093 19880506; CA-----1304686 C  
 1988CA-0566094 19880506; US-----5169640 A 1988WO-GB000350 19880504,  
 1989US-0297197 19890104; US-----5188839 A 1988WO-GB00349 19880504,  
 1989US-0295190 19890104; ES-----2040339 T3 1988EP-0304007 19880504;  
 JP----94045540 B2 1988JP-0503931 19880504, 1988WO-GB00350 19880504;  
 JP----2721219 B2 1988JP-0503930 19880504, 1988WO-GB00349 19880504;  
 KR-----9611236 B1 1988WO-GB00349 19880504, 1989KR-0700007 19890106  
 FDT US-----5169640 A Based on WO-----8808704; US-----5188839 A Based on  
 WO-----8808703; ES-----2040339 T3 Based on EP-----290229; JP----94045540  
 B2 Based on JP----02500747, Based on WO-----8808704; JP-----2721219 B2  
 Previous Publ. JP----01503385, Based on WO-----8808703  
 PRAI 1988GB-0010477 19880504; 1987GB-0010965 19870508;  
 1987GB-0010966 19870508  
 REP 5.Jnl.Ref; No-SR.Pub  
 IC ICM A61K-009-16; A61K-009-26; A61K-031-415  
 ICS A61K-009-20; A61K-031-41  
 AB EP 290229 A UPAB: 19970502  
 Pharmaceutical granule comprises cimetidine (I) and 2-20 (5-15), especially 10  
 weight % (on (I)) of a copolymer of dimethylaminoethyl methacrylate and  
 neutral methacrylic acid esters. Also claimed is a solid pharmaceutical  
 dosage form comprising the granule and opt. also an antacid or alginate.  
 USE/ADVANTAGE - (I) is a histamine H2-antagonist, useful in treatment  
 of duodenal, gastric, recurrent and stomal ulceration, and reflux  
 oesophagitis, and in the management of patients at high risk from  
 haemorrhage of the upper gastrointestinal tract. The granule is palatable  
 and has good dissolution characteristics in the stomach, and is especially  
 useful in production of chewable tablets. The granule does not need to  
 contain a high loading of sugar, and advantageously contains no sugar at  
 all.  
 Dwg.0/0  
 FS CPI  
 FA AB; DCN  
 MC CPI: A04-D09; A04-F06E5; A12-V01; B04-C03B; B07-D09; B12-D06A; B12-D07;  
 B12-E08; B12-L04; B12-M11D

=> d his

(FILE 'HOME' ENTERED AT 13:11:33 ON 06 JUL 2006)

FILE 'WPIX' ENTERED AT 13:16:27 ON 06 JUL 2006

noble jarrell 06/07/2006

L1 1 US2000-607602/AP, PRN  
 E DOYLE M/AU  
 L2 85 E3, E11  
 E HUNTER RINDERLE/AU  
 L3 7 E5  
 L4 27 E6, E15  
 E SINGER R/AU  
 L5 84 E3, E6  
 L6 12569 (PROCTER (1N) GAMBLE) /CS, PA  
 L7 12588 PROC/PACO  
 E PROC/PACO  
 E E3+ALL  
 L8 21669 (A12-V04B OR B12-M02A OR C12-M02A OR D08-B08? OR B12-L03 OR C12  
 L9 13169 (P910 OR P911 OR P912 OR P923) /M0, M1, M2, M3, M4, M5, M6  
 L10 6110 (A61C015 OR A61C017) /IPC, IC, ICM, ICS, ICA, ICI  
 L11 240 A61Q011/IPC, IC, ICM, ICS, ICA, ICI  
 L12 8994 (A61K007-16 OR A61K007-18 OR A61K007-20 OR A61K007-22 OR A61K00  
 L13 4 (A61K007:16 OR A61K007:18 OR A61K007:20 OR A61K007:22 OR A61K00  
 L14 31915 L8-13  
 L15 325 (B12-D06A OR C12-D06A OR B14-L11 OR C14-L11) /MC  
 L16 671 L14 AND L1-7  
 L17 17 L14 AND L15  
 L18 5 L16 AND L15  
 L19 12 L17 NOT L18  
 L20 5 L19 NOT (PY>2000 OR AY>2000 OR PRY>2000)  
 E B12-L04/MC  
 E E3+ALL  
 L21 7 L19 NOT L20  
 SEL AN 2-3 5  
 L22 3 E1-3 AND L21  
 SEL AN 2-5 L20  
 L23 4 E4-7 AND L20  
 L24 7 L22-23  
 E B12-L04/MC  
 E E3+ALL  
 E CIMETIDINE/CN  
 L25 4 E3-8  
 E ETINIDINE/CN  
 E ETINTIDINE/CN  
 L26 1 E3  
 E RANITDINE/CN  
 E RANITIDINE/CN  
 L27 3 E3-6  
 E ICIA 5165/CN  
 E ICIA-5165/CN  
 E TIOTIDINE/CN  
 L28 1 E3  
 E ORF/CN  
 L29 1 E4  
 E LUPITIDINE/CN  
 L30 1 E3  
 E DONETIDNE/CN  
 E DONETIDINE/CN  
 L31 1 E3  
 E FAMOTIDINE/CN  
 L32 2 E3-5  
 E ROXATIDINE/CN  
 L33 4 E3-6  
 E PIFATIDINE/CN  
 L34 1 E3  
 E LAMTIDINE/CN  
 L35 1 E3  
 E BL/CN  
 E BL-6548/CN  
 E BMY/CN  
 L36 1 E5

```

L37      E ZALTIDINE/CN
          1 E3
          E NIZATIDINE/CN
L38      1 E3
          E BMY/CN
L39      1 E6
          E BL/CN
L40      1 E16-17
          E ICI/CN
L41      1 E22
          E ICIA/CN
          E RAMIXOTIDINE/CN
L42      1 E3
          E WY/CN
          E WY-45727/CN
L43      1 E3
          E SR-58042/CN
          E SR 58042/CN
          E BMY/CN
L44      3 E18-20
          E LOXITIDINE/CN
          E LOXTIDINE/CN
L45      1 E3
          E DA/CN
          E BISFENTIDINE/CN
L46      1 E3
          E SUFOTIDINE/CN
L47      1 E3
          E EBROTIDINE/CN
L48      1 E3
          E HE/CN
          E D-16637/CN
          E D 16637/CN
          E FRG/CN
L49      1 E5
L50      1 E4
          E IMPROMIDINE/CN
L51      1 E3
          E L-643728/CN
          E HB/CN
L52      35 L25-51
          SEL DCSE
          EDIT /DCSE /DCRE
L53      450 E1-35/DCRE
          SEL SDCN L52
          EDIT /SDCN /DCN
L54      798 E36-75
L55      41 L14 AND L53-54
L56      39 L55 AND ((M782 OR P86?)/M0,M1,M2,M3,M4,M5,M6 OR (B12-C09 OR C12
L57      12 L56 NOT (PY>2000 OR AY>2000 OR PRY>2000)
          SEL AN 1-3 5-6 7-8 11
L58      8 E76-83 AND L57
L59      27 L56 NOT L57
L60      5 L59 AND L1-7
L61      13 L58,L60

```

=&gt;